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Prenatal diagnostic genetic tests are performed to assess individual pregnancies at risk 
for the presence of a genetic disorder due to an advanced maternal age, a positive family 
history, a positive screening test and/or the presence of a foetal abnormality detected 
by ultrasonography. The major aim of these tests is to reveal the presence of a 
chromosome abnormality that may severely affect the foetus, thus enabling future 
parents to decide in a well-informed manner about the course of the pregnancy (van 
Zwieten et al., 2005). During almost 50 years, chromosomal abnormalities have been 
identified through traditional karyotyping (TK), a microscopic method that allows the 
detection of gains, losses and/or rearrangements of chromosomal material in dividing 
cells. In recent years, however, new prenatal diagnostic tests have become available at 
an increasing rate, driven by rapid developments in molecular technologies, prenatal 
screening tests and ultrasound methodologies. These new tests may differ from the 
existing ones in various ways, i.e., they may be more accurate, less labour-intensive 
and/or less uncomfortable for pregnant women (Bossuyt et al., 2006). In addition, they 
may result in shorter reporting times and/or provide targeted test results that may be 
easier to interpret. The ongoing developments in high-resolution genomic profiling 
technologies, however, may also yield interpretation problems. The work described in 
this thesis aims at assessing the efficacy of the various prenatal diagnostic tests that are 
currently available and/or those that are anticipated to become available in the future to 
assure that pregnant women receive appropriate prenatal care.
1.1  Invasive testing and traditional karyotyping
In the past, amniocentesis and chorionic villus sampling have been widely used to 
collect material for prenatal karyotyping. In 1966, Steele and Breg reported for the first 
time that cells cultured from amniotic fluid (AF) can be used to determine the 
chromosomal constitution of the foetus (Steele and Breg, 1966). Since then, this method 
has been used for establishing the foetal karyotype by TK. Usually, TK is combined with 
a measurement of the α-foetoprotein (AFP) level in AF, which may serve as a biomarker 
for an open neural tube defect. Amniocentesis during the second trimester is relatively 
safe (Marthin et al., 1997), i.e., 15-20 ml AF is aspirated transabdominally and the proce-
dure-related risk for foetal loss is estimated to be 0.6% (Mujezinovic and Alfirevic, 2007). 
At present, amniocentesis is still used for a wide variety of purposes.
The chorion represents the moiety of the foetal membrane that eventually develops 
into the foetal part of the placenta. As such, chorionic villi can be used to assess the 
genetic makeup of the foetus. Since chorionic villus sampling is typically performed 
during the first trimester of a pregnancy, diagnostic test results can be provided earlier 
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detection of all numerical chromosome aberrations, as well as all major structural 
abnormalities (i.e., deletions, duplications, inversions, and translocations) larger than ~5 
megabase (Mb) in size. Next to routine Giemsa-trypsin-Giemsa (GTG) staining for 
obtaining chromosome-specific banding patterns, additional methods such as 
C-banding can be used for further cytogenetic characterization. Through this latter 
procedure centromeric regions and regions containing constitutive heterochromatin 
can specifically be identified. The resolution of these procedures, however, is limited by 
that of light microscopy. In addition, they require tissue culture, which is laborious and 
time consuming. Examples of GTG-based TK and C-banding are shown in Figure 1.
1.2  Measurement of biomarkers in amniotic fluid
The amniotic fluid surrounds the foetus and consists for 98% of water and metabolic 
products (i.e., proteins, salts, glucose, uric acid) that are required for, and by-products of, 
reproductive biological processes. The AF is in direct contact with the foetal oropharynx, 
lungs, gastrointestinal tract, skin, and urinary system and is the only body fluid that 
derives from multiple tissues (Slonim et al., 2009). The chemical composition of its 
substances varies with gestational age. Within certain limits, AF mirrors the metabolic 
status of the foetoplacental unit and, for that reason, measurement of its components 
and their respective variations in different weeks of pregnancy can provide useful 
information on the status of the foetus (Modena and Fieni, 2004).
In 1972, a relationship between abnormally high α-foetoprotein (AFP) levels in AF and 
open neural tube defects (NTDs) was established (Brock and Sutcliff, 1972). AFP is a 
protein specific to foetal life and is synthesized in both the foetal liver and the yolk sac. 
Due to foetal immaturity, AFP is filtered through the glomeruli and, subsequently, shed 
into the foetal urine. From here, AFP reaches the AF in which it is present in milligrams 
per litre. A peak in AFP level is found around 12 weeks of gestation, after which it steadily 
decreases by an average of 10% per week during the second trimester. Even though AFP 
was considered to be the ‘gold standard’ biomarker for NTDs, elevated AFP levels in AF 
can also be encountered in several other AFP-related foetal disorders. Due to this limited 
specificity, for several years a biochemical diagnosis of NTD has been based on the 
additional assessment of AF-derived cholinesterases (Wald et al., 1989). 
In recent years, it has become clear that deficiencies of intermediary metabolites can affect 
the overall activity of a specific biochemical pathway, and that this may result in an altered 
transport of metabolites within or outside the cell. Lysosomal storage disorders are known 
to result from such an inborn error of metabolism and cultured and uncultured AF cells have 
been used to detect deficiencies in the activity of e.g. lysosomal enzymes (Nadler, 1968). 
than those obtained after amniocentesis. A chorionic villus sample (CVS) can be retrieved 
via two alternative ways, i.e., transcervical or transabdominal. Both are performed in the 
10th-11th week of gestation under careful ultrasound guidance to prevent adverse effects. 
In comparison with amniocentesis, a slightly higher risk of pregnancy loss (0.7%) has 
been reported for CVS (Mujezinovic and Alfirevic, 2007). In 1973, the first foetal karyotype 
from a transcervical placental biopsy was reported (Kullander and Sandahl, 1973). During 
the past decades, twice as many pregnant women have undergone amniocentesis as 
compared to chorionic villus sampling in the Dutch population (WPDT, 2005), which 
conforms to the international situation (Martin et al., 2002). 
Traditional karyotyping of amniotic fluid cells
For TK, amniotic fluid (~20 ml) samples are cultured to obtain mitotic cells. After 6-8 days, 
an average number of nine colonies (representing different clones) per culture chamber 
is obtained. Subsequently, the cultures are harvested and processed for TK, resulting in 
a final reporting time of 14-21 days. To minimise the risk of contamination, or culture loss 
due to incubator failure, duplicate cultures are handled separately and two separate cell 
culture media are used. Examination of 10 metaphases from 10 different colonies results 
in an exclusion of a chromosomal mosaicism (see below) of 26% at a 95% confidence 
interval or more (Hook, 1977). 
Traditional karyotyping of chorionic villus samples
Before a chorionic villus sample can be cultured for prenatal diagnosis, the maternal 
decidua must be removed in order to prevent maternal cell contamination (MCC). The 
diagnostic accuracy obtained from this extra-embryonic tissue may be hampered by 
MCC and/or the presence of a genetic mosaicism in the placenta. TK is routinely 
performed on short-term culture (STC) and long-term culture (LTC) villi preparations to 
reduce the incidence of false-positive and false-negative findings, respectively. Together, 
these procedures result in a final reporting time of less than 10 days. In about 1-2% of the 
CVS, a chromosomal mosaicism is encountered. This may be due to a postzygotic 
nondisjunction event generating a trisomic cell line in an initially normal conceptus 
(mitotic origin) or to a postzygotic loss of one chromosome in an initially trisomic 
conceptus (meiotic origin and trisomy rescue). Depending on the distribution of the 
abnormal cell line, the mosaicism may either be confined to the placenta (CPM) or 
generalised to the foetus (TFM, true foetal mosaicism) with a possible risk of foetal 
uniparental disomy (UPD) (Hahnemann and Vejerslev, 1997).
Traditional karyotyping of AF or CVS has been the ‘gold standard’ for invasive prenatal 
diagnostic testing for nearly half a century. Both invasive test procedures allow the 
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1.3  Advances in ultrasound examination
During the last few decades, the use of ultrasonography for the detection of foetal 
abnormalities has become widespread in many industrialised countries. This has resulted 
in a shift in timing of the diagnosis of congenital abnormalities in infants from the 
neonatal period to the prenatal period. As equipment is improving, and as experience is 
growing, more precise diagnoses are obtained. These novel possibilities to examine the 
foetus and to concomitantly detect foetal anomalies has changed the daily practice of 
obstetrics and neonatology.
First trimester nuchal translucency measurement
The role of first trimester nuchal translucency (NT) measurement as a screening test for 
Down syndrome (DS) was first discovered in 1990 (Szabo and Gellen, 1990). Subsequently, 
NT measurement by ultrasound scan (US) at 10 to 14 weeks of gestation has been 
established as a screening test for the putative presence of foetal chromosomal 
anomalies in many prenatal centres (Snijders et al., 1998). The aim of this screening test 
is to preselect a high-risk group for invasive testing. Increased NT thickness, which is 
caused by the subcutaneous accumulation of fluid in the neck of the foetus, is a 
characteristic US finding in cases with trisomy 21, 18 and 13 and/or certain other 
chromosome abnormalities. However, even in the absence of aneuploidy, NT thickening 
is clinically relevant because it is associated with an increase in adverse perinatal 
outcome, which may be caused by a variety of malformations, dysplasias, deformations, 
disruptions and/or genetic syndromes (Souka et al., 2005). In addition, extensive studies 
have revealed strong associations between cardiac defects and increased NT thickness 
(Hyett et al., 1996; Bilardo et al., 1998). 
Second trimester ultrasound scan
The routine second trimester US, also named the 20-week anomaly scan or the foetal 
anomaly scan, was initially developed for the detection of NTDs and for ruling out other 
structural abnormalities. Nowadays, however, the second trimester scan has been 
implemented in national screening programs and has become an integral part of 
prenatal care. The optimal period for this scan lies between 18 and 21 weeks. When a 
foetal anomaly is detected, there are several options for subsequent obstetric 
management. In case an invasive procedure is initiated, laboratory test results should 
become rapidly available for clinical and parental decision-making (the Dutch law 
prohibits termination of a pregnancy at a gestational age of 24 weeks or beyond).
A side-effect of obstetric ultrasound scanning is the detection of so called soft markers. 
These soft markers are of interest since they may be related to foetal congenital 
There has been an increased recognition that hydrops foetalis (HF) may represent an extreme 
presentation of a lysosomal storage disorder (Stone and Sidransky, 1999). In such cases, a 
combined approach for prenatal diagnosis involving biochemical, molecular genetic and 
morphological studies is recommended (Lake et al., 1998). Awareness of lysosomal storage 
disorders causing HF is useful as it provides an opportunity for risk evaluation, genetic 
counselling and targeted prenatal diagnostics for ensuing pregnancies.
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Figure 1. 
(A) GTG banded karyotype. One chromosome 9 homolog exhibiting an enlarged hetero-
chromatic region is marked by an arrow. (B) Metaphase spread from the same sample again 
showing a chromosome 9 homolog (arrow) with an enlarged heterochromatic region.  
(C) C-banding confirming the heterochromatic nature of the enlarged region of one of the 
chromosome 9 homologs (arrow). Together, these analyses result in a 46,XY,9qh+ karyotype.
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1.5  Clinical aspects of chromosomal imbalances
Aneuploidy reflects a change in chromosome number which, concomitantly, results in 
an alteration of the normal amount of genes within a cell. An estimated 10-30% of 
fertilized human eggs exhibits aneuploidies, most of them being either trisomic or 
monosomic (Hassold and Hunt, 2001). Recently, a study of Vanneste et al. showed 
chromosomal aberrations in 90% of cleavage stage embryos by genome-wide microarray 
analysis of a single cell blastomere obtained from embryos for pre-implementation 
genetic diagnosis combined with aneuploidy screening. Compared to in vivo fertilized 
human eggs, these aberrations appeared to be mitotic of origin and, therefore, not 
representative for the genome of all cells of the embryo (Vanneste et al., 2009).
Approximately one-third of all miscarriages are aneuploid, which makes it the leading 
cause of pregnancy loss. Among the conceptions that survive to term, aneuploidy is the 
leading cause of developmental disability and mental retardation. Foetal aneuploidies 
arise mostly as a result of chromosomal nondisjunction during oogenesis or 
spermatogenesis during the first meiotic division. In the oocyte (>70% of all cases) this 
process is responsible for 93% of trisomies 18, 95% of trisomies 21 and 100% of trisomies 
anomalies, in particular those associated with aneuploidy. The detection of only one soft 
marker is not considered to be diagnostic. When two or more such markers are detected, 
however, TK should be offered (Loughna, 2009). Soft markers may create uncertainties 
for pregnant women and their care providers (Grijseels et al., 2008). Upon testing 
women’s perception and knowledge on the 20-week anomaly scan, it was found that 
95% correctly thought that its purpose was to check for structural abnormalities in the 
foetus. However, a concomitant awareness on the existence of soft markers was low, i.e., 
92% of the women indicated that they had never heard of it (Basama et al., 2004).
1.4  Implementation of a national prenatal screening program
From January 2007 on, all pregnant women in the Netherlands are offered information 
about first trimester screening (FTS) for DS by a combination test and a second trimester 
foetal US, originally designed for the detection of NTDs (see above). This FTS has the aim 
to inform pregnant women and their partners on the possible presence of DS in their 
unborn child. The combination test for DS is composed of three elements: i) assessment 
of the serum concentration of pregnancy-associated plasma protein A (PAPP-A) and the 
free ß subunit of human chorion gonadotrophin (fβ-hCG) between 8 and 14 weeks of 
gestation, ii) ultrasound NT measurement between 10 and 14 weeks of gestation, and iii) 
maternal age (Spencer et al., 1999; Wapner et al., 2003). In eight international studies, 
including a total of 77,000 women and 433 DS cases, an overall detection rate of 91% and 
a false-positive rate of 6.7% were reported, respectively (Cuckle, 2006). In the Netherlands, 
a screening-derived risk estimate of ≥1 in 200 (i.e., odds for an infant with trisomy 21 
born alive at term) is used as an objective criterion for classifying women at ‘high-risk’. 
Subsequently, invasive testing for foetal karyotyping is offered. In case the foetus is 
diagnosed with trisomy 21, the prospective parents have the possibility to choose for 
the birth of a child with DS or for a termination of the pregnancy. The implementation of 
DS screening results in fewer invasive procedures and, hence, in a decrease in the 
number of iatrogenic miscarriages. Therefore, it is a more effective method to identify 
women at risk for carrying a DS foetus than maternal age alone (Bornstein et al., 2008). 
Figure 2 provides an overview of the participation of pregnant women for FTS in relation 
to the number of invasive prenatal tests in the Netherlands. This overview shows an 
impressive increase in the number of women applying for the FTS test from 2,251 in 
2002 to 41,699 (23% of all pregnant women) in 2007 (Wortelboer et al., 2009), the year of 
national implementation. The number of pregnancies in which invasive prenatal 
diagnoses were carried out was 9,552 in 2005 (WPDT, 2005) of which 76% had an 
increased risk for DS. 
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Figure 2. 
Overview of the participation of pregnant women in first trimester screening and invasive 
testing in the period 2000-2007.
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Although DS is mostly associated with an impairment of cognitive abilities and physical 
growth, as well as with a typical facial appearance, it is estimated to be associated with 
approximately 80 distinct phenotypes (Vacik et al., 2005). These phenotypes include, 
next to cognitive impairment, craniofacial dysmorphologies, congenital heart defects, 
gastrointestinal tract abnormalities, acute megakaryoblastic leukemia, immunologic 
defects, endocrine abnormalities, neuropathology leading to dementia, and dysmorphic 
physical features. Although preliminary attempts have been made to genetically assign 
these phenotypes, their exact susceptibility still remains to be explored. 
Edwards syndrome (trisomy 18)
Edwards syndrome is a genetic disorder caused by the presence of an extra chromosome 
18 or a part thereof. It is named after John H. Edwards, who first described the syndrome 
in 1960 (Edwards et al., 1960). It is the most common autosomal trisomy after DS that 
carries to term and affects 1 in 6,000 live born infants. An estimated 60% of trisomy 18 
cases is associated with maternal meiosis II nondisjunction events (Bugge et al., 1998). 
The overall survival rate of Edwards syndrome is low. About 95% of the infants die in 
utero. Of the resulting live born infants, survival statistics indicate that the first year 
mortality rates range from 90% to 100%. The vast majority of these infants die during the 
first neonatal month (Rasmussen et al., 2003). Those who do live beyond the first year 
experience shortened lives marked by severe neurological and physical impairments. 
The major causes of death include respiratory arrest and heart abnormalities. It is 
impossible to predict the exact prognosis of an Edwards syndrome child during 
pregnancy and/or its neonatal period. Because major medical interventions are routinely 
withheld from these children, it remains difficult to assess what the survival rate or 
prognosis would have been with aggressive medical treatment. One percent of children 
born with this syndrome lives to an age of ten years, typically in cases with a less severe 
mosaic pattern.
In Edwards syndrome two non-contiguous regions encompassing 18q12.3-q22.1 are 
thought to be associated with severe mental retardation (Boghosian-Sell et al., 1994). In 
addition, it has been suggested that a decreased cholesterol synthesis may act as an 
aetiological factor in the occurrence of Edwards syndrome-associated malformations 
(Lam et al., 2003). 
Patau syndrome (trisomy 13)
Patau syndrome is a genetic disorder caused by the presence of an extra chromosome 
13 or a part thereof. This syndrome and its cause were first described by Klaus Patau in 
1960 (Patau et al., 1960). The presence of trisomy 13 results in developmental anomalies 
which are characteristic of Patau syndrome. In approximately 90% of the cases the extra 
16 (Hassold, 1996). A full understanding of the molecular mechanisms underlying meiotic 
nondisjunction has so far remained elusive. Critical steps in oogenesis occur during 
three distinct developmental stages: i) meiotic initiation in the foetal ovary, ii) follicle 
formation in the perinatal period, and iii) oocyte growth and maturation in the adult. 
Studies in both humans and mice suggest that the genetic quality of the egg may be 
affected during either one of these three stages (Hunt and Hassold, 2008). However, 
additional studies on these processes are required in order to gain a better understanding 
of the occurrence of aneuploidy in human genetic disorders.
1.5.1  Most common chromosomal aneuploidies 
Down syndrome (trisomy 21)
Down syndrome (DS) is associated with the most common form of aneuploidy and 
involves the presence of a complete or partial extra copy of chromosome 21. It is named 
after John Langdon Down, who first described the syndrome in 1866. Subsequently, the 
underlying genetic cause was resolved through the identification of a chromosome 21 
trisomy by Jérôme Lejeune in 1959. The first prenatal diagnosis of DS by means of 
amniocentesis was reported in 1968 (Valenti et al., 1968). The presence of three free 
copies of chromosome 21 is encountered in approximately 95% of DS cases. In 4% of the 
cases a chromosome 21 translocation, and in 1% of the cases a chromosome 21 
mosaicism, is observed (Mutton et al., 1996). Several studies have provided evidence that 
in 72% of the cases chromosomal nondisjunction occurred during maternal meiosis I 
and in 21% of the cases during maternal meiosis II, i.e., around conception (Peterson et 
al., 1992; Yoon et al., 1996). In addition, Antonarakis disclosed that in 2.7% of the cases 
nondisjunction occurred during paternal meiosis I and in 4.3% of the cases during 
paternal meiosis II (Antonarakis, 1998).
Worldwide, the overall prevalence of DS is 10 in 10,000. In countries in which abortion is 
illegal, such as Ireland (Dolk et al., 2005) and the United Arab Emirates (Murthy et al., 
2007) prevalence is higher, varying from 17 to 31 per 10,000. Conversely, the prevalence 
in France is relatively low (7.5 per 10,000), which is probably due to a high percentage 
(77%) of DS pregnancy terminations. A recent Dutch national study reported a DS live 
birth prevalence of 16 in 10,000 (Weijerman et al., 2008).
The life expectancy of children with DS continues to improve. The current five year 
survival rate is 90% (Halliday et al., 2009) and the overall life expectancy is ~60 years 
(Morad et al., 2009). Due to this improved life expectancy and the stable or even slightly 
increasing world-wide prevalence of DS, its total population is expected to grow 
substantially (Weijerman et al., 2008). 
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hypogonadism, gynaecomastia or infertility (Lanfranco et al., 2004). In infancy, 47,XXY 
males may undergo a chromosomal evaluation due to the presence of hypospadias, a 
small phallus, cryptorchidism and/or developmental delay. School-aged 47,XXY children 
may present with language delay, learning disabilities or behavioural problems. 
Androgen replacement therapy should begin at puberty, around the age of 12 years, in 
increasing dosage sufficient to maintain age-related serum concentrations of 
testosterone, estradiol, follicle stimulating hormone and luteinizing hormone (Visootsak 
and Graham, Jr., 2006). 
The information that parents across Europe receive after a prenatal diagnosis of Klinefelter 
syndrome has been made varies with the specialty and country-of-origin of the health 
professional consulted and his/her perception of a quality of life with that condition. This 
variation seems to reflect both personal, cultural and professional differences (Hall et al., 
2001).
Triple X syndrome
About 1 in 1,000 females has an extra X chromosome, a condition referred to as triple X 
syndrome (Jacobs, 1979). In 1959, Jacobs described the first 47,XXX case (Jacobs et al., 
1959). Triple X syndrome often remains undiagnosed. Affected girls tend to be tall with 
particularly long legs. The behavioural phenotype often includes abnormal auditory 
processing, distorted language development and problems in forming stable 
interpersonal relationships. Also psychiatric disorders seem to be relatively common in 
triple X syndrome patients (Otter et al., 2009). Prenatal cases of triple X syndrome do not 
show ultrasound abnormalities and, thus, are mostly diagnosed incidentally through 
cytogenetic analysis for another reason. 
XYY syndrome
Males with an additional Y chromosome (47,XYY) exhibit physical and behavioural 
features that may result from an increased Y chromosomal gene dosage (Park et al., 
2008). About 1 in 1,000 males is born with one or more extra Y chromosomes. Affected 
males are sometimes taller than average, but show a normal sexual development and, 
usually, a normal fertility. Most of them have a normal intelligence, though some may 
have learning disabilities, speech/language problems and/or behavioural problems. As 
with triple X females, most affected males are unaware of the presence of a chromosomal 
abnormality unless it was incidentally diagnosed during e.g. prenatal testing.
The clinical information presented to prospective parents has changed considerably 
over time. The first information, introduced in the 1960s, was based on case reports and 
studies performed in mental and penal institutions. In 1968 the 47,XYY condition was 
linked to criminal behaviour (Jacobs et al., 1968). This link, which was based on an 
chromosome 13 is maternal in origin, with an almost equal distribution between 
causative meiosis I and II nondisjunctional events (Bugge et al., 1998).
Patau syndrome affects approximately 1 in 5,000 live births. Like all nondisjunction- 
related disorders, its risk increases with maternal age. Most embryos with trisomy 13 die 
in utero thus resulting in spontaneous abortions. After live birth, 85% of the infants die 
during the first month and 90% do not survive longer than one year. Severe malformations 
of the central nervous system are the major cause of this high mortality rate. Infants that 
survive over one year often suffer from long term neurological disabilities, feeding 
difficulties and respiratory infections such as pneumonia. As yet, little is known about 
putative genotype-phenotype correlations in Patau syndrome.
1.5.2  Sex chromosomal aneuploidies 
In the past, the prenatal detection of sex chromosome aneuploidies (SCA) has been 
increasing due to the widespread use of amniocentesis and CVS (Brun et al., 2004). Such 
a finding is usually the unexpected by-product of a test carried out for another purpose, 
especially for advanced maternal age or an increased estimated risk resulting from a 
screening test. Most SCA cases are compatible with a normal life expectancy and often 
go undiagnosed (Abramsky and Chapple, 1997). It has been estimated that SCA may be 
present in about 0.26% of live births (Jacobs,1979). These SCAs include 45,X (Turner 
syndrome), 47,XXY (Klinefelter syndrome), 47,XXX, 47,XYY, and mosaics and/or structural 
variants of the sex chromosomes. Genetic counselling of parents faced with a SCA 
diagnosis is often challenging because of i) the genotypic variability within these 
syndromes and ii) the uncertain prognosis due to phenotypic variability (Verp et al., 
1988; Sagi et al., 2001). 
Klinefelter syndrome
Klinefelter syndrome was first described in 1942 as an endocrine disorder characterised 
by small firm testes, gynaecomastia, hypogonadism, and higher than normal 
concentrations of follicle-stimulating hormone (FSH) (Klinefelter et al., 1942). With a 
reported prevalence of 0.1 to 0.2% in the general population and of up to 3.1% in the 
infertile male population (Ekerhovd and Westlander, 2002), the syndrome is the most 
common form of male hypogonadism and concomitant chromosome aneuploidy in 
human beings. Approximately 64% of the patients with Klinefelter syndrome remain 
undiagnosed, whereas 10% is diagnosed prenatally, and 26% is diagnosed during 
childhood or adult life (Abramsky and  Chapple, 1997). The commonest clinical indication 
for a male to be karyotyped suspect for Klinefelter syndrome is the presence of 
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1.5.3  Other chromosomal abnormalities
Marker chromosomes
Small supernumerary marker chromosomes (sSMCs) are defined as structurally abnormal 
chromosomes that cannot be identified or characterized unambiguously by TK alone. 
They are generally equal in size or smaller than chromosome 20 (Liehr et al., 2004). Most 
sSMCs have been identified postnatally in individuals with congenital malformations 
and/or mental retardation. This ascertainment bias hampers a reliable estimation of 
geno type-phenotype correlations. The risk for abnormal phenotypes in prenatally 
ascertained de novo cases has been estimated to be 7% for sSMCs derived from 
chromosomes 13, 14, 21 or 22 and 28% for sSMCs derived from all non-acrocentric 
autosomes, respectively (Crolla, 1998). In addition, this risk has recently been estimated 
to be 30% for all sSMC carriers (Liehr and Weise, 2007). In spite of these estimations, in 
approximately 30-50% of prenatally detected sSMC cases the pregnancy is terminated. 
These pregnancies may include healthy children (Liehr et al., 2009). The application of 
novel molecular cytogenetic techniques (see below) may provide a better prenatal test 
for these sSMCs and, thus, allow the establishment of more accurate sSMC/phenotype 
correlations.
Triploidy
Triploidy commonly occurs during human gestation and is observed in 2-3% of 
pregnancies. This anomaly often culminates in an early spontaneous abortion, but 
occasionally it persists throughout the foetal period, resulting in the birth of an affected 
infant. Gestations with a 69,XYY karyotype are less frequently encountered than those 
with a 69,XXX or 69,XXY karyotype. This latter phenomenon is as yet not well understood 
and, therefore, requires further investigation. In spite of the fact that in almost all clinically 
recognized cases significant developmental abnormalities have been detected using 
US, this latter method does not allow a reliable distinction between cases with a 69,XXY 
or 69,XXX karyotype (McWeeney et al., 2009). 
Triploidy may be the result of either digyny (extra haploid set from mother) or diandry 
(extra haploid set from father). Digynic triploidy predominates in foetuses, whereas 
diandry accounts for 50-60% of early triploid spontaneous abortions (McFadden et al., 
1993; Redline et al., 1998; McFadden and Langlois, 2000). Two distinct phenotypes 
observed in triploid foetuses have been shown to be associated with this parental origin: 
i) the diandric phenotype is characterized by a normally sized or mildly growth retarded 
foetus with normal adrenal glands, and is associated with an abnormally large cystic 
placenta with histological features known as partial hydatidiform mole, ii) the digynic 
phenotype is characterized by an asymmetric intrauterine growth restriction, marked 
ascertainment bias, resulted in the stereotype ‘supermales’ with a tendency to criminal 
behaviour (Bender et al., 1987). The ascertainment bias of these early investigations was 
avoided in subsequent longitudinal studies. As a consequence, more positive and 
accurate information has become available to prospective parents faced with a prenatal 
diagnosis of 47,XYY.
Turner syndrome
Turner syndrome (TS) is caused by the absence of all or part of one X chromosome. It is 
a common cause of early pregnancy loss and accounts for about 7% of spontaneous 
abortions. Based on a live born frequency of 1-2 in 10,000, it is estimated that less than 
1% of 45,X conceptuses survive to term (Chu et al., 1995). 
About 30% of all individuals with TS are mosaics, with both a 45,X cell line and either a 
46,XX cell line or a cell line containing a rearranged X chromosome (Hook and Warburton, 
1983). Mosaic individuals (observed in AF or peripheral blood) will on average have a 
milder phenotype than those with a 100% 45,X constitution (Baena et al., 2004). TK 
revealed the presence of a Y chromosome mosaicism in about 5% of individuals with TS. 
Such a mosaicism represents a risk factor for the development of gonadoblastoma. 
Therefore, molecular screening for the presence of cryptic Y chromosomal sequences in 
TS individuals, who are negative for a Y chromosome by TK, is recommended in order to 
estimate the future risk for developing gonadoblastoma (Sallai et al., 2009). Molecular 
studies have shown that the remaining X chromosome is of maternal origin in 60 to 80% 
of the cases (Uematsu et al., 2002). 
TS may present with a broad spectrum of phenotypic features, ranging from major heart 
defects to mild cosmetic issues. Almost all affected individuals with TS have a short 
stature and exhibit ovarian failure (Elsheikh et al., 1999). 
There is an association between foetal nuchal cystic hygroma and TS (Azar et al., 1991; 
Nicolaides et al., 1992). Often other characteristic anomalies such as aortic arch hypoplasia, 
short femurs, and renal anomalies are present, which can already be seen at 14 to 16 
weeks of gestation (Bronshtein et al., 2003; Papp et al., 2006). When 45,X or another 
karyotype known to lead to TS is encountered in the foetus, the prospective parents are 
faced with the difficult question of whether or not to continue the pregnancy. Genetic 
counselling of parents usually includes a detailed discussion of the variability of somatic 
abnormalities and the high likelihood of short stature and ovarian failure. The prognoses 
of 45,X and 45,X mosaicism are different. In addition, the identification of a low level 
mosaicism is highly relevant for providing accurate prenatal counselling to the parents 
(Baena et al., 2004).
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lineages (Norwitz et al., 2001). The simplest scenario for the occurrence of a mosaicism is 
a normal conception with an abnormal cell line that arises after blastocyst formation. If 
it arises in the ‘foetal cells’ the foetus will be affected. If it arises in the ‘extra-embryonic’ 
cells the foetus will not be affected. 
When after traditional karyotyping of a chorionic villus sample (CVS) a low-level of 
mosaicism is observed, the questions arises as to whether it represents the foetal or the 
extra-embryonic tissue (Wallerstein et al., 2000).
Several studies have indicated the strength of CVS analysis when a combination of 
‘semi-direct’ preparations (short-term cultured villi; STC-villi) and long-term cultured 
preparations (LTC-villi) are used to reduce the incidence of false-negative findings for the 
detection of chromosomal aberrations (Pittalis et al., 1994; Hahnemann and Vejerslev, 
1997; van den Berg et al., 2000; van den Berg et al., 2006). Grati et al. reported 273 cases 
of mosaicism in a consecutive series of 15,109 STC and LTC analyses (Grati et al., 2006). 
They found that the mosaicisms were confined to the placenta in 87.2% of the cases: 
39.9% type I (confined to the trophoblast), 40.4% type II (confined to the mesenchyme) 
and 6.9% type III (mosaicisms in both tissues). In the remaining 12.8% the presence of the 
chromosomal abnormality was also encountered in foetal amniocytes. The phenotypic 
effect of a mosaicism is thought to depend on the nature of the anomaly and the cell 
type in which it occurs, and inversely correlates with the percentage of cells that are 
euploid (Youssoufian and Pyeritz, 2002). 
Chromosomal mosaicisms frequently occur in human foetuses and are known to underlie 
25% of spontaneous abortions (Vorsanova et al., 2005). Although chromosomal 
mosaicisms are thought to be confined to specific tissues, it has recently been found 
that almost all somatic tissues, if thoroughly analyzed, may contain aneuploid cells 
(Iourov et al., 2008). The exact relevance of these aneuploid cells is as yet unclear and 
requires further investigations. Such investigations are expected to lead to new insights 
into the pathobiology of human diseases and the role of intercellular genomic variation 
therein.
1.5.4  Structural chromosomal abnormalities
Structural chromosomal abnormalities are considered balanced if there is no gain or loss 
of chromosomal material, and unbalanced if there is gain or loss. In general, balanced 
abnormalities do not elicit phenotypic effects. There are, however, important exceptions: 
a gene may be disrupted or a chromosomal break may affect the expression of a 
neighbouring gene by separating it from a control element and/or by inducing local 
chromatin alterations. 
adrenal hypoplasia, and a very small non-molar placenta (McFadden et al., 1993; 
McFadden and Langlois, 2000).
While triploid foetuses may exhibit a wide variety of congenital anomalies such as 
complete syndactyly of the third and fourth fingers, syndactyly of the toes, abnormal 
genitals and cardiac, urinary tract and brain anomalies, these features do not appear to 
differ between the digynic and diandric foetuses. Also, there does not appear to be any 
difference in growth between the diandric and digynic embryos, suggesting that these 
differences develop later during gestation (McFadden and Robinson, 2006).
Early prenatal recognition of triploid pregnancies, particularly those with placental 
findings of partial hydatidiform mole, is important since these pregnant women are at 
risk of pre-eclampsia and persistent trophoblastic disease (Ngan et al., 2006). 
Chromosomal mosaicisms
A mosaicism is denoted as the occurrence of more than one genetically distinct cell line 
within an individual. In case of cytogenetic abnormalities, such a mosaicism usually reflects 
one normal and one abnormal cell line. Less frequently, multiple cell lines may be present 
and/or the occurrence of a normal cell line may not be apparent. A mosaicism arises either 
due to a clonal somatic (mitotic) error in a normal conception or, alternatively, due to a clonal 
somatic correction event in an abnormal conception. The former somatic error occurs most 
commonly and results in mosaicisms encompassing a wide range of numerical and structural 
abnormalities. The latter somatic error is predominantly related to the correction of a wide 
range of trisomies (zygote rescue). This zygote rescue mechanism may lead to uniparental 
disomy (UPD) in case both remaining foetal chromosomes are of either paternal or maternal 
origin (Kalousek and Vekemans, 2000). UPD may result in distinct abnormal phenotypes in 
case imprinted genes (i.e., genes whose expression depends on whether they are inherited 
from the mother or the father) are located on the chromosomes involved. Theoretically one 
third of the zygote rescue cases will result in UPD, but this number may very well be biased 
(Kalousek and Vekemans, 1996). 
The occurrence of mosaicisms for chromosomal anomalies, usually aneuploidies, has 
important implications for prenatal genetic counselling. The key to predicting the clinical 
significance of such mosaicisms is to understand how these error/correcting events 
affect early embryonic development. In early cleavage stage embryos all cells are 
totipotent. Approximately 5-7 days post-fertilization, however, the first major cell 
differentiation steps have taken place. At this (blastocyst) stage, the embryo has become 
a hollow sphere of trophoblast cells with a clump of cells, the inner cell mass, located 
inside this sphere. The trophoblast cells will eventually form the trophoblast layers of the 
chorionic villi. A sub-population of the inner cell mass cells will form the foetus proper, 
whereas the remaining inner cell mass cells will form all other extra-embryonic cell 
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Angelman syndrome (AS) is usually caused by deletion or inactivation of genes on the 
maternally inherited chromosome 15 (Cassidy and Schwartz, 1998). About 70% of AS 
cases result from de novo maternal deletions of 15q11-q13, about 2% from paternal 
uniparental disomy of 15q11-q13, and another 2-3% from imprinting defects. A subset of 
the remaining ~25% is caused by mutations in the gene encoding the ubiquitin-protein 
ligase E3A (Kishino et al., 1997). AS is diagnosed with a frequency of approximately 1 in 
10,000-15,000 newborns and is characterized by intellectual and developmental delay, 
sleep disturbance, seizures, jerky movements especially hand-flapping, and frequent 
laughter or smiling (Clayton-Smith and Laan, 2003). 
Miller-Dieker syndrome is associated with deletions of chromosome region 17p13.3 
(Dobyns et al., 1993) and is characterized by type I lissencephaly caused by incomplete 
neuronal migration. It occurs in about 1 in 100,000 newborns (Verloes et al., 2007). 
Phenotypic features include a characteristic facial appearance, delayed growth and 
Robertsonian translocations, which involve acrocentric chromosomes (i.e., 13, 14, 15, 21 
and 22) are among the most common structural chromosomal rearrangements found in 
humans, with an incidence of 12 in 10,000 live births (Nielsen and Wohlert, 1991). Since 
the breaks occur in the proximal short arms of the chromosomes involved, the resulting 
translocation chromosomes are dicentric. Due to the fact that the two centromeres are 
very close to each other they actually function as one, and the translocation chromosomes 
segregate normally. The acentric distal parts of the two short arms, containing stretches 
of repeated ribosomal RNA genes, are lost. Since this has no phenotypic consequences, 
Robertsonian translocations are considered as balanced.
Unbalanced abnormalities can arise directly through deletion or duplication, or indirectly 
through mis-segregation of chromosomes during meiosis in a carrier of a balanced 
abnormality. The parental origin of chromosomal abnormalities seems to depend on its 
type: while autosomal aneuploidies are mainly maternal in origin (Hassold et al., 1993), 
de novo structural aberrations are mainly paternal in origin (Hill et al., 2003). In a study of 
115 de novo unbalanced structural chromosome abnormalities (i.e., 39 terminal deletions, 
35 interstitial deletions, 8 ring chromosomes, 12 duplications and 21 unbalanced 
translocations) the majority was of paternal origin, varying from 84% for interstitial 
deletions and rings to 58% for duplications (Thomas et al., 2006). 
1.5.5  Sub-microscopic aberrations
Sub-microscopic aberrations may result from small hemizigous losses (microdeletions) 
or gains (microduplications) of DNA, ranging in size from 1 to 5 Mb. These losses and 
gains cannot be detected by TK, of which the best resolution does not surpass ~5 Mb. 
These sub-microscopic aberrations may result in specific syndromes, such as 
microdeletion syndromes, which are estimated to be among the major causes of mental 
retardation, next to Down syndrome and Fragile X syndrome (Zahir and Friedman, 2007). 
The most common microdeletion and microduplication syndromes are briefly discussed 
below and the loci and genes involved are listed in Table 1. 
Prader-Willi syndrome (PWS) is associated with a deletion of the paternal copies of the 
imprinted SNRPN gene, the necdin gene and, possibly, other genes within chromosomal 
region 15q11-q13. PWS affects approximately 1 in 10,000-15,000 newborns and is 
characterized by hypotonia, short stature, polyphagia, obesity, small hands and feet, 
hypogonadism, and mild mental retardation (Cassidy and Driscoll, 2008).
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Table 1. Common microdeletion/duplication syndromes 
Syndrome deletion (del)  or 
duplication (dup)
Locus
 
MIM Genes
Prader-Willi 
syndrome
del 15q11-q13 #176270 SNRPN gene (182279)
Necdin gene (602117)
Angelman syndrome del 15q11-q13, 
Xq28
#105830 UBE3A gene (601623)
Miller-Dieker 
syndrome
del 17p13.3 #247200 Several genes on 17p
22q11 microdeletion 
syndrome
del 22q11.2 #188400 TBX1 gene (602054)
Cri-du-Chat 
syndrome
Smith-Magenis 
syndrome
del
del
5p15.2
17p11.2
#123450
#182290
TERT gene (187270)
RAI1 gene (607642)
Williams-Beuren 
syndrome
Wolf-Hirschhorn 
syndrome
del
del
7q11.2
4p16.3
#194050
#194190
Several genes on 7q11.23
Several genes on 4p
17p11.2 
microduplication
syndrome
dup 17p11.2 #118200 MPZ gene (159440)
PMP22 gene (601097)
CX32 gene (304040)
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Distal 22q microdeletion syndrome, also named 22q13.3 microdeletion syndrome or 
Phelan-McDermid syndrome, is characterized by neonatal hypotonia, global developmental 
delay, normal to accelerated growth, absent to severely delayed speech, autistic behavior, 
and minor dysmorphic features (Precht et al., 1998). Monosomy of SHANK3, one of the 
genes included in the minimum critical region is possibly responsible for the neurologic 
deficits, i.e., developmental delay and delayed/absent speech, in this syndrome (Bonaglia 
et al., 2006). The prevalence of 22q13.3 microdeletion syndrome is unknown (Phelan, 2008). 
Paucity of significant dysmorphic features and the clinical variability observed may lead to 
under-recognition of this syndrome in the newborn period. Because of the absence of 
multiple major and/or minor anomalies, a chromosomal abnormality would usually not be 
suspected (Phelan et al., 2001). As more cases are reported and the phenotype becomes 
better delineated, associated structural anomalies that will aid in an improved recognition 
of the syndrome may become apparent (Manning et al., 2004).
Wolf-Hirschhorn syndrome (WHS) is characterized by severe growth retardation and 
mental retardation, microcephaly, ‘Greek helmet’ facies, and closure defects (cleft lip or 
palate, coloboma of the eye, and cardiac septal defects) (Hirschhorn et al., 1965; Wolf et 
al., 1965). The incidence is estimated to be 1 in 20,000-50,000 births. The disorder is 
caused by a partial deletion of the short arm of chromosome 4 (4p16.3), and is generally 
considered to be a contiguous gene syndrome. Indeed, gene(s) causing prenatal and/or 
postnatal growth retardation and microcephaly are located in the 4p16.3 region. Despite 
the broad spectrum of clinical manifestations, however, it is also thought that a single 
gene may underlie the distinct phenotypic features (Maas et al., 2008).
17p11.2 microduplication syndrome results from a mutation in the gene encoding myelin 
protein zero, first identified in Charcot-Marie-Tooth (CMT) families, and underlies one of 
the most frequent hereditary neuromuscular disorders affecting approximately 1 in 
2,500 newborns (Skre, 1974). Most cases of CMT are associated with a 1.5 Mb tandem 
duplication in 17p11.2-p12, including the PMP22 gene. Other forms of CMT are associated 
with mutations in the MPZ (CMT1B) and Cx32 (CMTX) genes. Thus, alterations in different 
genes within 17p11.2-12 can result in similar phenotypes (Murakami et al., 1996). 
1.6  Application of molecular tests
Fluorescence in situ hybridization
The implementation in the mid-1990s of rapid aneuploidy detection (RAD) in interphases 
of uncultured AF cells by fluorescence in situ hybridization (I-FISH) has enabled the 
mental development, and multiple abnormalities of the brain, heart, kidney and 
 gastrointestinal tract (Jones et al., 1980).
22q11 microdeletion syndrome is caused by hemizygous deletions of chromosome 
region 22q11.2 (Scambler, 2000; Wilson et al., 1992). Haploinsufficiency of the TBX1 gene 
appears to be responsible for most of the congenital malformations observed (Yagi et 
al., 2003). The syndrome has an estimated incidence of 1 in 4,000 live births. Phenotypic 
characteristics include mild dysmorphic facial features, learning difficulties, hypernasal 
speech and multisystem medical history, especially in the presence of a psychiatric 
illness or congenital anomalies (Kapadia and Bassett, 2008). Additionally, the microdeletion 
is associated by cardiac anomalies involving the conotruncus and includes lesions such 
as tetralogy of Fallot, pulmonary atresia and/or ventricular septal defects, and truncus 
arteriosus (Goldmuntz et al., 1998).
Cri-du-Chat syndrome patients carry a deletion of chromosome 5 region p15.3, where 
the telomerase reverse transcriptase (TERT) gene is localized (Niebuhr, 1978). Its incidence 
ranges from 1 in 15,000-50,000 live births (Cerruti, 2006). The syndrome was named after 
a characteristic cry of the affected infants, due to problems with the larynx and the 
nervous system. Furthermore, the syndrome is characterized by microcephaly, round 
face, hypertelorism, micrognathia, epicanthal folds, low-set ears, hypotonia, and severe 
psychomotor and mental retardation. 
Smith-Magenis syndrome is in most cases caused by either a 17p11.2 deletion 
encompassing the retinoic acid-induced 1 (RAI1) gene or by a mutation of the RAI1 gene 
(Smith et al., 1986). The incidence of this disorder is estimated to be 1 in 25,000 live births 
(Finucane et al., 2001). Phenotypically, Smith-Magenis syndrome represents a complex 
disorder characterized by variable levels of mental retardation, sleep disturbance, 
craniofacial and skeletal anomalies, self-injurious and attention-seeking behaviors, and 
speech and motor delay (Elsea and Girirajan, 2008). 
Williams-Beuren syndrome is in the majority of patients associated with a deletion that 
encompasses ~1.5 Mb on chromosome 7q11.2, containing 25-30 genes (Peoples et al., 
2000). The estimated prevalence of the disorder is 1 in 7,500-25,000 newborns, most 
cases being sporadic (Stromme et al., 2002). Williams-Beuren syndrome is a neurodevel-
opmental and multisystemic disorder characterized by mental retardation and multiple 
dysmorphic and metabolic features (Osborne, 1999).
General introduction and outline of this thesis Chapter 1 1
34 35
(Adinolfi et al., 1997; Pertl et al., 1999). The clinical utility of this assay has repeatedly been 
confirmed together with its high sensitivity and specificity (Schmidt et al., 2000; Cirigliano 
et al., 2001; Mann et al., 2001). One of the main advantages of QF-PCR over FISH is the 
possibility to automate part of the procedure, which allows a high throughput of samples 
at a low cost (Cirigliano et al., 2001; Hulten et al., 2003). An example of QF-PCR is shown 
in Figure 4.
QF-PCR analysis involves the amplification, detection and analysis of highly polymorphic 
chromosome-specific short tandem repeats (STRs). Fluorescently labelled marker-specific 
primers are used for PCR amplification and the resulting copy numbers of the markers 
reflect the original copy number of the corresponding chromosome. The PCR products 
can be analyzed and quantified using an automated genetic analyzer. STRs may vary in 
detection of aneuploidies of chromosomes 13, 18, 21, X and Y within 48 hours. The initial 
reason for applying FISH to prenatal testing was its speed (Ward et al., 1993; Divane et al., 
1994) and it has predominantly been applied to pregnancies with an ultrasound 
abnormality. Next to its speed, FISH could overcome some of the other limitations of 
light microscopy such as its relatively low resolution. Therefore, FISH has challenged the 
role of TK. Additional new FISH applications include:
I. The composition of rearranged chromosomes can be identified by using whole 
chromosome painting probes, WCP-FISH (Schrock et al., 1996), multicolor spectral 
karyotyping, SKY (Nietzel et al., 2001) or probes encompassing terminal chromosome 
regions for the detection of subtle sub-telomeric chromosomal rearrangements 
(Souter et al., 2003).
II. The characterization of marker chromosomes can be performed by chromosome 
microdissection in conjunction with FISH Reverse painting with a probe generated 
by chromosome microdissection of the marker chromosome onto a metaphase 
spread from a healthy person enables the identification of the chromosomal origin 
of the marker (Engelen et al., 1996; de Pater et al., 2006). 
III. Targeted diagnosis of several common chromosomal microdeletion syndromes, 
such as the most common 22q11 deletion syndrome, can be performed with 
locus-specific probes. A microdeletion probe set can be used as an adjunct to 
routine prenatal diagnosis for the detection of additional conditions that are known 
to cause mental retardation and/or birth defects and that escape detection by TK. 
FISH examples are shown in Figure 3.
Quantitative fluorescent PCR
A main limitation of FISH is its unsuitability for automation. In addition, the technique is 
labour-intensive. During the past 10 years, quantitative fluorescent PCR (QF-PCR) has 
been introduced as an alternative for RAD of the chromosomes 13, 18, 21, X and Y 
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Figure 3. 
Examples of FISH on interphase (A) and metaphases (B,C and D). FISH probes can be classified into 
centromere-specific (A), locus-specific  (B), chromosome-specific (C), or telomere-specific (D). 
A B C D
Figure 4. 
Genotyper profile of a male trisomy 21 sample obtained after QF-PCR and subsequent 
processing using a genetic analyzer. One marker (D21S1414) on chromosome 21 shows a 
trisomic tri-allelic pattern (1:1:1), two markers (D21S1411 and D21S1446) show 2:1 ratios and one 
marker (D21S1435) shows a homozygous (non-informative) pattern. Both the X- and Y-specific 
products (AMXY) are present in a normal 1:1 ratio, together with the SRY-specific product. The 
XY male chromosome constitution is also evident from the normal heterozygous pattern of 
both pseudo-autosomal markers (X22 and DXYS218) and the single product obtained from the 
X-linked HPRT locus.
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Microarray-based genomic profiling
Methods such as FISH, QF-PCR and MLPA are difficult to scale up to a genome-wide level. 
In contrast, recently developed microarray-based methods such as array CGH allow a 
genome-wide assessment of genomic copy number anomalies, i.e., microdeletions and/
or microduplications. Microarray analysis has the potential to be used for prenatal 
diagnosis and may address many of the limitations of both TK and the above mentioned 
molecular cytogenetic methods. The question, however, has been raised whether to use 
length between individual chromosomes and subjects, depending on the number of 
repeated sequences present. The relative copy number of each allele is determined by 
calculating the ratio of the peak areas or peak heights measured for each marker. A 
normal diploid sample has two alleles of a chromosome-specific marker, detected as 
two peaks in a 1:1 ratio when the marker is heterozygous, and as one peak when the 
marker is homozygous. The detection of an additional allele as three peaks in a 1:1:1 ratio 
or as two peaks in a 2:1 or a 1:2 ratio is indicative for the presence of an additional copy 
of the corresponding chromosome, as in case of a trisomy. 
An additional advantage of this genotyping technique is the ability to detect maternal 
cell contamination (MCC) through the presence of extra allele peaks or inconsistent 
dosage ratios for each chromosome. It should be noted, however, that such a pattern 
may also be indicative for the presence of a twin or a chimera. Using QF-PCR, MCC rates 
of 3.1% for CVS (Craig et al., 1989; Antoniadi et al., 2002) and 0.7% for AF have been 
reported (Liao et al., 2009). Another advantage of the QF-PCR technique is its capacity to 
distinguish trisomy errors originating from nondisjunction events in meiosis I or meiosis 
II, or to identify the parental origin of an allele. This is for example relevant for the 
diagnosis of hydatidiform mole pregnancies. A recently diagnosed sample of a mole 
pregnancy in our clinic e.g. revealed a 46,XX karyotype. QF-PCR analysis revealed 
homozygosity for all markers tested. Subsequent QF-PCR analysis of parental blood cells 
showed that the mole was of complete paternal origin. Therefore, the mole appeared to 
be derived from an anuclear empty ovum that was fertilized by a haploid (23,X) sperm, 
which then replicated its own chromosomes (Kooper et al., unpublished results).
Multiplex Ligation-dependent Probe Amplification
An alternative test for RAD is Multiplex Ligation-dependent Probe Amplification (MLPA), 
a PCR-based technique that enables robust quantification of up to 40 sequences in a 
single test (Schouten et al., 2002) locus one pair of probes is used, designed in such a 
way that they hybridize adjacent to each other on one DNA target sequence. MLPA kit 
P095 contains probes for eight target sequences on each of the chromosomes 13, 18, 21 
and X and four for the Y chromosome. These target-specific probes also contain a 
universal forward or reverse PCR primer-binding site. In between these, one of the 
probes contains a so-called stuffer sequence, varying in length from 130 to 490 base 
pairs (bp). This length is specific for each target sequence. After hybridization, the probes 
are ligated and PCR is performed using a universal fluorescent-labeled primer pair. The 
relative amount of each PCR product is proportional to the amount of the target 
sequence present in the test sample. The differently sized amplification products are 
separated by capillary electrophoresis. An MLPA example is shown in Figure 5. 
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Figure 5. 
Detection of trisomy 18 by MLPA. Capillary electrophoresis patterns from a normal female 
sample (upper panel) and a female sample with a trisomy 18 (lower panel) analysed with kit 
P095 are shown. The P095 probe-mix contains 36 different markers with amplification products 
ranging in size from 136 to 454 bp. Four of the probes will only generate a signal on male DNA 
samples (i.e., Y chromosome-specific). Every set of four peaks represents markers on 
chromosome 21, 18, 13 and X, respectively. The arrows mark the alterations: an increase of the 
fluorescent signals for 18m1-18m8 in the trisomy 18 sample relative to the same markers in the 
normal sample. 
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second trimester foetal anomaly scan. In Chapter 3 we describe a targeted strategy to 
diagnose lysosomal storage diseases in hydrops foetalis pregnancies. In Chapters 4 and 
5 we describe the implementation and performance of a novel MLPA test for rapid 
aneuploidy detection in amniotic fluid cells and in Chapter 6 we describe the application 
of this test in chorionic villus samples. The prenatal detection of sub-microscopic 
aberrations through microarray-based analyses and its implications for prenatal use are 
discussed in Chapter 7. A general discussion and future prospects on prenatal testing 
are provided in Chapter 8.
a targeted or a whole-genome array. Targeted arrays contain clones from genomic 
regions of known clinical significance, for example all known microdeletion syndrome 
regions and all sub-telomeric regions, which are known to be frequently affected in 
patients with mental retardation (Bejjani et al., 2005; Cheung et al., 2005; Wong et al., 
2005). However, the current diagnostic use of targeted microarrays will likely be surpassed 
by the availability of affordable whole-genome arrays combined with rapid increases in 
our knowledge on the clinical interpretation of these microarrays (Veltman and de Vries, 
2006). Current whole-genome arrays can detect the most important types of genomic 
variants, i.e., i) single nucleotide polymorphisms (SNPs) and ii) copy number variations 
(CNVs) and enables the genotyping of almost 2 million markers (about 1 million SNPs 
and one million CNVs) dispersed throughout the human genome (Genome-wide Human 
SNP Array 6.0) (Bugert, 2009).
Microarray analysis has the potential to enhance or replace current approaches to 
prenatal diagnosis (Rickman et al., 2005). With its application on uncultured samples, the 
time required to report results back to patients could be significantly reduced. In 
addition, its enhanced resolution will enable the simultaneous detection of common 
aneuploidies and sub-microscopic aberrations, which may be considered of major 
benefit in prenatal diagnosis. A microarray example is shown in Figure 6.
1.7  Outline of this thesis 
Since the introduction of prenatal genetic diagnosis about 50 years ago, chromosomal 
abnormalities have been identified through traditional karyotyping (TK). In recent years, 
however, new prenatal diagnostic tests have become available at an increasing rate, 
driven by rapid developments in molecular technologies, prenatal screening tests and 
ultrasound methodologies. These new tests may be more accurate and/or less labour-
intensive than TK. In addition, they may result in shorter reporting times and/or provide 
targeted test results that may be easier to interpret. The rapid and accurate diagnosis of 
the foetal condition has become an essential part of clinical management and has 
changed routine prenatal care. However, also major difficulties may arise by introducing 
these innovations into daily practice. The main aim of this thesis was to assess the effects 
of laboratory innovations in a routine prenatal setting with the goal to improve prenatal 
care. To this end, the following question was formulated: ‘what prenatal diagnostic tests 
should be offered now and in the future to assure that pregnant women receive 
appropriate prenatal care’.
In Chapter 2, we re-evaluate the diagnostic value of routine measurement of AFP in 
amniotic fluid for the detection of neural tube defects in light of the introduction of the 
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Figure 6. 
Microarray profile showing a deletion of a 2.7 Mb region on chromosome 12. Each probe 
present on the array is arranged along the X-axis according to its location on the chromosome, 
with the distal p-arm clones towards the left and the distal q-arm clones towards the right. The 
log2 test-over-reference (T/R) ratio values are plotted on the Y-axis. The red dots in the upper 
panel represent individual probes. In the lower panel (blue) each dot represents the averaged 
T/R value of 10 neighbouring probes.
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Introduction
For more than 30 years, it has been a policy to always include amniotic fluid α-foetoprotein 
(AFAFP) measurement in invasive prenatal diagnostics for the detection of neural tube 
defects (NTDs), even when there is no increased risk of NTDs. There are two reasons for 
this: NTDs are considered to be severe disorders that often form the reason to request 
termination of pregnancy (WPDT, 2003); and the test is relatively simple, quick and cheap 
to perform. In the Netherlands, only 2% of the approximately 8,000 amniocenteses 
performed annually is because of an a priori increased risk of an isolated NTD. Besides 
measurement of the AFAFP concentration, these women receive advanced ultrasound 
examination in a foetal medicine unit to exclude NTDs.
There are three different types of isolated NTDs: spina bifida, encephalocele and 
anencephaly. A characteristic of spina bifida is the defective closure of the vertebrae. 
This is accompanied by the absence of skin in the case of spina bifida aperta (open spina 
bifida) or a defect covered by skin in the case of spina bifida occulta (closed spina bifida). 
In 90% of the foetuses with spina bifida, the defect is open and gives rise to increased 
AFAFP levels. 
In general, NTDs are often accompanied by an increased AFAFP concentration. In the 
literature, a cut-off point of 2.5x the MoM (multiple of the median) is applied. Using a 
cut-off point >2.5x the MoM will enable the detection of 95% of the open NTDs (Milunsky, 
1980). The Dutch Minister of Health has decided to make the prenatal second trimester 
foetal anomaly scan available to all pregnant women and to include it in basic health 
insurance from January 2006. The foetal anomaly scan is an advanced ultrasound scan 
and takes place between the 18th and 22nd week of pregnancy. The scan includes 
evaluation of the structures of the central nervous system (shape and sonographic 
density of the skull, presence of midline, cavum septum pellucidum, examination of 
cerebellum and lateral ventricular system, measurement of posterior ventricle) and 
examination of the spine and intactness of the skin to ensure that NTDs conform to 
protocol 3 of the Dutch Society for Obstetrics and Gynaecology (NVOG, 2005). 
Now that the foetal anomaly scan is available to all pregnant women, the question arises 
as to whether a separate measurement of AFAFP to detect NTDs has any additional 
diagnostic value. To answer this question, we performed a retrospective study on 
women who had undergone amniocentesis for karyotyping and measurement of AFAFP. 
Reasons were sought for increased AFAFP concentrations, with special attention to the 
karyotype, foetal ultrasound findings and/or postnatal clinical findings.
Abstract 
Objectives
Introduction of the second trimester foetal anomaly scan and the decision to offer this 
scan to every woman in the 18th-22nd week of pregnancy necessitates a re-evaluation of 
the diagnostic value of the measurement of α-foetoprotein (AFP) concentrations in the 
amniotic fluid (AF) for the detection of neural tube defects (NTDs). 
Methods
In this study of 6,501 women who underwent amniocentesis, amniotic fluid AFP (AFAFP) 
concentrations were measured. The women were divided into three categories: group I, 
without any increased risk of foetal NTD (N=6,188); group II, with an increased risk of 
foetal NTD (N=258); and group III, with a clinically diagnosed foetal NTD with known 
AFAFP concentrations (N=55). 
Results
In 27 women of group I (0.4%), the MoM (multiple of the median) level was >2.5 times the 
median AFP concentration for the corresponding gestational age, and in two foetuses 
this was related to NTD. In two pregnancies of group II (0.8%), an increased AFAFP was 
related to NTD. In group III, 44 of the 55 (80%) samples had an increased AFAFP. 
Conclusion
In the near future, it is likely that imaging will replace AFAFP assays for the detection of 
foetal NTDs because high quality ultrasound imaging will detect NTDs accurately. 
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Results
In group I, 6,188 samples of AF were karyotyped and the AFAFP concentrations 
determined. A total of 6,161 samples (99.6%) had normal AFAFP concentrations 
(<2.5×MoM). No cases of NTDs were reported during the follow-up of these pregnancies. 
In the remaining 27 samples (0.4%), the AFAFP concentrations increased (>2.5×MoM) for 
the corresponding gestational period. In this group, all increased AFAFP concentrations 
measured were in the AF of women with the referral reason of advanced maternal age. 
In the group of women whose foetus showed increased nuchal translucency at first 
trimester screening (N=111), no increased AFAFP was detected. Ultrasound examination 
revealed open spina bifida in two pregnancies, one of which was terminated and the 
other resulted in foetal demise. There was no evidence of NTDs in 17 of the remaining 25 
cases, and the increased AFAFP concentration could possibly be explained by other 
AFP-related anomalies, such as foetal demise (N=9), chromosomal anomalies (trisomy 13, 
N=1; trisomy 21, N=1; trisomy 18, N=3), unilateral foetal hydronephrosis (N=1) and 
di-amniotic twin pregnancies (N=2). In one twin pregnancy there was an increased 
AFAFP concentration in one foetus and both infants were born without complications, 
while in the other twin pregnancy there was a slightly increased AFAFP concentration in 
both samples, but ultrasound examination did not show any structural anomalies.
In the eight pregnancies with unexplained increase in the AFAFP value, advanced 
ultrasound examination was normal in six cases. The follow-up data on the remaining 
two cases reported one foetus with a clubfoot (who died after premature delivery at a 
gestational age of 24 weeks). The other pregnancy showed an AFAFP value of 5.8×MoM. 
This pregnancy showed signs of utero placental insufficiency, but the pregnancy 
outcome was normal (normal birth weight).
In group II (women with an increased risk of NTDs), there was one case with an increased 
AFAFP value among the 63 users of anti-epileptic drugs. The subgroup with familial 
NTDs (N=141) also contained one case with an increased value. In these two cases with 
increased AFAFP, NTD was confirmed by advanced ultrasound examination, which made 
the parents opt for early termination of pregnancy. None of the women with diabetes 
mellitus (N=54) had increased AFAFP values. 
In group III, among the women in whom foetal NTDs had been diagnosed using 
advanced ultrasound examination, 44 of the 55 cases (80%) had increased AFAFP 
concentrations. Table 1 represents an overview of the increased AFAFP values in groups 
I, II and III. Test performance tables are given in Table 2. The sensitivity in groups I, II and 
III is 100, 100 and 80%, respectively. The positive predictive value for group I is 7.4%.
Patients and methods
A retrospective study was performed between 1999 and 2005 on amniotic fluid (AF) 
samples obtained for prenatal cytogenetic evaluation and routine measurement of 
α-foetoprotein (AFP). The samples were grouped into three categories and included 
normal and abnormal karyotypes.
•   Group I: women without any increased risk of foetal NTDs (referral reason was advanced 
maternal age (N=6,077) or increased nuchal translucency at first trimester screening 
(N=111)).
•   Group II: women with an increased risk of foetal NTDs (women with diabetes mellitus 
(N=54), women using anti-epileptic drugs (N=63) and women with familial NTDs 
(N=141)).
•   Group III: women in whom ultrasound examination showed a foetal NTD during 
pregnancy (N=55).
AF was collected at the outpatient clinics located in Nijmegen, Arnhem, Tilburg and 
Enschede. The samples (∼20 ml) were split and amniocytes were cultured for karyotyping, 
and 2 ml cell-free supernatant was used for AFAFP measurements. All AFAFP 
measurements were performed in one laboratory (i.e., Department of Chemical 
Endocrinology, Radboud University Nijmegen Medical Centre). AFAFP was measured 
using a random access analyser type AxSYM from the Abbott Laboratories Diagnostics 
Division (Chicago, IL, USA). Under standard conditions the AF specimens were 
automatically diluted 101-fold by AxSYM. In case the initial measurement of AFAFP gave 
a result >25,000 g/l, the sample was manually diluted two-fold and four-fold and further 
processed with automatic predilution (101-fold) by the AxSYM. The AFAFP concentration 
was expressed in micrograms per litre. In a normal pregnancy, the AFAFP concentration 
can be expected to decrease by about 10% per week in the second trimester. Reference 
values were obtained by measuring the AFAFP concentrations per gestational week in a 
number of normal pregnancies and expressing the results in terms of the MoM. Using 
these median values, it was possible to establish an upper margin of the normal range 
per gestational week. From samples with an increased AFAFP concentration, the details 
of cytogenetic analysis, pregnancy follow-up and pregnancy outcome were obtained 
from their medical records when available, or by contacting the referring physician.
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Test performance values in group III
NTD + NTD - Total
AFAFP > 2.5 MoM 44 0 44
AFAFP ≤ 2.5 MoM 11 0 11
55 0 55
Sensitivity = 80%, specificity = 0%
Positive predictive value = 100%, negative predictive value = 0% 
Discussion
The present results showed that in group I (no increased risk of NTD), in group II (increased 
risk of NTD) and group III (known NTDs) the detection rate for NTD by AFAFP measurement 
was 0.4%, 0.8% and 80%, respectively.
The total number of live births in the Netherlands is about 195,000 per year (Statistics 
Netherlands, 2006). On the basis of an NTD incidence of 1.2 per 1,000 births (Anthony et 
al., 2001) approximately 230 babies (including 152 live births) per year are born with an 
isolated NTD (EUROCAT, 1997).
In group I, 6,188 samples of AF were karyotyped and the AFAFP values were determined. 
A total of 6,161 (99.6%) had a normal AFAFP concentration (<2.5xMoM). No cases of NTDs 
were reported during the follow-up of these pregnancies. It is reasonable to assume that 
there is an almost 100% follow-up on these 6,188 patients. All these patients (except four, 
see Table 1) were informed in writing that (on the basis of a normal AFAFP) an open NTD 
can be excluded with a high degree of certainty. Consequently, it is not reasonable to 
assume that no recall would have taken place in those cases in which NTD would have 
been the clinical outcome. Thus, the incidence of NTDs in group I was equivalent to 
approximately three cases of foetal NTD detected in a year on a national scale (WPDT, 
2003). We found that AFAFP measurements contributed very little to the early detection 
of NTDs and, moreover, it was likely that these NTDs were identifiable with foetal anomaly 
scan screening. In addition, for every foetal NTD detected by AFAFP measurement, 12 
women would receive a false-positive result for NTDs. The lack of an explanation for 
increased AFAFP concentration leads to unnecessary follow-up examinations and 
resultant anxiety.
We also found that 20% of the known NTDs (group III) gave a false sense of security 
because of normal AFAFP concentrations due to closed NTDs. This corresponds to the 
reported sensitivity of 80% to detect all forms of NTDs (Milunsky, 1980). Our results, 
indicate a sensitivity of 100% for detecting an open NTD, which is in line with the results 
of Milunsky who reported 95% at the same cut-off value of 2.5xMoM.
Table 1. Overview of increased AFAFP values in group I, II and III
No. of 
patients
No. > 2.5 
MoM
‘f’ x MoM values
(min – max)
Increased AFAFP 
prevalence rate (%)
Group Ia
Foetal demise
Chromosomal aneuploidy
Spina bifida
Hydronephrosis
Twin pregnancy
Unexplained elevation
6,188 27
9
5
2
1
2
8
9 – 36
4 – 37
9.8 – 10.3
7.0
3.1 – 3.4
2.6 – 5.8
0.4
Group IIb
Spina bifida
258
2
2
2 5.5 – 9.4
0.8
Group IIIc
Spina bifida
Encephalocele
Anencephaly
55
19
12
24
44
15
5
24
0.9 – 17
0.6 – 31
10 – 46
80
f = multiplication factor 
aGroup I: patients without increased risk of NTDs (advanced maternal age (N=6,077) and patients whose 
foetus showed increased nuchal translucency at first trimester  screening (N=111))
bGroup II: patients with increased risk of foetal NTDs (patients with diabetes mellitus (N=54), anti-epileptic 
users (N=63) and patients with familial NTDs (N=141))
cGroup III, women with clinically diagnosed foetal NTD pregnancy (N=55).
Table 2.  Test performance values in group I, II en III 
Test performance values in group I
NTD + NTD - Total
AFAFP >2.5 MoM 2 25 27
AFAFP ≤2.5 MoM 0 6,161 6,161
2 6,186 6,188
Sensitivity = 100%, specificity = 99.6%
Positive predictive value = 7.4%, negative predictive value = 100% 
Test performance values in group II
NTD + NTD - Total
AFAFP > 2.5 MoM 2 0 2
AFAFP ≤ 2.5 MoM 0 256 256
2 256 258
Sensitivity = 100%, specificity = 100%
Positive predictive value = 100%, negative predictive value = 100% 
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the literature, the sensitivity of the foetal anomaly scan to diagnose anencephaly is close 
to 100%, while for spina bifida the percentage is showing a steady increase, depending 
on technician training and strict quality control. In the most recent data, the sensitivity 
for spina bifida was 93% and for encephalocele it was 94% (Norem et al., 2005). Although 
the foetal anomaly scan seems very promising in terms of screening for structural 
anomalies, it also has limitations. For example, with the foetal anomaly scan, it is difficult 
to detect congenital nephrosis or skin defects such as aplasia cutis congenita (1:3,000) 
and epidermolysis bullosa (1:50,000) (Mandruzzato et al., 2002). The prevalence of the 
latter two anomalies is very low, so the only indication is to measure AFAFP concentrations 
on familial grounds. Furthermore, particularly in cases with persistent spine posterior 
position, or maternal morbid obesity, it is not always able to study NTDs. 
Foetal anomaly scan screening provides direct indication about the presence of any 
NTDs (open and closed NTDs) and the diagnosis NTD can be confirmed by advanced 
ultrasound examination. This prevents patients with an increased risk of NTDs from 
having unnecessary invasive procedures with their inherent risk of miscarriage. 
In the near future, it is likely that imaging could replace AFAFP assays for the detection of 
NTDs, especially for patients without an increased risk, because high quality ultrasound 
imaging will detect open as well as closed NTDs accurately; however, the condition of 
implementing the 20-week foetal anomaly scan needs to be fulfilled in routine prenatal 
screening programmes. In the Netherlands, such programmes have been started and 
this work is currently in progress. We therefore intend to initiate a prospective 
 population-based study in order to evaluate the efficacy of ultrasound screening data of 
the foetal anomaly scan before it is safe to abolish routine AFAFP assays. We hope that 
these findings will prompt other investigators in this field to perform prospective 
studies.
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There are other anomalies that can cause increased AFAFP values. These include 
abdominal wall defects, skin defects and foetal demise. NTDs and abdominal wall 
defects are often associated with the presence of the protein acetylcholinesterase 
(AChE) (Milunsky and Sapirstein, 1982). The AChE assay is performed incidentally and 
enables the distinction of NTDs from other AFAFP related defects. Renal anomalies can 
also give rise to increased AFAFP concentrations when renal AFP resorption is poor or 
absent. Chromosomal defects (trisomy 13, 18, 21 or 45,X) may be associated with elevated 
AFAFP in the absence of NTD by leakage of AFP through skin (Milunsky, 1992). Furthermore, 
in twin pregnancies and multiple pregnancies, AFAFP concentrations can be increased 
(Speroff et al., 1994) and may be difficult to interpret owing to foetal proteins that may 
diffuse across the membranes and cause false-positive or false-negative results (Johnson 
et al., 1989). 
Isolated NTDs have a multifactorial aetiology. Genetic factors, environmental factors 
(ethnicity, diet, medication use) and periconceptional folic acid supplementation play 
important roles. It is well known that women with a previous NTD pregnancy have an 
increased risk, as well as women who take anti-epileptic drugs (e.g. valproic acid) (Frey 
and Hauser, 2003; Ornoy, 2006) or women with insulin-dependent diabetes (Loeken, 
2005). There have been several clinical studies suggesting that the incidence and severity 
of diabetic pregnancy-induced malformations are correlated with poor glycemic control 
(Langer and Conway, 2000). Nevertheless, even in the twenty-first century, there are 
reports that birth defects, particularly those affecting the neural tube, are significantly 
increased (up to five-fold) in diabetic pregnancies (Loeken, 2005). In addition, a number 
of chromosomal abnormalities are associated with the risk of congenital anomalies, 
including NTDs, but these make up only a small percentage of the NTDs in live births. 
Another prenatal screening method for NTDs is maternal serum AFP analysis (MSAFP as 
part of the triple test) (Canick et al., 2003). Little or no use is made of this prenatal 
procedure in the Netherlands owing to its limited sensitivity (80% in all NTDs, 60% for 
spina bifida) (Health Council of the Netherlands, 2001). The ultrasound detection of NTDs 
is high, partly because of the NVOG quality norm 6 for ultrasound technicians, prenatal 
screening and also because closed NTDs can be detected (Health Council of the 
Netherlands, 2004). 
Over the past 10 years, the second trimester foetal scan (and consequently, screening for 
NTDs) has become an integral part of prenatal care in most West-European countries. 
Until recently, this did not include the Netherlands, but projects have now been started 
to train a sufficient number of ultrasound operators. The availability of high-resolution 
ultrasound equipment and expertise in scanning with the use of accurate examination 
protocols will improve the detection rate of NTDs. At present, there are regional 
differences in the progress to implement foetal anomaly scan screening. According to 
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Introduction
The diagnosis of hydrops foetalis (HF), the presence of excessive fluid in more than one body 
cavity in the foetus, is being made increasingly and at an earlier stage during pregnancy 
owing to routine prenatal ultrasound screening. Estimates of the incidence of HF vary 
between one in 600 and 4000 pregnancies (Norton, 1994; Stone and Sidransky, 1999). 
Estimates of mortality vary between 60% and 90% (Cassady, 2004). HF can have diverse and 
widely ranging causes due to disease processes in the cardiovascular or thoracic regions, 
foetal arrhythmia, monochorial twin pregnancies, foetal anaemia, chromosomal aberrations 
and genetic syndromes (Walkinshaw, 2000). Traditionally, HF is subdivided in immunological 
and non-immunological HF (NIHF). Inborn errors of metabolism are among the causes of 
NIHF and the group of lysosomal diseases is the most important subgroup. Prenatal diagnosis 
of a lysosomal disease in families at risk is well established in chorionic villi and in amniocytes. 
For the prenatal diagnosis of a lysosomal disease in NIHF cases, the accumulating substrate 
of the defective enzyme and/or the enzymatic activity can be determined (Beck et al., 1984; 
Guibaud et al., 1985; Piraud et al., 1996; Bouvier and Maire, 1997). We have investigated a 
series of 75 pregnancies with NIHF at the metabolite level and at the enzyme level by 
measuring 21 lysosomal enzymes. Reference values for mucopolysaccharides (MPS) and 
neuraminic acid are not available in literature. This paper gives gestational age-related 
reference ranges for MPS and neuraminic acid and gives examples of abnormal 
oligosaccharide profiles of amniotic fluid. Four definite and two probable cases of NIHF 
pregnancies due to lysosomal aetiology are described.
Patients and methods
Patients
We have investigated a series of 75 pregnancies with NIHF. In all pregnancies, routine 
maternal antibody screening had excluded irregular antibodies. The classification of 
NIHF is based on the maternal blood group and the absence of irregular antibodies to 
red cell antigens Rhesus, c, E and Kell. Chromosomal abnormalities had been excluded in 
all cases. Investigations were carried out at the metabolite level and at the enzyme level 
to diagnose lysosomal diseases. In amniotic fluid these included the measurement of 
MPS, oligosaccharides and neuraminic acid. A panel of lysosomal enzyme determinations 
was performed in the cultured amniocytes. Forty control pregnancies were included in 
this study. Measurements on 75 NIHF pregnancies were performed as follows: in 42 
pregnancies amniotic fluid was obtained and amniocytes were cultured; in 29 cases only 
amniotic fluid could be investigated and in four cases only cultured amniocytes were 
available. In our series four definite cases of lysosomal disease were found.
Abstract
Background
At least 20 inborn errors of metabolism may cause hydrops foetalis. Most of these are 
lysosomal storage diseases. The study proposes a diagnostic flowchart for prenatal 
diagnosis of non-immune hydrops foetalis.
Methods
This study contains a series of 75 non-immune hydrops foetalis pregnancies. Mucopoly-
saccharides, oligosaccharides, neuraminic acid and 21 lysosomal enzymes were 
measured in amniotic fluid and cultured amniotic cells.
Results
The study gives reference values for mucopolysaccharides and neuraminic acid at 
various stages of gestation. Four definite and two probable lysosomal diagnoses were 
found among the 75 investigated cases (=5.3–8%). Foetal death was found to cause 
false-positive values for mucopolysaccharides in amniotic fluid. In the galactosialidosis 
case, two novel mutations were found in the cathepsin A gene.
Conclusions
Reference values for mucopolysaccharides and neuraminic acid depend on gestational 
age. In a relatively high percentage of the hydrops foetalis pregnancies, a lysosomal 
aetiology is found. This study provides a strategy to diagnose lysosomal diseases in 
hydrops foetalis pregnancies. Awareness of lysosomal storage diseases causing hydrops 
foetalis is useful as it gives an opportunity for risk evaluation, genetic counselling to 
parents and targeted prenatal diagnostics for ensuing pregnancies.
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Basel, Switserland; absorbance 550 nm). The assay requires correction for the presence of 
pyruvate in the sample. The protein content of the samples was measured with a 
modified Folin–Lowry method.
Oligosaccharides were analysed using thin layer chromatography (TLC) with modifications 
on the method described by Blom et al. (Blom et al., 1983). Samples were deproteinised 
first on a 10-kDa filter (Sartorius, Goettingen Germany; reagent no. 13239E) and 
subsequently desalted with an Amberlite mixed bed resin ion exchanger (Sigma A-5710; 
200 mg/ml). After concentrating the sample by a factor 20, 5 μl sample/cm was applied 
on silicagel 60 TLC plates (Merck, Darmstadt, Germany; no. 5553). TLC plates were 
developed in n-butanol–acetic acid–water (2:1:1, by volume). Oligosaccharides were 
visualised by orcinol staining (100 mg orcinol (BDH Laboratory Supplies, Poole, UK; no. 
29418) in 100 ml acetone and 5 ml sulfuric acid). Plates were heated for 10 min at 90 °C.
For biochemical studies a panel of 21 lysosomal enzymes was measured in 6×106 
amniocytes, washed three times with saline. These included arylsulfatase A, 
β-galactosidase, α-galactosidase A, N-acetyl β-glucosaminidase (total and A-isoform), 
β-glucosidase, sphingomyelinase, galactocerebrosidase, α-iduronidase, iduronate 
2-sulfatase, heparine sulfaminidase, N-acetyl α-glucosaminidase, α-glucosaminide N-
acetyltransferase, N-acetylglucosamine 6-sulfatase, arylsulfatase B, β-glucuronidase, 
neuraminidase, α-fucosidase, α-mannosidase, β-mannosidase and α-glucosidase. 
Methods used for these assays are essentially similar to the methods used for routine 
measurement of lysosomal enzymes in leucocytes.
Results
Reference ranges
No reference ranges are available for MPS and neuraminic acid in amniotic fluid. To 
establish these we have expressed both compounds per protein (MPS, Figure 1A; 
neuraminic acid, Figure 1B). Figure 1 gives the individual values for the control samples 
and the NIHF cases. The figure shows a gradual increase in concentration of both 
parameters with gestational age. The increase is more pronounced for neuraminic acid.
Amniotic fluid
Out of 75 NIHF pregnancies and 40 control pregnancies, 71 were investigated at the 
metabolite level (amniotic fluid obtained between 14 and 36 weeks of gestation). 
Standard investigations including quantitative analysis of MPS and neuraminic acid 
(bound + free), and oligosaccharide TLC revealed abnormal results in five samples (Figure 
Case 1
In the second pregnancy of non-consanguineous parents (the first pregnancy had 
ended in miscarriage) ultrasound abnormalities were detected at 27 weeks of gestation. 
The male foetus had hydrops, polyhydramnion and ascites. Premature contractions 
started at 35 weeks and delivery was initiated. The baby died during delivery.
Case 2
In the third pregnancy of consanguineous parents (one healthy child and one 
spontaneous abortion) ultrasound abnormalities were detected at 27 weeks of gestation. 
The male foetus had HF. In view of the infaust prognosis and after consultation of the 
parents the pregnancy was terminated in week 31. Pathological investigation of the 
placenta showed intra-cytoplasmatic storage material. Electron microscopic inspection 
revealed large numbers of round cysts with a transparent content.
Case 3
In the third pregnancy of consanguineous parents, intrauterine foetal death of a female 
foetus was established with hygroma colli and hydrops at 21 weeks of gestation. Electron 
microscopic investigation of the placenta revealed an increased number of strongly 
vacuolised Hofbauer cells in the villi. An earlier pregnancy had resulted in intrauterine 
foetal death with hygroma colli and hydrops foetalis for which no causative factor was 
found.
Case 4
The patient was a 16-week hydropic foetus from non-consanguineous parents of Dutch 
ancestry. Two previous pregnancies resulted in an affected hydropic foetus. In the first 
pregnancy, which ended after 34 weeks, hydrops was detected at week 25. Increased 
intra- and extra-medullary haematopoiesis were documented. In the second pregnancy, 
hydrops, granulocytopenia and anaemia were noted at week 15. The parents have one 
healthy child.
Biochemical tests
MPS were quantified using the dimethylmethylene blue test in 180 mmol/l Tris buffer pH 
8.8 essentially as described by the Jong et al. for urine samples (De Jong et al., 1992). The 
mixture of the colour reagent and the buffer is not stable and has to be prepared within 
15 min of performing the assay. Under these conditions, the amniotic fluid samples do 
not require deproteinisation before measuring MPS. Bound plus free neuraminic acid 
(sialic acid) was determined enzymatically using a spectrophotometric assay from Roche 
Mannheim Germany (reagent no. 784192) on a Cobas Fara analyzer (Hoffmann-LaRoche, 
Lysosomal storage diseases in non-immune hydrops foetalis pregnancies Chapter 3
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1 and Figure 2). Among these, two cases with highly increased MPS could not be followed 
up by additional investigations and remained without primary diagnosis. The protein 
concentration in these samples was normal. We consider these two cases as probable 
mucopolysaccharidoses (Figure 1A: MPS unspecified). The other three cases could be 
further investigated on amniocytes.
An increased MPS concentration was also found in two HF pregnancies with intrauterine 
foetal death (Figure 1A). The protein content was high amounting to 15.5 and 14.3 g/l, 
respectively. The neuraminic acid concentration in both samples was normal.
Amniotic cells
Data obtained at the metabolite level on amniotic fluid were confirmed by enzyme 
determinations on cultured amniotic cells in 42 out of 71 NIHF pregnancies. The enzyme 
determinations confirmed galactosialidosis (OMIM 256540) in case 1, GM1-gangliosidosis 
(OMIM 230500) in case 2 and β-glucuronidase deficiency (OMIM 253220) in case 3. Additionally 
amniocytes from four other NIHF pregnancies (in which amniotic fluid was not available) 
were investigated revealing one additional case of β-glucuronidase deficiency. The enzyme 
assays did not reveal any deficiencies of lysosomal diseases that would not have shown up 
in the metabolite assays (for instance: arylsulfatase A, α-galactosidase A, β-glucosidase, 
sphingomyelinase, galactocerebrosidase). In the two foetal death cases, all mucopolysac-
charidoses enzymes in amniotic cells showed normal activity. This excludes a primary defect 
in the catabolism of MPS in these cases and indicates intrauterine foetal death as an 
independent cause for increased MPS in amniotic fluid.
Pregnancies with lysosomal diagnoses
Case 1: Galactosialidosis
In amniotic fluid obtained at 27 weeks of gestation neuraminic acid was clearly increased 
(Figure 1B: 142 μmol/g protein, reference value for this gestational age <90 μmol/g 
protein). TLC of oligosaccharides in the amniotic fluid showed the abnormal presence of 
several neuraminic acid containing oligosaccharides (Figure 2, lane 4). β-d-Galactosidase 
and neuraminidase deficiency in cultured amniocytes suggested the diagnosis of galac-
tosialidosis. It was confirmed by demonstrating the primary cathepsin A defect (Table 1). 
The final diagnosis of galactosialidosis (OMIM 256540) was performed on foetal 
fibroblasts and leukocytes from umbilical cord blood. Molecular analysis on the PPGB 
gene (GenBank ID no. 5476) identified two novel mutations: 1. c.292C > T (in exon 3 
leading to replacement of His98 by Tyr; 2. c.707T > G in exon 8 leading to Arg substitution 
of Leu236 (nomenclature including the signal peptide). In a later pregnancy specific 
enzymes were measured in chorionic villi and found normal. This pregnancy resulted in 
the delivery of a healthy child.
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Figure 1. 
(A) Quantification in amniotic fluid of 40 control pregnancies (×) and 71 non-immune hydrops 
foetalis pregnancies (♦): MPS in mg/g protein. The amniotic fluid samples from case 3 (β-
glucuronidase deficiency) and two further cases with MPS unspecified were clearly abnormal. 
(B) Quantification in amniotic fluid of 40 control pregnancies (×) and 71 non-immune hydrops 
foetalis pregnancies (♦): total neuraminic acid (= bound + free) in μmol/g protein. Case 1 (ga-
lactosialidosis) and a case of sialidosis (OMIM 256550; obtained as a gift from Dr. I. Maire (Lyon, 
France)) were clearly abnormal.
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Case 2: GM1-gangliosidosis
TLC showed abnormal oligosaccharide bands indicative for GM1-gangliosidosis (Figure 
2, lane 2). Cultured amniocytes revealed decreased β-d-galactosidase activity but normal 
neuraminidase activity (Table 1). After birth, the diagnosis GM1-gangliosidosis (OMIM 
230500) was confirmed in fibroblasts and leukocytes. In the GLB1 gene on chromosome 
3p (GenBank ID no. 2720) encoding for β-d-galactosidase a novel homozygous mutation 
c.442C > T was found in exon 4 by direct sequencing of all exons of the genomic DNA. 
The mutation was confirmed with restriction enzyme analysis. It did not occur in 100 
control alleles. At the protein level the mutation leads to replacement of Arg by Cys 
(R148C). A mutation in the same codon leading to R148S has been described in infantile 
GM1-gangliosidosis (Hilson et al., 1994). Due to the position of the mutation both gene 
products β-d-galactosidase as well as elastin binding protein are likely to be affected. 
Both parents were heterozygous for the mutation. In the subsequent pregnancy, specific 
enzyme analysis was performed on amniocytes at 16 weeks of gestation. A deficiency of 
β-d-galactosidase was found indicating an affected foetus. This led to the parents’ 
decision to terminate the pregnancy.
Lysosomal storage diseases in non-immune hydrops foetalis pregnancies Chapter 3
3
Figure 2. 
Thin layer chromatography of oligosaccharides in amniotic fluid from two pregnancies affected 
by HF (orcinol dye). Lane 1: dextran hydrolysate, Lane 2: GM1-gangliosidosis (case 2), Lane 3: 
normal amniotic fluid, Lane 4: galactosialidosis (case 1), Lane 5: reference containing (from top 
to bottom) fucose/xylose, glucose, galactose, maltose/glucuronic acid, lactose, raffinose, 
tetraglucoside, sialyllactose. Abnormal lanes of both HF amniotic fluid samples are indicated by 
arrows. In both HF cases, amniotic fluid was aspirated in the 27th week of pregnancy, shortly 
after HF had been established. 
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(Burin et al., 2004). When chromosomal abnormalities were first excluded in this series of 
33 NIHF cases the estimate becomes even higher (21%). Burin et al indicate that their 
numbers probably are an overestimation as they are a national reference centre for 
lysosomal diseases. This is likely to cause a selection bias in their series which is illustrated 
by the fact that 3 of the 5 positive cases had a suggestive family history for a lysosomal 
disease. Comparing the various studies, the gestational age must be taken into account. 
We have analyzed NIHF pregnancies between 14 and 36 weeks of gestation, while the 
study of Piraud mainly included third trimester samples (Piraud et al., 1996). The low 
urinary volume production of the foetus in the first two trimesters may imply that LSD 
cannot be diagnosed at the metabolite level before a certain gestational age. These 
Cases 3 and 4: Mucopolysaccharidoses
Amniotic fluid from case 3 showed an MPS increase with a factor 1.5 compared to 
controls (Figure 1A). Further analysis with one-dimensional electrophoresis showed an 
increase in chondroitin sulfate and dermatan sulfate. A deficiency of β-glucuronidase 
was found in serum obtained by pericardial puncture of the foetus (6 nmol/h/mg 
protein; reference values 600–1200) and in foetal fibroblasts (6 nmol/h/mg protein; 
reference values 200–700). Based on these findings, mucopolysaccharidosis type VII 
(MPS VII; OMIM 253220) was diagnosed.
The same enzyme defect was found in case 4. The β-glucuronidase activity amounted 
to 7 in amniotic cells (reference 140–660). The deficiency was confirmed by enzyme 
analysis in leucocytes from cord blood (β-glucuronidase = 10 nmol/h/mg protein; 
reference 600–1200). At the molecular genetic level, a 27-nucleotide deletion 
c.1084_1107del was found in the cDNA of the GUSB gene (GenBank ID no. 2990). This 
mutation in exon 7 was present in heterozygous form. It leads to the loss of nine amino 
acids (p.362_370del) at the protein level. A second pathogenic mutation was found by 
sequencing the genomic DNA (c.1069C > T). This heterozygous mutation also is in exon 
7. It results in reduced amounts of stable mRNA and to premature truncation at the 
protein level (p.R357X) (Vervoort et al., 1997). 
Discussion
Lysosomal storage diseases (LSD) are extremely rare. However, the estimated combined 
birth incidence for all lysosomal diseases is 14 per 100,000 live births (Poorthuis et al., 
1999). Deficiency of a lysosomal enzyme (nearly always) results in accumulation of the 
substrate of the specific enzyme in the lysosomes and leads to cell and tissue damage, 
swelling and organomegaly. The liver, spleen and bone marrow are among the targets. 
Damage to these organs and bone marrow may result in decreased haematopoiesis, 
hypoalbuminaemia, visceromegaly, damage of the myocardium, inhibited venous 
drainage of the heart and ascites due to portal hypertension. It is believed that these 
changes lead to the development of HF that represents the severe end of the wide 
spectrum of LSD phenotypes (Machin, 1989; Norton, 1994). Table 2 lists LSD and 
non-lysosomal diseases found in association with HF. Machin (Machin, 1989) and Jauniaux 
et al. (Jauniaux et al., 1997) reported that 1.0–1.4% of NIHF is due to LSD. 
In the present study we have found four definite and two probable LSD diagnoses 
among 75 NIHF pregnancies (5.3–8%). Our figures on the prevalence of LSD are in line 
with three more recent studies presenting estimates ranging from 5.9% to 15% (Burin et 
al., 2004; Groener et al., 1999; Piraud et al., 1996). The highest estimate is from Burin et al. 
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Table 2. Hereditary metabolic diseases found in association with HF 
Lysosomal storage diseases Non-lysosomal diseases
Mucopolysaccharidoses: Glycogenoses:
Mucopolysaccharidosis I (Hurler)1 Glycogenosis type IV (Anderson disease)2 
Mucopolysaccharidosis IVA (Morquio A)3
Mucopolysaccharidosis VII (β-glucuronidase 
deficiency) 4
Oligosaccharidoses: Fatty acid oxidation defects:
Galactosialidosis5 
Sialidosis7
Long-chain hydroxyacyl CoA dehydrogenase 
deficiency6
GM1-gangliosidosis8
Lysosomal transport defects: Cholesterol biosynthesis defects:
Sialic acid storage disease9 Smith–Lemli–Opitz syndrome10
3β-hydroxysterol-Δ14-reductase deficiency11
Sfingolipidoses: Congenital disorders of glycosylation:
Gaucher type 212 CDG Ix13 
Niemann-Pick A14 
Niemann-Pick C15 
Lipogranulomatosis (Farber)16
Wolman17 
Mucolipidoses: Others:
Mucolipidosis II (I-cell disease)18 Citric acid cycle-defect19 
Others: Hereditary hemochromatosis20 
Multiple sulfatase deficiency
 1,14,17(Lake et al., 1998), 2(Cox et al., 1999), 3(Bouvier and Maire, 1997), 4,9(Piraud et al., 1996),
5,8,15,16,18(Stone and Sidransky, 1999), 6(Tercanli et al., 2000), 7(Beck, 2001), 10(Angle et al., 1998),  
11(Waterham et al., 2003), 12(Stone et al., 2000), 13(De Koning et al., 1998), 19(Remes et al., 1992), 20(Machin, 1989). 
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that will not be picked up. Diagnostic centres may want to include a selection of the 
enzymes involved in these diseases in their NIHF protocol.
In NIHF pregnancies that have not been investigated prenatally, postnatal tests for LSD 
should always be performed. This became even more important through the availability 
of enzyme replacement therapy for an increasing number of LSD (Desnick, 2004).
Vacuolization in the placenta or in foetal cells may be further clues in the direction of a 
lysosomal etiology (Norton, 1994; Stone and Sidransky, 1999). A systematic approach of HF 
as proposed in this paper will contribute to our understanding of HF in individual cases, 
improve genetic counselling and provide chances for family planning in families at risk.
diagnoses will be missed if investigations are performed at the metabolite level only. Of 
course, these would also be found in the second trimester by enzyme testing in cultured 
amniocytes. As we have included 29 cases where we only tested at the metabolite level, 
this may explain partly why we found a somewhat lower percentage of lysosomal 
diagnoses than the French study by Piraud et al. (Piraud et al., 1996). The six diagnoses in 
our study all were found in the period between weeks 21 and 36 of gestation. This study 
describes a case of NIHF due to β-glucuronidase deficiency in the 21st week (case 3). This 
could be shown also at the metabolite level, suggesting that the urine production at this 
stage of the pregnancy is sufficient to find lysosomal diagnoses. However, it is uncertain 
whether all cases will be diagnosed at the metabolite level in these early stages.
In conclusion, our data suggest that the prevalence of LSD is significantly higher than the 
estimate of 1.0–1.4% in previous studies. Therefore, we recommend the inclusion of metabolic 
analyses of amniotic fluid and amniocytes in the routine diagnostic work-up of NIHF.
Techniques described in this paper will facilitate establishing a diagnosis in cases that 
would have previously been considered idiopathic. Finding the primary cause of HF will 
not only provide better understanding of the mechanism, but will also enable more 
accurate risk estimates and genetic counselling in future pregnancies. The present study 
applied a new diagnostic strategy using a protocol of prenatal diagnostic procedures. 
Figure 3 presents a flowchart illustrating the strategy to detect LSD in HF pregnancies. At 
the metabolite level, the protocol relies on the measurement of MPS and neuraminic acid 
and on TLC of oligosaccharides. The cases with LSD gave unequivocal abnormal results 
that were well above the established reference ranges. Foetal death may cause increased 
MPS concentration in amniotic fluid and therefore complicates the interpretation of the 
laboratory result. The protein concentration of the amniotic fluid was clearly increased in 
the foetal death cases in our study while a normal value for protein was found in the 
β-glucuronidase deficient cases. At the enzyme level this study worked with a panel of 21 
lysosomal enzymes. Obviously for routine diagnostic purposes this would not be feasible 
in most centres. The laboratory workload can be diminished by measuring only those 
lysosomal enzymes that are frequently involved in the aetiology of HF (such as 
β-glucuronidase, β-glucosidase). Before week 18 of gestation, urine production of the 
foetus is limited, bringing the risk that a lysosomal diagnosis would be missed at the 
metabolite level. Therefore, it may be considered to add β-galactosidase to the enzyme 
panel to pick up cases with GM1-gangliosidosis and galactosialidosis is such cases. This 
combination of measurements at the metabolite and the enzyme levels will allow a 
diagnostic laboratory to pick up the most frequent LSD known to be associated with NIHF. 
However, defects that do not result in an increase of MPS, neuraminic acid or oligosaccha-
rides in amniotic fluid will be missed with this strategy. Niemann-Pick types A and C, 
Wolman, Farber, mucolipidosis II and multiple sulfatase deficiency are among the diseases 
Lysosomal storage diseases in non-immune hydrops foetalis pregnancies Chapter 3
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Figure 3. 
Proposed flowchart for prenatal diagnosis of non-immune hydrops foetalis
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Introduction
In recent years, several studies have reported that molecular techniques such as 
quantitative fluorescence-polymerase chain reaction (QF-PCR) and multiplex ligation-
dependent probe amplification (MLPA) may represent accurate, rapid and cost-effective 
options for high-throughput testing of common chromosomal aneuploidies (i.e., 13, 18, 
21, X and Y) in amniotic fluid cells (Grimshaw et al., 2003; Slater et al., 2003; Nicolini et al., 
2004; Gerdes et al., 2005b; Hochstenbach et al., 2005; Cirigliano et al., 2006). An obvious 
next step would be the implementation of such molecular tests in routine prenatal 
clinical practice.
However, there is an ongoing debate on whether these targeted tests may serve as such 
(Leung et al., 2004a; Caine et al., 2005; Ogilvie et al., 2005b; Bui, 2007). Here we aimed to 
assess the suitability of targeted testing by MLPA as a stand-alone test for the detection 
of common chromosomal aneuploidies in amniotic fluid cells in prenatal clinical practice. 
Therefore, we first performed an MLPA evaluation study in a research setting, followed 
by a prospective evaluation study in a clinical diagnostic setting. In both studies, the 
results obtained were compared with traditional karyotyping (TK), the gold standard. 
Specifically, we evaluated the accuracy, reporting time and failure rates of the MLPA test 
in order to assess its technical suitability for routine diagnostic application. Additionally, 
the clinical significance of the chromosomal abnormalities that would have remained 
undetected when MLPA was used as stand-alone test in a group of patients referred for 
an increased risk of Down syndrome was determined. Finally, relative merits of the MLPA 
test are discussed, including its putative implementation as a stand-alone test in prenatal 
clinical practice. In addition, a flowchart for integrating the MLPA test into the cytogenetic 
laboratory workflow is presented. 
Material and methods
A total of 1,000 amniotic fluid samples from various gestational ages and with different 
referral reasons were collected at the outpatient clinics in Nijmegen, Arnhem, Tilburg, 
’s-Hertogenbosch and Enschede (the Netherlands). First trimester risk assessment for 
trisomy 21 was based on maternal age, biochemical serum markers, i.e., maternal serum 
free beta-human chorionic gonadotrophin (hCG), fβ-hCG and pregnancy-associated 
plasma protein-A (PAPP-A), and a nuchal translucency (NT) measurement and TK was 
performed on all samples following standard procedures. DNA from amniotic fluid cells 
was isolated through lysis of cell pellets and proteinase K treatment using standard 
procedures. Subsequently, this DNA was purified using a QIAamp kit (Qiagen, Hilden, 
Abstract 
Objective 
This study aimed to determine the diagnostic application of multiplex ligation- 
dependent probe amplification (MLPA) as a stand-alone test for targeted detection of 
common chromosomal aneuploidies (i.e., 13, 18, 21, X and Y) in amniotic fluid cells in 
routine prenatal clinical practice. 
Methods 
In this evaluation study, the MLPA test using kit P095 was performed on 1,000 consecutive 
amniotic fluid samples and the results obtained were compared with traditional 
karyotyping (TK), the gold standard. 
Results 
The absolute specificity and sensitivity of the MLPA test were 100%. The test yielded a 
rapid reporting time: 94% within three working days and 5% within seven working days. 
The test failure rate was 0.8%. The percentage of abnormalities undetectable using this 
specific test was 2.4%: abnormal foetal ultrasound (N=9), increased risk first trimester 
screening (N=2), advanced maternal age (N=3) or other reason for referral (N=10). These 
abnormalities can be categorised in clinically significant (N=8), clinically uncertain (N=4) 
and clinically non-significant (N=12). 
Conclusions 
MLPA P095 is suitable as a stand-alone test for the rapid and efficient detection of the 
most common chromosomal aneuploidies in routine prenatal clinical practice. 
A flowchart for integrating the MLPA test into the cytogenetic laboratory workflow is 
presented. 
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total, 740 pregnancies at risk for Down syndrome. In Figure 1, the karyotype results of all 
1,000 amniotic fluid samples are shown compared with the MLPA results.
MLPA and traditional karyotyping in a research setting
The mean volume of amniotic fluid used for DNA isolation was 3.0 ml (range 1.0-8.0 ml). 
From all normal samples (N=370), the MLPA test was non-informative in 17 samples 
(4.3%), mostly due to low DNA concentrations. The MLPA was concordant with TK in 353 
normal samples, and in 21 samples with trisomies 21, 18, 13 and/or copy number changes 
of the sex chromosomes, there were no false-positive or false-negative diagnoses. TK 
revealed nine chromosomal abnormalities that were not detected by MLPA: one 69,XXX 
and two unbalanced structural rearrangements in patients with foetal ultrasound 
abnormalities, four known familial balanced rearrangements and in two pregnancies at 
risk for Down syndrome de novo balanced translocations. In one of these latter samples, 
the MLPA test failed.
MLPA and traditional karyotyping in a routine clinical setting
The mean volume of amniotic fluid used for DNA isolation was 4.0 ml (range 2.0-4.0 ml). 
Concordant MLPA measurements were obtained within three working days in 94% of 
the samples, 5% of the samples had a reporting time of seven days and in 0.8% of the 
cases, the MLPA test failed. Test failure occurred in three samples in which one of the 
duplicate measurements failed after repeated testing, and in two cases with an 
intrauterine foetal death, which resulted in (partial) DNA degradation.
All normal samples (N=548) and cases with trisomies 21, 18, 13 and/or copy number 
changes of the sex chromosomes and male triploidies (N=30) were correctly identified 
by MLPA and there were no false-positive or false-negative results. TK revealed three 
unbalanced structural rearrangements in patients with foetal ultrasound abnormalities. 
These abnormalities represented one trisomy 21 due to a Robertsonian translocation, 
Germany). The MLPA test, using kit P095, was performed according to the instructions of 
the manufacturer (www.mrc-holland.com). The polymerase chain reaction (PCR) 
products obtained were quantified by capillary electrophoresis on an ABI 3100 analyser, 
using Genescan analysis software (version 3.7) and Genemapper (version 4.0) software, 
all from Applied Biosystems. Samples were examined by visual inspection of the peak 
profiles in the electropherogram of the MLPA products. Substantial differences in peak 
heights in at least two consecutive loci were considered to be suspect for a structural 
chromosomal abnormality. Next, the MLPA peak areas were exported to a Microsoft 
Excel datasheet.
First an intra-sample normalisation of each probe peak area was performed, followed by 
an inter-sample normalisation with respect to the two normal reference samples (one 
male and one female) included in the same run. This normalisation was essential because 
variations in experimental conditions may lead to quantitative differences. Subsequently, 
MLPA results were expressed as the mean ratio per chromosome with a 95% confidence 
interval (CI). By doing so, the expected mean value of 1.0 represents two copies of the 
target sequence in the sample, whereas one or three copies of the target sequence 
result in expected mean values of 0.5 or 1.5, respectively.
On the 400 amniotic fluid samples collected in 2006, a single MLPA reaction was 
performed in a research setting, i.e. the results were compared with TK and not reported 
to the patient or the obstetrician. On the 600 consecutive samples collected in 2007, 
MLPA was performed in a clinical setting, i.e., the MLPA results were reported to both the 
patient and the obstetrician. Independent duplicate measurements were carried out to 
exclude sample mishandling. Repeated measurements were performed in case the 
duplicate measurements were discordant or when one of the MLPA tests failed. A test 
result was considered abnormal when the theoretical value (=expected value in a normal 
case) was not included in the CI 95% in both duplicate measurements and when at least 
one of the mean probe ratios differed 10% of the expected value. This notion was 
subsequently tested by extended karyotyping (all available clones were examined for 
the abnormality). Two different failure criteria were used in order to measure the effect 
of the test failure on the reporting time: technical failure and discordant results of the 
duplicate measurements.
Results
Patient characteristics
In Table 1, an overview of all referral reasons is given. The median age of the 595 patients 
with referral ‘advanced maternal age’ was 38 (range, 36-45) years. In addition, 145 of the 
patients were ‘screen positive’ after first trimester screening, resulting in a group of, in 
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Table 1. Overview of the referral reasons of the 1,000 amniocentesis
Referral reason N
Advanced maternal age 595
Increased risk first trimester screening
<36 years 
≥36 years
83
62
Abnormal foetal ultrasound 179
Others 81
Total 1,000
72 73
(N=51, the three samples with 46,XY,del(13)(q31.2), 46,XY,der(14;21),+21 and 
47,XY,t(11;18),+18 were not included). All MLPA test results were concordant with TK 
resulting in a 100% absolute specificity (95% CI: 99.6-100) and sensitivity (95% CI: 93.0-100). 
Table 2 shows an overview of the referral reasons of the 54 samples with an abnormality 
detected with MLPA. The aneuploidies included trisomy 21 (N=24), trisomy 18 (N=15), 
trisomy 13 (N=5), 69,XXY (N=2), 47,XYY (N=2), 45,X (N=2) and 48,XYY,+21 (N=1). In Figure 
2, the results of the mean probe ratios for the target chromosomes are presented as box 
plots, showing the medians, as well as the 5th, 25th, 75th and 95th percentiles. 
46,XY,der(14;21),+21 and a 47,XY,t(11;18),+18 karyotype. The third sample was indicative 
for a partial deletion of chromosome 13, since three of the distal consecutive MLPA 
probes for chromosome 13 showed decreased peak heights. TK of this sample revealed 
a 46,XY,del(13)(q31.2) karyotype. Four samples resulted in a failure of TK, whereas in three 
of these cases a positive MLPA result (one with trisomy 21) was obtained. In the remaining 
cases, TK revealed chromosomal rearrangements that were not detected by MLPA: one 
69,XXX and four unbalanced structural rearrangements in patients with foetal ultrasound 
abnormalities and eight balanced rearrangements (two of which were determined 
familial after karyotyping of the parents). In two pregnancies at risk for Down syndrome, 
a de novo balanced translocation was detected.
High absolute specificity and sensitivity 
The capability to detect all abnormalities that the MLPA test is able to identify, compared 
with TK, was calculated based on all detectable euploidies (N=901) and aneuploidies 
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Figure 1. 
Results of traditional karyotyping and MLPA in 1,000 amniotic fluid samples
 *trisomy 21 (N=25) 48,XXY,+21 included in group with trisomy 21.
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Reduced relative sensitivity 
The ability to detect any abnormality with MLPA within the range of all possible 
abnormalities that can be identified by TK was determined. This was based on 78 
abnormal karyotypes from which 24 were detected by TK, but not by MLPA, and resulted 
in a relative sensitivity of 69.2% (95% CI: 57.7-79.2). Table 3 shows an overview of the 
referral reasons of the 24 samples with a MLPA result discordant with TK. Excluded were 
26 samples: 22 with MLPA failures and 4 with TK failures. The number of abnormalities 
detected by TK in samples encompassing all referral reasons that were technically 
undetectable by MLPA was 24 (2.4%). Within this group, a categorisation can be made 
between clinically significant (N=8), uncertain clinical significance (N=4) and clinically 
non-significant (N=12). All clinically significant abnormalities were detected in amniotic 
fluid cells from pregnancies with a foetal ultrasound abnormality. For the group of 
pregnancies at risk for Down syndrome (N=740), the relative sensitivity was 77.3% (95% 
CI: 54.6-92.2), based on 22 abnormal karyotypes from which 17 were detected by MLPA. 
The five undetectable abnormalities included four balanced de novo translocations with 
uncertain clinical relevance and one sample with a familial translocation.
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Figure 2. 
Mean probe ratios of the chromosome 21, 18, 13, X and Y targets, with 50% of the mean probe 
ratios within the box.
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site may also result in a reduced relative peak level. However, MRC Holland has designed 
its probes such that, it avoids polymorphisms known from the Genbank databases. 
Overall, we used independent duplicate measurements in order to reduce any risk of 
sample mishandling. 
It is relevant to note that results obtained with the uncultured amniotic fluid cells, as is 
the case with molecular tests such as MLPA, have stronger associations with pregnancy 
outcome than results obtained with the cultured amniotic fluid cells, as is the case with 
TK (Robinson et al., 2002). This notion is based on the fact that uncultured amniotic fluid 
cell populations contain different cell types and thus provide a better indication of the 
overall foetal status than cultured cell populations, which are clonal outgrowths of 
cellular subpopulations and thus affect the genetic make-up of a (mosaic) cell population 
studied (Donaghue et al., 2005). Although no mosaic samples were available in our 
prospective study, we performed a series of artificial dilution experiments. The results 
showed that the lowest detectable mosaicism for trisomy 21 was 20%, with a mean 
probe ratio of 1.17 with a CI 95%: 1.01–1.32 (Kooper et al., 2008). The expected mean 
value of 1.0 or 1.5 representing two or three copies for chromosome 21, respectively, was 
outside the CI 95% and was therefore indicative for a mosaic trisomy 21. Whenever a 
mosaicism for one of the target chromosomes is suspected, follow-up analysis is 
warranted.
In recent years, there has been ample debate on whether targeted testing can replace 
TK. The main argument against replacing TK is that targeted prenatal testing holds an 
a-priori risk of detection limitation. Several studies have addressed the issue of residual 
risk of undetected chromosome abnormalities in relation to clinical significance. As far 
as the clinical relevance of these anomalies is concerned, it is anticipated that at least a 
number of these pregnancies will result in miscarriages and/or will be associated with 
abnormalities detectable by ultrasound (Bui, 2007). For pregnancies with an increased 
risk of Down syndrome, a change of policy from full karyotype analysis to rapid molecular 
aneuploidy testing would result in a failure to detect chromosome abnormalities likely 
to have serious clinical consequences. This residual risk was estimated to be 0.06% (1 in 
1,659) by Ogilvie (Ogilvie et al., 2005b), 0.1% (1 in 1,000) in a retrospective audit of about 
14,000 invasive prenatal diagnoses by Bui (Bui, 2007) and 0.07% (1 in 1,500) in our own 
retrospective study of 7,140 women with an advanced maternal age (Kooper et al., 
unpublished data). Within this context, it is important to note that unavoidable detailed 
information obtained with TK with unpredictable outcomes requires intensive genetic 
counselling and may even result in unwarranted pregnancy terminations (Leung et al., 
2004b; Ogilvie, 2003). It is also important to realise that a first trimester screening is 
designed to screen for Down syndrome and, therefore, that follow-up diagnosis with 
targeted testing alone should realistically fulfil the expectations of the couples and 
Discussion 
It has been reported that QF-PCR and/or MLPA may serve as suitable methods for a rapid 
detection of the most common (non-mosaic) chromosome abnormalities in amniotic 
fluid cells (Grimshaw et al., 2003; Slater et al., 2003; Nicolini et al., 2004; Gerdes et al., 
2005b; Hochstenbach et al., 2005; Cirigliano et al., 2006). It has also been reported that 
both the technologies have their benefits and limitations (Shaffer and Bui, 2007). The 
accuracy of QF-PCR in prenatal diagnosis has already been demonstrated in a number of 
large studies (Nicolini et al., 2004; Cirigliano et al., 2006). One of the rationales for 
introducing the MLPA P095 test in our laboratory setting was based on the availability of 
a commercial kit, produced by MRC Holland. MLPA tests are suited for further tailor-made 
applications, including the detection of common aneuploidies, microdeletions and 
single-gene mutations such as those encountered in cystic fibrosis. Also, a mental retar-
dation-tailored assay can be devised including known microdeletion-associated and 
sub-telomeric targets which could be used for the genetic analysis of pregnancies with 
an ultrasound abnormality, but a normal karyotype (Northrop et al., 2005; Rooms et al., 
2006; Faas et al., 2008). In reverse, as compared with QF-PCR, MLPA is relatively sensitive 
to DNA quality and does not allow the detection of maternal cell contamination in 
samples from females and/or the detection of female triploidies. Since there is only one 
commercial supplier of MLPA kits, a sufficient amount of kits should be stored in order to 
guarantee a prenatal diagnostic service. 
To assess the cost-effectiveness of introducing molecular tests for prenatal diagnosis of 
chromosome abnormalities, the costs of QF-PCR were calculated in an extensive report 
(Grimshaw et al., 2003). A comparable study will be performed for MLPA within a 
nationwide study M.A.K.E. (MLPA and karyotyping, an evaluation) in the Netherlands 
(Boormans et al., 2008). The use of interphase-fluorescence in situ hybridization (I-FISH) 
as stand-alone test for pregnant women at risk for Down syndrome compares 
unfavourably to MLPA and/or QF-PCR, i.e. with our standard routine quality assessment 
to perform a stand-alone test via independent duplicate measurements; I-FISH is not 
suitable for high-throughput analysis. 
From our combined results, we conclude that the MLPA P095 test allows a fast, reliable 
and accurate detection of (an)euploidies of the chromosomes 13, 18, 21, X and Y in 
amniotic fluid cells. Although this MLPA kit was designed to detect copy number changes 
of the selected target chromosomes, partial deletions or duplications can also be 
detected through reduced or increased levels of individual peaks. On the basis of this 
notion, one of the MLPA results was indicative for a partial deletion of chromosome 13. 
This finding was subsequently confirmed with TK. Decreased levels of a single probe 
may be due to a point mutation. Theoretically, polymorphisms close to the probe ligation 
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obstetricians. In this study, four apparently balanced de novo structural rearrangements 
remained undetected by MLPA in the group of pregnancies with an increased risk of 
Down syndrome. The risk of a serious congenital anomaly is estimated to be 6.1% for de 
novo reciprocal translocations (Warburton, 1991). It should be noted, however, that such 
unexpected findings are mostly not foreseen and result inevitably in uncertainties about 
the pregnancy. 
Since a few years, women in Stockholm, Sweden, with an increased risk of Down 
syndrome undergoing amniocentesis can choose between rapid aneuploidy detection 
(by QF-PCR) and full karyotyping. Experience based on over 6,000 clinical cases has 
shown that about 70% of these women choose rapid aneuploidy detection by QF-PCR 
(Bui, 2007). In the Netherlands, as yet, little is known about the patient’s preference 
(Leung et al., 2008). Therefore, we plan to implement the Swedish model in which 
women have the autonomy to choose between rapid aneuploidy testing (by MLPA) and 
TK. In Figure 3, we provide a laboratory flowchart for samples obtained from women at 
risk for Down syndrome. Inclusion of back-up protocols is needed in a targeted 
stand-alone policy to avoid pregnant women from having repeated amniocentesis. 
The back-up protocols we use are i) storage of DNA in all samples with a normal MLPA 
test, this allows follow-up examination, in case a foetal anomaly is detected with the 
scan taken at 20 weeks and ii) TK when a MLPA test failure occurs. We recommend the 
suggested routine of duplicate analysis as a standard routine quality assessment for all 
types of stand-alone tests in a prenatal diagnostic setting, predominantly to prevent 
sample mishandling. 
We anticipate that in the near future, next to QF-PCR, implementation of the MLPA P095 
test as a stand-alone test will be one of the major steps forward in assessing the genetic 
constitution of the foetus.
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Figure 3. 
Laboratory flowchart for amniotic fluid samples obtained from women with an increased risk 
for Down syndrome (referral reason advanced maternal age and/or increased risk at first 
trimester screening, with a nuchal translucency <3.5 mm). When the MLPA result is normal, 
DNA from 12 ml back-up amniotic fluid is isolated and stored. Additional MLPA for the detection 
of sub-microscopic  rearrangements is performed when an abnormality is detected with the 
foetal anomaly scan (week 20 of gestation). When the MLPA result is abnormal, follow-up 
karyotype analysis is carried out to identify the origin of the aneuploidy.
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Introduction
Recently, rapid methods such as quantitative fluorescence (QF)-PCR and multiplex liga-
tion-dependent probe amplification (MLPA) for the detection of common chromosome 
aneuploidies have been reported (Slater et al., 2003; Grimshaw et al., 2003; Nicolini et al., 
2004; Mann et al., 2004; Hochstenbach et al., 2005; Gerdes et al., 2005a; Cirigliano et al., 
2006). As a consequence, a validated QF-PCR test is currently offered to pregnant woman 
in a number of prenatal centres in Europe (Cirigliano et al., 2001; Ogilvie et al., 2005a). 
Previously, Slater et al. reported that MLPA with kit P001 may serve as a rapid, flexible, 
sensitive and robust test for prenatal aneuploidy detection (Slater et al., 2003). 
Subsequently, Hochstenbach et al. reported on the performance of the P001 probe set 
in uncultured amniocytes (Hochstenbach et al., 2005). In 2005 MLPA kit P095, an improved 
version of the P001 kit, became available. Gerdes et al. developed software for fully 
automated analysis of the P095 kit and examined the probe reliabilities and corresponding 
SDs (Gerdes et al., 2005a). Very recently, van Opstal et al. (Van Opstal et al., 2009) reported 
that MLPA serves as a reliable method that could be used as a stand-alone test for rapid 
aneuploidy detection (RAD). Here we aimed to assess the individual probe performances 
of the P095 MLPA kit. Previously, mosaics for aneuploidies of chromosomes 21, 18, 13, X 
and Y have been reported to occur in 0.016% (Worton and Stern, 1984) and in 0.007% (Bui 
et al., 1984) of amniotic fluid samples. The phenotypic consequences of these mosaic 
aneuploidies span a broad range from full clinical manifestation to clinically unaffected. 
The detection of mosaicisms, however, represents a major problem in prenatal 
diagnostics and they may remain undiagnosed due to low-grade levels. Therefore, we 
also assessed the lowest limit of mosaic detection by MLPA kit P095. 
Material and methods
Clinical samples
Amniotic fluid samples were collected at the outpatient clinics located in Nijmegen, 
Arnhem, Tilburg, ‘s-Hertogenbosch and Enschede in the Netherlands. The referral 
reasons of these samples covered the whole range from low-risk to high-risk, with known 
clinical abnormalities detected by ultrasound and/or maternal serum screening. 
Sample preparation and MLPA application 
The MLPA test was performed through independent duplicate measurements using 
purified DNA from amniotic fluid cells. DNA from 2-4 ml amniotic fluid was isolated using 
a QIAamp kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. 
Abstract 
Objectives
To assess individual probe performances of the multiplex ligation-dependent probe 
amplification (MLPA) test kit P095 for the detection of aneuploidies and mosaics of 
chromosomes 21, 18, 13, X and Y in uncultured amniotic fluid samples. 
Methods
A set of 199 euploid and 50 aneuploid uncultured amniotic fluid samples was used. 
Since exclusion of poor performing probes may improve overall sensitivity, individual 
MLPA performance of the probes in kit P095 were assessed. In addition, artificial dilution 
experiments were carried out to establish the (mosaic) detection limits of the test.
Results
In the euploid and aneuploid amniotic fluid samples tested, the MLPA test yielded an 
absolute sensitivity and specificity of 100% for the detection of trisomies of chromosomes 
21, 18 or 13. The pooled standard deviation (SD) for the autosomal chromosomes was 
0.044. Theoretical exclusion of the autosomal probes with the highest individual SD 
resulted in a slight decrease of this pooled SD to 0.037. In addition, we found that 
mosaicisms of approximately 20% are detectable by the MLPA test. 
Conclusion
The MLPA test (kit P095) is suitable for the detection of non-mosaic (an)euploidies in 
amniotic fluid samples and yields abnormal results in manufactured mosaics when cell 
populations contribute at least 20% to the sample. Individual probes performed well; 
exclusion of the poorest performing probes only slightly affected the test sensitivity.
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karyotyping. A full description of the data analysis procedure is shown in data supplement 
I an example given in data supplement II (see Supplemental Data I and II).
Inclusion criteria 
A set of 249 amniotic fluid samples with an informative MLPA result, 199 normal results 
and 50 results indicative for an aneuploidy for one of the target chromosomes, was 
selected. This selection was based on the following eligibility criteria: input of 2-4 ml 
amniotic fluid (exclusion of heavily blood-stained samples) and sufficient input of DNA 
by visual fragment examination. Because tests results were obtained as two duplicate 
measurements per sample, one of these results was randomly included in this study. 
MLPA was performed prospectively in 239 of the 249 (96%) of the samples in a clinical 
setting, i.e., the MLPA results were reported to both the patient and the obstetrician. 
To extend the number of aneuploid samples, ten cases (seven with a trisomy 21 and 
three with a trisomy 18) were included from previous sampling in a preclinical setting.
Probe performance 
Average, standard deviation (SD) and chromosome ratio were determined on a set of 
199 euploid samples and 50 aneuploid samples with trisomy 21 (N=31), trisomy 18 (N=16), 
trisomy 13 (N=3), respectively. The standard deviations per probe were used to provide 
information on the performance of each probe. Based in this information, probes with 
the highest SD were theoretically excluded in order to assess its effect on the overall 
performance of the MLPA test. 
Lower limit of detection mosaic
To determine the lowest limit of mosaicism, three step-wise dilution experiments (100:0, 
90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90, 0:100%) were performed using 
a normal sample and a sample with trisomy 21, trisomy 18 or trisomy 13, respectively. 
MLPA tests were performed on all mixtures of every dilution.
Results
Statistics of the chromosome ratios
An overview of the mean chromosome ratios in the cohort of 249 amniotic fluid samples 
(199 euploid and 50 aneuploid) is presented in Table 1. The observed mean chromosome 
ratios for the presence of two copies of a target chromosome were in the range of 0.98 
to 1.04 and, thus, close to the expected value of 1.0. The mean ratios for a single copy or 
three copies were in the range of 0.47 to 0.51 and 1.46 to 1.51, respectively. The SD for the 
The principle of the MLPA has been described in detail previously (Schouten et al., 2002).
The MLPA test with the SALSA MLPA kit P095 Aneuploidy was performed as described by 
Schouten (MRC Holland, Amsterdam, the Netherlands). The P095 probe mix contains 36 
different probes generating amplification products ranging in size between 136 and 454 
nucleotides. Four of these probes (Y-chromosome) only generate signals from male 
samples, whereas for each of the chromosomes 21, 18, 13 and X eight probes are included 
in the mix. Each amplified probe product was identified and quantified by capillary 
electrophoresis on an ABI 3100 analyzer, using Genescan analysis software (version 3.7) 
and Genemapper (version 4.0) software, all from Applied Biosystems. Independent 
duplicate measurements were performed, i.e., all steps from DNA extraction, PCR to 
MLPA analysis were performed in complete independent experiments predominantly to 
exclude sample mishandling.
Peak examination and normalization
Routine visual examination of peak heights of individual MLPA probes in the electro-
pherogram were compared with the peaks in the electropherogram of normal 
gender-matched reference samples. Subsequently, data analysis was carried out upon 
the transfer of GeneMapper results to a modified spreadsheet for normalization and ratio 
computation of the peak areas. First an intra-sample normalization of each probe peak 
area was performed, followed by an inter-sample normalization with respect to the two 
normal reference samples (one male and one female) included in the same run. 
Inter-sample normalization is essential because variations in experimental conditions 
may lead to quantitative differences. As a consequence of this normalization procedure, 
mean probe ratios per chromosome (called chromosome ratios) skew in case of a trisomy, 
since the probe ratios of the targets with two copies scale down to 80% when a trisomy 
for one of the targets is present. This decrease in chromosome ratios is not corrected for 
in the data analysis. The mean and standard deviation (SD) of each target chromosome 
was determined, followed by the 95% confidence interval (CI) defined as mean ± t0.05 * 
(SD/√n), where t0.05 is the percentage point of the t-distribution with (n-1) degrees of 
freedom, which gives a two-tailed probability of 0.05 and n is the number of targets on 
the chromosome (8 for chromosomes 13, 18, 21 and X and 4 for chromosome Y). In case 
of disomy (two copies of each target chromosome), these calculations will result in an 
expected or theoretical value of 1.0, representing two copies of the target sequence in 
the sample. One or three copies of the target sequence in a sample will result in theoretical 
values of 0.5 or 1.5, respectively. A test result is considered abnormal when the theoretical 
value (= expected value in a normal case) is not included in the 95% CI in both duplicate 
measurements and when at least one of the mean probe ratios differs 10% of the 
expected value. Follow-up analysis of these abnormal samples was performed by 
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revealed that these outlier effects cannot be ascribed to the performance of specific 
individual probes. Results interpreted as inconclusive represented 95% CIs too wide to 
be useful for the chromosomes 13, 18, 21 and X in females, and were all confined to the 
same samples. After elimination of these inconclusive results, which are likely due to 
DNA impurities, we conclude that the MLPA test results yield a sensitivity for the 
detection of trisomies 13, 18 and 21 of 100% (95% CI: 29.2-100), (95% CI: 79.4-100) and 
(95% CI: 88.8-100), respectively, and a specificity of 100% (95% CI: 98.2-100) for the 
detection of disomies 13, 18 and 21.
Assessment of individual probe performance 
To evaluate the performance of the individual probes of all target chromosomes, the 
standard deviation (SD) of each probe was calculated in the euploid (Table 2) and for the 
autosomes in the aneuploid (Table 3) samples. In Table 2, the probes with the highest 
mean probe SD are highlighted: 13m7, 18m7, 21m8, Xm1 (in female), Xm8 (in male) and 
Ym3 with a SD of 0.281, 0.126, 0.135, 0.119, 0.084 and 0.085, respectively. 
chromosome ratios was calculated from the totals of euploid and aneuploid samples. 
The SDs were, for chromosomes 13, 18, 21 and X in the euploid samples, in the range of 
0.03 to 0.05, and for the Y chromosome 0.06. The SDs of the chromosomes in the 
aneuploid samples were in the range of 0.04 to 0.07, which may be due to the relatively 
limited number of samples included in this set (50 versus 199). 
To identify outliers in each sample, all individual chromosome ratios at 95% CIs were 
assessed. Subsequent evaluation of the outliers with a chromosome ratio >0.25 SD 
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Table 1.  Statistics of chromosome ratios of 199 normal samples, 50 samples 
exhibiting a non-mosaic aneuploidy and 3 samples exhibiting 20% and 
80% of mosaic trisomies 13, 18 or 21.
Chromosome Sample set N Expected
mean
Observed
mean
95% CI SD
13 Trisomy 13 3 1.5 1.51 - 0.07
13
13
Trisomy 13 (80%)
Trisomy 13 (20%)
1
1
1.4
1.1
1.35
1.11
1.31-1.38
1.10-.112
-
-
13 Normal 199 1.0 0.99 - 0.05
18 Trisomy 18 16 1.5 1.46 - 0.04
18
18
Trisomy 18 (80%)
Trisomy 18 (20%)
1
1
1.4
1.1
1.39
1.13
1.33-1.46
1.08-1.19
-
-
18 Normal 199 1.0 0.98 - 0.04
21 Trisomy 21 31 1.5 1.49 - 0.04
21
21
Trisomy 21 (80%)
Trisomy 21 (20%) 
1
1
1.4
1.1
1.43
1.17
1.40-1.46
1.01-1.32
-
-
21 Normal 199 1.0 1.04 - 0.04
X (female) Normal 99 0.98 0.97-0.99 0.04
X (male) Normal 100 0.51 0.51-0.52 0.03
Y (male) Normal 100 0.47 0.46-0.48 0.06
After exclusion
of probes
Sample set N Mean 95% CI SD
13m7 Normal 199 0.99 0.99-1.00 0.04
18m7 Normal 199 0.97 0.96-0.97 0.03
21m8 Normal 199 1.03 1.03-1.04 0.04
Xm1 Normal female  99 0.98 0.97-0.99 0.04
Xm1
Xm7
Xm7
Normal male
Normal female
Normal male
100
 99
100
0.51
0.96
0.50
0.51-0.52
0.95-0.97
0.50 0.51 
0.03
0.05
0.03
Ym3 Normal male 100 0.47 0.45-0.48 0.06
Table 2.   Statistics of the individual probes for chromosome 21, 18 and 13  
in 199 normal samples, X in 99 normal female samples, and X and Y in  
100 normal male samples.
Chr* No Mean 95% CI SD
21m1 199 1.056 1.043-1.070 0.096
21m2 199 1.076 1.064-1.087 0.083
21m3 199 1.074 1.064-1.084 0.069
21m4 199 0.996 0.983-1.009 0.094
21m5 199 1.039 1.025-1.053 0.101
21m6 199 1.032 1.020-1.045 0.088
21m7
21m8
199
199
0.958
1.113
0.942-0.974
1.094-1.132
0.114
0.135
18m1 199 0.989 0.980-0.997 0.061
18m2 199 0.910 0.901-0.918 0.060
18m3 199 0.917 0.906-0.928 0.077
18m4 199 1.015 0.998-1.032 0.118
18m5 199 0.999 0.987-1.011 0.087
18m6 199 0.987 0.973-1.001 0.010
18m7 199 1.061 1.043-1.079 0.126
18m8 199 0.955 0.939-0.970 0.111
13m1 199 0.961 0.951-0.971 0.074
13m2 199 1.028 1.017-1.039 0.079
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discrimination between individual mean probe ratios for euploidy and aneuploidy 
results. There are two outliers, probes Xm7, in both female and male samples with an 
increased mean probe ratio of 1.092 (95% CI: 1.074-1.110) and 0.577 (95% CI: 0.562-0.591), 
respectively (Figure 4). Based on the highest mean SDs measured in 199 samples, we 
conclude that probes 21m8, 18m7, 13m7 and outlier Xm7 represent the least reliable 
probes in kit P095. 
In the aneuploid samples (Table 3) probes for 13m5, 18m7 and 21m4 showed the highest 
mean SD, i.e., 0.187, 0.167 and 0.153, respectively. Probe 18m7 also showed a high mean 
SD in the euploid samples and, therefore, represents the least reliable probe. For 
chromosomes 13 and 21, the probes with the highest SD differ from the results of the 
euploid samples. 
This inconsistency is probably due to the small number of the aneuploid samples 
included (see above). The mean ratios of all individual probes of all target chromosomes 
of the euploid and aneuploid samples are depicted in Figure 4, resulting in a complete 
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Table 2.   Continued.
13m3 199 1.021 1.008-1.035 0.098
13m4 199 0.999 0.986-1.013 0.099
13m5 199 0.975 0.960-0.990 0.108
13m6 199 0.990 0.974-1.006 0.112
13m7 199 1.003 0.964-1.043 0.281
13m8 199 0.961 0.944-0.978 0.123
Xm1
Xm2
Xm3
Xm4
Xm5
Xm6
Xm7
Xm8
 99  
 99
 99
 99
 99
 99
 99
 99
0.978
0.904
0.963
1.005
0.954
0.930
1.092
0.997
0.955-1.002
0.882-0.925
0.947-0.979
0.984-1.026
0.933-0.975
0.913-0.946
1.074-1.110
0.980-1.014
0.119
0.106
0.081
0.105
0.105
0.085
0.092
0.087
Xm1
Xm2
Xm3
Xm4
Xm5
Xm6
Xm7
Xm8
100
100
100
100
100
100
100
100
0.506
0.481
0.521
0.527
0.504
0.486
0.577
0.507
0.493-0.519
0.470-0.492
0.509-0.533
0.514-0.540
0.492-0.515
0.476-0.496
0.562-0.591
0.450-0.523
0.066
0.055
0.063
0.066
0.058
0.049
0.075
0.084
Ym1
Ym2
Ym3
Ym4
100
100
100
100
0.485
0.410
0.476
0.503
0.468-0.502
0.395-0.426
0.459-0.493
0.491-0.514
0.084
0.078
0.085
0.056
*Probes with the highest mean probe SD are highlighted.
Table 3.   Statistics of the individual probes for chromosome 21, 18 and 13 in samples 
with an aneuploidy (trisomy 21, N=31, trisomy 18, N=16, trisomy 13, N=3).
Chr* Sample set Mean 95% CI SD
21m1 Trisomy 21 1.506 1.465-1.547 0.111
21m2 Trisomy 21 1.528 1.491-1.564 0.099
21m3 Trisomy 21 1.520 1.479-1.561 0.112
21m4 Trisomy 21 1.417 1.361-1.473 0.153
21m5 Trisomy 21 1.427 1.386-1.467 0.110
21m6 Trisomy 21 1.506 1.453-1.600 0.146
21m7 Trisomy 21 1.464 1.411-1.516 0.140
21m8 Trisomy 21 1.570 1.521-1.620 0.131
18m1 Trisomy 18 1.423 1.389-1.457 0.064
18m2 Trisomy 18 1.358 1.296-1.421 0.118
18m3 Trisomy 18 1.400 1.355-1.445 0.085
18m4 Trisomy 18 1.522 1.465-1.576 0.102
18m5 Trisomy 18 1.448 1.397-1.498 0.094
18m6 Trisomy 18 1.538 1.478-1.600 0.115
18m7 Trisomy 18 1.532 1.443-1.621 0.167
18m8 Trisomy 18 1.440 1.372-1.509 0.128
13m1 Trisomy 13 1.398 1.271-1.524 0.051
13m2 Trisomy 13 1.577 1.402-1.753 0.070
13m3 Trisomy 13 1.546 1.340-1.753 0.083
13m4 Trisomy 13 1.553 1.305-1.801 0.100
13m5 Trisomy 13 1.564 1.095-2.032 0.187
13m6 Trisomy 13 1.459 1.355-1.562 0.042
13m7 Trisomy 13 1.364 1.164-1.564 0.022
13m8 Trisomy 13 1.482 0.569-2.395 0.102
*Probes with the highest mean probe SD are highlighted.
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this pooled SD to 0.037. The exclusion of the Xm1 and Ym3 probes with the highest SD 
had no effect on the pooled SDs. Exclusion of probe Xm7 resulted in an increase of SD in 
normal female samples from 0.04 to 0.05 and had no measurable effect in normal male 
samples.
We conclude that the impact of this optimization step through probe selection has a 
minimal impact on the overall MLPA test performance. 
The detection level of trisomy 21, 18 or 13 mosaics 
In Figure 5 step-wise dilution experiments are depicted using samples with trisomy 21, 
18, 13 and a normal disomic sample. In this graphical plot, chromosome 21, 18 and 13 
show a shift from a normal ratio of 1.0 towards a complete trisomy with a ratio of 1.5. The 
lowest detectable manufactured mosaics (80% normal DNA - 20% trisomic DNA) in the 
dilution experiments yielded mean probe ratios of 1.17 (95% CI: 1.01-1.32), 1.13 (95% CI: 
1.08-1.19) and 1.11 (95% CI: 1.10-1.12) for the chromosomes 21, 18 and 13, respectively. 
These chromosome ratios are significantly increased since the 95% CI in a 80-20% mixture 
does not include 1.0 and are ≥1.1. In Figure 5 the mean probe ratios of 1.43 (95% CI: 
1.40-1.46) for chromosome 21, 1.39 (95% CI: 1.33-1.46) for chromosome 18, and 1.35 (95% 
CI: 1.31-1.38) for chromosome 13 in the three dilution experiments (80% trisomic DNA - 
20% normal DNA) are marked. These 20-80% mixtures do not include probe ratios of 1.5, 
whereas the mean probe ratios of the target chromosomes are nearly 1.4. An overview 
of all ratios of the chromosomes 21, 18 and 13 and the theoretical profiles in the dilution 
experiments are shown in Table 4. Chromosome ratios and 95% CI of the 80-20% and the 
20-80% mixtures are included in Table 1 next to the results of normal samples or samples 
with a non-mosaic aneuploidy.
Assessment of the optimal probe selection 
In order to optimize the probe set, average and standard deviations for the chromosome 
ratios of the autosomes were re-calculated after a theoretical elimination of the probes 
with the highest SD, i.e., 21m8, 18m7 and 13m7. This optimization step resulted in a 
minimal decrease of the SD of the ratios for chromosomes 21, 18 and 13 from 0.04, 0.04 
and 0.05 to 0.04, 0.03 and 0.04, respectively (Table 1). The pooled SD, calculated as the 
square root of the mean variance for these autosomal chromosomes, was 0.044. 
Theoretical exclusion of the probes with the highest SD resulted in a slight decrease of 
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Figure 4. 
Quantitative MLPA analysis of individual mean probe ratios of the chromosome 21, 18, 13, X and 
Y targets, with 50% of the probes within the box. The outliers (marked by o) are probes with 
values between 1.5 and 3 box-lengths from the boundaries of the box. There are two outliers, 
both for probe Xm7, in both female and male samples with an increased mean probe ratio of 
1.092 (95% CI: 1.074-1.110) and 0.577 (95% CI: 0.562-0.591), respectively.
Table 4.  Chromosome ratios and theoretical profile of dilution experiments.
Trisomy (%) 0 10 20 30 40 50 60 70 80 90 100
Theoretical  1.00 1.05 1.10 1.15 1.20 1.25 1.30 1.35 1.40 1.45 1.50
profile
trisomy 21 1.01 1.06 1.17 1.21 1.26 1.31 n.a. 1.34 1.43 1.42 1.46
trisomy 18 0.98 1.02 1.13 1.12 1.19 1.23 1.22 1.34 1.39 1.42 1.45
trisomy 13 1.00 1.04 1.11 1.13 1.23 1.24 1.31 1.30 1.35 1.43 1.41
n.a. not available
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with Gerdes et al. (Gerdes et al., 2005a) a more detailed probe analysis revealed that 
probe 13m7 (Table 2) is the probe with the highest mean SD in this kit. Exclusion of the 
least reliable autosomal probes from the mix, however, resulted in only a slight decrease 
in the pooled probe SD of 0.007 and, therefore, does not contribute significantly to the 
reliability of the test. 
Since our data analysis approach is based on statistics of mean probe ratios in conjunction 
with a 95% CI, it may provide a better diagnostic power for the detection of mosaic 
anomalies than the employment of fixed thresholds for normal and abnormal samples 
(Li et al., 2005). The criteria we used for the presence of a potential mosaicism were i) the 
expected mean probe ratios of both duplicate measurements were outside the 95% CI 
and ii) at least one of these mean probe ratios differed 10% from the expected value. In 
our experiments, the detection level of mosaicisms for trisomies 21, 18 or 13 with the 
MLPA test appeared to be approximately 20% and were therefore in the same range as 
traditional karyotyping of cultured cells. Within this context, it is relevant to mention 
that uncultured amniotic fluid cell populations contain different cell types and, thus may 
provide a better indication of the overall foetal status than cultured cell populations 
(Robinson et al., 2002), which are clonal outgrowths of sub-populations and thus have an 
effect upon the genetic make-up of a cell population (Donaghue et al., 2005). Therefore 
molecular tests such as MLPA, that make use of DNA from uncultured cells, may provide 
stronger associations with pregnancy outcome than traditional karyotyping. Although 
the main objective of the MLPA test kit P095 is to detect prevalent aneuploidies, it may 
also uncover unexpected partial cryptic chromosomal imbalances of the target 
chromosomes because the methodology involves relative quantification of single 
probes by examination of the electropherogram. This notion raises the question what 
criteria should be used for determining the significance of single losses or gains in probe 
signals. Van Opstal et al. (Van Opstal et al., 2009) encountered 0.08% (3 of 4,000) cases 
with a structural chromosome defect initially found by an amplification or a deletion of 
one or two of the MLPA probes. An example of the detection of a structural chromosomal 
imbalance by MLPA is depicted in Figure 6. The electropherogram shows three decreased 
peaks for chromosome 18. The ideogram of chromosome 18 illustrates the location of 
the MLPA probes on the distal q arm of chromosome 18 and is, therefore, indicative for 
a distal deletion of chromosome 18q. Follow-up cytogenetic analysis yielded a 
46,XX,del(18)(q21.2) karyotype. From a clinical point of view, it may be advantageous to 
detect deletions or duplications of one or two probes for the identification of structural 
chromosomal defects. On the other hand, however, these deletions or duplications may 
equally well represent harmless sub-microscopic copy number variations. Since the 
MLPA performance of kit P095 has not yet been validated at this level, we agree with van 
Opstal et al. (Van Opstal et al., 2009) that if MLPA is used as a stand-alone test (for 
Overall, we conclude that these three dilution experiments yield abnormal results when 
either the abnormal or the normal cell population contributes at least 20% to the sample.
Discussion
We tested a cohort of 199 euploid and 50 aneuploid amniotic fluid samples for the 
performance of the MLPA kit P095 and observed an absolute specificity and sensitivity 
of 100% with a 95% CI of 98.2-100 and 92.9-100, respectively. This means that this MLPA 
kit is designed in such a way that a good probe performance is obtained. In agreement 
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Three dilution experiments in which samples with a trisomy 21, 18 or 13 were mixed with a 
normal sample. Eleven dilutions are plotted on the horizontal axis representing mixtures of 
(from left to right) 100-0, 90-10, 80-20, 70-30, 60-40, 50-50, 40-60, 30-70, 20-80, 10-90, 0-100% 
normal DNA and DNA with trisomy 21, 18 or 13, respectively. In this plot, the mean probe ratios 
for chromosome 21, 18 and 13 show a shift from a normal value of 1.0 towards a complete 
trisomy with a value close to 1.5. The black circle marks the lowest detectable mosaics (80-20% 
mixtures), with a mean probe ratio of 1.17 (95% CI: 1.01-1.32) for chromosome 21, a mean probe 
ratio of 1.13 (95% CI: 1.08-1.19) for chromosome 18 and a mean probe ratio of 1.11 (95% CI: 
1.10-1.12) for chromosome 13. The red circle marks the dilutions of 20% normal DNA with 80% 
of trisomy 21, 18 or 13 DNA. These mixtures show a mean probe ratio of 1.43 (95% CI: 1.40-1.46) 
for chromosome 21, 1.39 (95% CI: 1.33-1.46) for chromosome 18 and 1.35 (95% CI: 1.31-1.38) for 
chromosome 13. 
94 95
pregnant women with an increased risk for Down syndrome), the interpretation of single 
probe quantification should be neglected. Furthermore, we propose that only in cases 
where at least two flanking probes are amplified or deleted in both duplicate 
measurements, further tests are warranted to confirm or disprove the suspected 
structural chromosomal anomaly.
In addition, it should be noted that the MLPA test kit P095 does not allow the detection 
of maternal cell contamination (MCC) in female prenatal samples and/or the detection of 
female triploidies and is not able to distinguish a complete male triploidy from a male 
sample with MCC. Therefore, heavily blood-stained samples are considered unsuitable 
for MLPA testing and amniotic fluid from pregnancies suspected for a triploidy should 
be subjected to other detection methods. Prenatal microarrays provide the potential to 
scan for genomic abnormalities at a high resolution (Rickman et al., 2006) and may be 
used in pregnancies with a foetal ultrasound abnormality and a normal karyotype.
Molecular genetic tests like FISH and QF-PCR are already available to clinical cytogenetics 
laboratories for the rapid detection of the most common aneuploidies in amniotic fluid 
cells. In several laboratories within Europe (Stockholm, Sweden (Bui, 2007) and London, 
UK (Mann et al., 2008)). QF-PCR is already used as a targeted stand-alone test for 
pregnancies with an increased risk for Down syndrome. Similarly, the MLPA test appeared 
to be suitable for the rapid and efficient detection of the most common chromosomal 
aneuploidies in routine prenatal clinical practice (Kooper et al., 2008). Within a nationwide 
study M.A.K.E. (MLPA And Karyotyping, an Evaluation) the patient’s preference for either 
rapid aneuploidy testing or traditional karyotyping are evaluated (Boormans et al., 2008).
Taken together, we conclude that the MLPA probe kit P095 shows a good probe 
performance and that exclusion of the least reliable probes only slightly affects the 
sensitivity of the assay.
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Figure 6. 
Electropherograms illustrating a normal female reference sample (A) and a patient sample  
(B). The eight series of four peaks represent MLPA probes for chromosomes 21, 18, 13 and X, 
respectively. Three peaks in sample B, representing 18m2, 18m4 and 18m6, are decreased as 
compared to the peaks of the normal reference sample and, therefore, indicative for a partial 
imbalance of chromosome 18. The corresponding probe ratios showed a mean of 1.09 (95% CI: 
0.82-1.35) for 21, 0.84 (95% CI: 0.47-1.21) for 18, 1.14 (95% CI: 0.83-1.45) for 13 and 1.09 (95% CI: 
0.93-1.25) for the X chromosome, respectively. The ideogram of chromosome 18 (C) shows the 
locations of the three decreased probes (18m2, 18m6 and 18m4) on the distal region of the long 
arm of chromosome 18. Follow-up karyotyping revealed a 46,XX,del(18)(q21.2) karyotype (D).
A
B
C
D
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Data supplement II   Example of peak normalization procedure. 
This example gives for the first two series of markers (m1 and m2) and for all eight 
chromosome 21 markers of one particular sample, the observed peak areas (Y), the 
intra-sample normalized values (Yn), the intra-sample normalized values of the female 
and male controls (reff respectively refm), the reference values (ref) and finally the 
inter-sample normalized values (Ynn). 
Yn for the first marker of chromosome 21 was calculated as the observed peak area 
divided by the sum of the observed values of Y on the first markers of chromosome 18 
and 13: 32606/(34218+34200)=0.47657. 
Yn for the first marker of chromosome 18 was calculated as the observed peak area 
divided by the sum of the observed values of Y on the first markers of chromosome 21 
and 13 34218/(32606+34200)=0.51220. 
Yn for the first marker of chromosome 13 was calculated as the observed peak area 
divided by the sum of the observed values of Y on the first markers of chromosome 21 
and 18 34200/(32606+34218)=0.51179.
Yn for the first marker of chromosome X is calculated as the observed peak area divided 
by the sum of the observed values of Y on the first markers of chromosome 21, 18 and 
13: 16600/(32606+34218+34200)=0.16432. 
Data supplement I   Full description of the data analysis procedure 
Intra-sample normalization with flanking probes (on either side or on one side of the 
probe) was performed as follows: normalized value of probe 21m1=observed peak area 
21m1 divided by sum of observed peak areas of 18m1 and 13m1; normalized value of 
probe 18m1=observed peak area 18m1 divided by sum of observed peak areas of 21m1 
and 13m1; normalized value of probe 13m1=observed peak area 13m1 divided by sum of 
observed peak areas of 18m1 and 21m1; normalized value of probe Xm1=observed peak 
area Xm1 divided by sum of observed peak areas of 21m1, 18m1 and 13m1; normalized 
value of probe Ym1=observed peak area Ym1 divided by sum of observed peak area of 
21m2, 18m2 and 13m2 (for males). For females the normalized value of the Y probes was 
set to 0. The same procedure was followed for the normalized value of probe 
21m2=observed peak area 21m2 divided by sum of observed peak areas of 18m2 and 
13m2, and so on. The next step was to further normalize these probe values with respect 
to reference values derived from the tray-specific references (one male and one female). 
The inter-sample normalization with tray-specific references was performed as follows: 
the reference value for a probe on chromosome 21, 18 or 13 was the mean of the 
corresponding intra-sample normalized probe values in both tray-specific references; 
the reference value for a probe on the X chromosome was 2/3 times the sum of the 
corresponding intra-sample normalized probe values in both tray-specific references; 
the reference value for a probe on the Y chromosome was 2 times the corresponding 
intra-sample normalized probe value of the male reference. Finally, an inter-sample 
normalized probe value was defined to be the ratio of the intra-sample normalized value 
and the reference value derived from the tray-specific references as described above. 
The mean and standard deviation (SD) of each target chromosome was determined, 
followed by the 95% confidence interval (CI) defined as mean ± t0.05 * (SD/√n), where 
t0.05 is the percentage point of the t-distribution with (n-1) degrees of freedom, which 
gives a two-tailed probability of 0.05 and n is the number of targets on the chromosome 
(8 for chromosomes 13, 18, 21 and X and 4 for chromosome Y). 
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Yn for the first marker of chromosome Y was calculated as the observed peak area 
divided by the sum of the observed values of Y on the second markers of chromosome 
21, 18 and 13: 19620/(32938+30488+30285)=0.20937.
The observed peak areas for the female and male controls are not displayed, only the 
 intra-normalized values obtained in the same manner as described above: reff and refm.
The reference value (ref) for a probe on chromosome 21, 18 or 13 is the mean of the 
corresponding intra-sample normalized probe values in both references ref=(reff+refm)/2. 
The reference value for a probe on the X chromosome is 2/3 times the sum of the 
corresponding intra sample normalized values within the controls: ref=2/3*(reff + refm).
The reference value for a probe on the Y chromosome is 2 times the corresponding 
intra-sample normalized values of the male control: ref=2*refm.
Finally, the inter-sample normalized values Ynn are defined to be the quotients Yn / ref. 
For example: the intra-sample normalized peak area for the first chromosome 21 repeat: 
0.98523=0.47657/0.48373.
In order to construct a 95% confidence interval, for example for the ‘true’ value of chromosome 
21 in this example, the mean and the standard deviation of the 8 Ynn values are needed:
Mean (0.98523, 1.11778, 1.14324, 0.97437, 1.00403, 0.98914, 0.94777, 1.063540)=1.02814.
The corresponding standard deviation is SD = 0.07155. Applying the formula for the 95% 
CI yielding a 95% CI: 0.97 – 1.09.
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Detection of chromosome aneuploidies 
in chorionic villus samples by MLPA
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Introduction 
Chorionic villus sampling has been widely accepted as a technique for first trimester 
prenatal diagnosis and is performed from 11 weeks of gestation. Until recently, prenatal 
diagnosis of chorionic villus samples (CVS) was accomplished through tissue culture and 
subsequent cytogenetic analysis. This procedure is labour-intensive and time-consuming. 
Therefore, more rapid and comprehensive methods for the prenatal diagnosis of CVS are 
currently being developed and implemented. In a number of prenatal centres in Europe, 
quantitative fluorescent PCR (QF-PCR) analysis is already being offered to women 
undergoing invasive testing by chorionic villus sampling (Cirigliano et al., 2004). In 
parallel, we have implemented multiplex ligation-dependent probe amplification (MLPA) 
for the rapid detection of (an)euploidies of chromosomes 21, 18, 13, X, and Y in amniotic 
fluid cells (Slater et al., 2003; Hochstenbach et al., 2005; Kooper et al., 2008). A general 
disadvantage of the use of CVS in comparison with amnion fluid is the extra-embryonic 
nature of this tissue. Although foetus and placenta originate from the same zygote, a 
discrepancy between the chromosomal constitution of cells in the placenta and cells in 
the foetus, known as chromosomal mosaicism, can occur. Such mosaicisms are well 
documented in the literature and are detected in 1% to 2% of the CVS (Kalousek and 
Vekemans, 1996; Stetten et al., 2004). Abnormal mosaic cells can be found in both foetal 
and placental tissues, or may be confined to either the placenta (confined placental 
mosaicism, CPM) or the foetus (Simoni and Fraccaro, 1992). Karyotypes of CVS represent 
cells from chorionic ectoderm (cytotrophoblasts) in short-term cultures (STC) and 
chorionic mesoderm (mesenchymal core) in long-term cultures (LTC). In molecular 
testing of CVS it is, therefore, of obvious importance to establish that both cell lineages 
are adequately represented by the pool of cells from which the DNA is extracted (Mann 
et al., 2007). In this study we investigated the suitability of the MLPA test for the detection 
of (an)euploidies in CVS and assayed to what extent this test compares to traditional 
karyotyping (TK) of STC, LTC, or both. 
Materials and methods 
Clinical samples
CVS with a weight of >30 mg (N=152), were collected at the outpatient clinics located in 
Nijmegen, Arnhem, Tilburg, ‘s-Hertogenbosch and Enschede (Network Prenatal 
Diagnostics Nijmegen, the Netherlands) from pregnant women at 11 to 21 weeks of 
gestation. From these 152 CVS, 125 were consecutively collected between May 2006 and 
June 2007. Additionally, twenty CVS with known aneuploidies for one of the target 
Abstract
The objective of this study was to examine the suitability of multiplex  ligation- depen dent 
probe amplification (MLPA) in chorionic villus samples as a replacement for traditional 
karyotyping for the detection of (an)euploidies of chromosomes 21, 18, 13, X, and Y. 
Chorionic villus samples were diagnosed by traditional karyotyping using short-term 
cultures (STC) and long-term cultures (LTC), and by MLPA using kit P095. DNA was 
extracted after digestion of whole villi with proteinase K and/or trypsin and collagenase. 
Different cell-dissociation procedures were tested to obtain MLPA results representative 
of the cytotrophoblast layer and the mesenchymal core. Over 95% of the MLPA results 
were in concordance with the traditional karyotyping of STC and LTC. Traditional 
karyotyping revealed seven mosaics. After digestion of whole villi with proteinase K, 
only abnormal cell lines confined to the STC gave rise to abnormal MLPA results. In one 
sample, the complete discrepancy between STC and LTC was resolved after enzymatic 
dissociation of cells from the cytotrophoblast layer and the mesenchymal core. MLPA in 
chorionic villus samples was found to be a reliable test for the detection of (an)euploidies 
of chromosomes 21, 18, 13, X, and Y. Whole villi digestion with proteinase K resulted in 
the over-representation of cytotrophoblasts in the DNA pool. To obtain MLPA results 
representative for STC and LTC, enzymatic dissociation of cells from the cytotrophoblast 
layer and mesenchymal core is required.
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DNA extraction following proteinase K treatment of whole villi
This method was used for all CVS. DNA from at least two chorionic villi was extracted 
using a QIAamp DNA Mini Kit (Qiagen) following the protocol “Isolation of DNA from soft 
tissues using the TissueLyser and QIAamp DNA Mini Kit” (Qiagen, Westburg bv, the 
Netherlands) In this procedure, incubation at 56°C with proteinase K results in lysis of the 
villi before DNA extraction. Proteinase K has a specific activity and degrades tissue to 
facilitate the purification of the DNA. Finally, DNA was eluted in 50 µl AE buffer (10 
mmol/l Tris-HCl, 0.5 mmol/l EDTA, pH 9.0). The DNA was quantified using a Nanodrop 
spectrophotometer (NanoDrop Technologies Wilmington, Delaware) and varied from 
2.5 to 650 ng/µl elution buffer. 
DNA extraction following enzymatic dissociation of villi
Two methods were designed to obtain cell populations from the cytotrophoblast layer 
and the mesenchymal core separately. In the first method, a modification of the method 
described by Mann (Mann et al., 2007), ie, digestion of cleaned villi with collagenase (800 
units/ml; 37°C, 30 minutes), was followed by trypsin digestion (0.5% trypsin/EDTA, 37°C, 
30 minutes). After collagenase digestion, the suspension was separated from the 
remaining villi and transferred to a tube containing 4 ml PBS and 10% foetal calf serum 
to stop the digestion. After centrifugation (1200 rpm, 5 minutes) the supernatant was 
removed and the cell pellet was re-suspended in 300 µl PBS (fraction C). After digestion 
of the remaining villi with trypsin, 4 ml PBS + 10% foetal calf serum were added to stop 
the reaction. After centrifugation (1200 rpm, 5 minutes) the supernatant was removed 
and the cell pellet was re-suspended in 300 µl PBS (fraction M). Finally, 100 µl of fraction 
C and 100 µl of fraction M were mixed (1:1) (fraction T) and used for DNA isolation as 
described below. 
In the second method, digestion of cleaned villi was first performed with trypsin (0.5% 
trypsin/EDTA, 37°C, 1 hour) followed by collagenase digestion (800 units/ml; 37°C, 40 
minutes). After both digestion steps, cell fractions C, M, and T were obtained as in the 
first method. DNA extractions were performed by incubation of the cell population with 
proteinase K at 56°C. DNA was purified using a QIAamp DNA Mini Kit (Qiagen) following 
the protocol “Blood and body fluid spin protocol.” Finally, DNA was eluted in 50 µl AE 
buffer (10 mmol/l Tris-HCl, 0.5 mmol/l EDTA, pH 9.0). Both methods were performed on 
CVS case 7 with discrepant results in STC and LTC, i.e., 46,XY and 47,XY,+18, respectively. 
MLPA test
The MLPA test was performed with SALSA MLPA kit P095 for aneuploidy detection as 
described by Schouten (MRC Holland, Amsterdam, the Netherlands) (Schouten et al., 
2002). The MLPA analyses were performed blinded to the cytogenetic analyses until 
chromosomes and seven CVS diagnosed by TK as mosaic were added. The referral 
reasons of the pregnant women ranged from low-risk to high-risk. The CVS were washed 
in PBS and the villi were separated from maternal decidua and blood clots under an 
inverted microscope. 
Karyotyping
Approximately 20 to 30 mg of the villi was used for conventional karyotyping according 
to standard STC and LTC procedures. Briefly, 10 to 15 mg of the villi was used for STC and, 
subsequently, incubated for 30 minutes in colcemid, followed by a short hypotonic 
treatment after which the cells were fixed in methanol/acetic acid (3:1) and rehydrated. 
Finally, the trophoblast (interphase and metaphase) cells were released from the villus 
core using 60% acetic acid and spread on microscopic slides. The remaining 10 to 15 mg 
of the villi were used for LTC, after incubation for one hour in trypsin-EDTA and a 
40-minute incubation in collagenase. Metaphases were harvested in situ using standard 
procedures on Labtek II chamber slides. Cytogenetic investigation of STC and LTC was 
routinely performed and 4 and 8 metaphases were analyzed, respectively, to exclude 
discrepancies between STC and LTC (Mellink et al., 2003). Cytogenetic examination of the 
LTC was expanded to 29 metaphases when an abnormal karyotype was detected in STC 
or LTC cells. CVS karyotypes with a tetrasomy or triploidy were excluded from this study. 
Definition of mosaic levels
CVS encompass cells from both the trophoblasts and the mesenchymal core. Discordant 
findings between STC and LTC and/or foetal tissues have been either referred to as pseu-
domosaicisms or true mosaicisms (Gardner and Sutherland, 1996). Here, three levels to 
define mosaicism were used: level I, detection of a single abnormal cell (single cell 
pseudomosaicism), level II, the same abnormality was detected in two or more cells in 
the same culture vessel (multiple cell pseudomosaicism) or level III, the same abnormality 
was observed in two or more independent culture vessels (true mosaicism) (Gardner 
and Sutherland, 1996). Discrepancies between karyotypes of villus and foetal tissues may 
occur as a result of a cpm. Three types of CPM can be discerned and categorized by the 
placental cell lineage exhibiting the abnormal cell line, i.e., confined to the cytotrophoblast 
(type I), the mesenchymal core (type II), or both (type III)(Kalousek and Vekemans, 1996). 
Fluorescence in situ hybridization analysis
Interphase-fluorescence in situ hybridization (I-FISH) analyses were performed on nuclei 
(N=100) of STC villi cells in samples exhibiting a mosaicism of any of the target 
chromosomes using an AneuVysion prenatal detection kit (Vysis Inc, Downers Grove, 
Ilinois) for an accurate establishment of the distribution of normal and abnormal cells. 
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A summary of the test results on all 152 samples is displayed in Figure 1, showing a box 
plot with the mean ratios for the chromosome 21, 18, 13, X, and Y probes in euploid 
(N=124: normal male N=58 and normal female N=66), aneuploid (N=21), and (pseudo)
mosaic samples (N=7). In all normal samples, the mean ratios for the autosomes were 
completion. Data analyses were performed on the transfer of electropherogram-based 
GeneMapper results to a modified spreadsheet for normalization and ratio computation 
of the peak areas (Kooper et al, submitted). First an intra-sample normalization of each 
probe peak area was performed, followed by an inter-sample normalization with 
tray-specific references. Normalization is essential because variations in experimental 
conditions may lead to quantitative differences. 
As a consequence of our normalization procedure, mean probe ratios skew in case of a 
trisomy, since the probe ratios of the targets with two copies scale down to 80% when a 
trisomy for one of the targets is present. This decrease in mean probe ratios is not 
corrected in the data analysis. The mean and SD of each target chromosome were 
determined, followed by a 95% confidence interval (CI). In cases of disomy (two copies of 
each target chromosome), these calculations will result in a theoretical (expected) value 
of 1.0, representing two copies of the target sequence in the sample. One or three copies 
of the target sequence in a sample will result in theoretical values of 0.5 or 1.5, respectively. 
A result is considered abnormal when the theoretical value (= expected value in a normal 
case) is not included in the confidence interval and the mean probe ratio is more or less 
than 10% of the expected value. Follow-up of these samples is performed by karyotyping 
and/or amniocentesis. 
MLPA does not detect female triploidies. As a consequence of the normalization 
procedure ie, relative peak areas do not differ in intra-sample normalizations as the copy 
numbers of all of the targets is the same. A male triploidy will yield normal mean probe 
ratios for 21, 18, and 13, an increased mean probe ratio for X and a decreased mean 
probe ratio for Y. In addition, there is limited potential to discriminate maternal 
contamination in a normal male sample from 69,XXY and, therefore, careful CVS cleaning 
before sample preparation is of critical importance. 
The Levene’s test was used to determine equality of variances of the pooled standard 
deviations of the mean probe ratios for the target chromosomes 13, 18, 21, and X 
between CVS and amniotic fluid samples. 
Results
Proteinase K treatment of whole villi
In all 152 CVS, the MLPA test was performed successfully. The results were compared 
with cytogenetic analyses of both STC villi and LTC villi. There was a correct assignment 
of sex in all 152 samples. No evidence for the presence of maternal contamination was 
noted in male samples, i.e., the expected normalization effect of a decreased mean 
probe ratio for the Y chromosome combined with an increased mean probe ratio for the 
X chromosome was observed in none of the male samples. 
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Figure 1. 
Quantitative MLPA analysis with mean probe ratios of the 21, 18, 13, X, and Y targets with 50% of 
the samples within the box. The outliers are cases ‘o’ with values between 1.5 and 3 box-lengths 
from the boundaries of the box. Case 3 shows an increased mean probe ratio for chromosome 
21 of 1.24 (95% CI: 1.02-1.46). Inspection of individual probe ratios of this chromosome showed 
an increase for all individual probes, indicative for a mosaic of trisomy 21. Case 7 is illustrated as 
an extreme (*) in the box plot with an increased mean probe ratio for chromosome 18 of 1.18 
(95% CI, 1.08–1.28), i.e., this ratio is increased for the expected value of 1.0 for a disomy 18 and 
decreased for the expected ratio of 1.5 for a trisomy and, therefore, indicative for a mosaic 
trisomy 18. Case 1 is illustrated as an extreme (*) in the box plot with a mean probe ratio for the 
Y chromosome of 0.17 (95% CI: 0.14-0.21). Case 2 is illustrated as an outlier ‘o’. The mean probe 
ratio for X is 0.80 (95% CI: 0.70-0.90), i.e., this ratio is increased for the expected value of 0.5 for a 
monosomy X and decreased for the expected ratio of 1.0 for a disomy and, therefore, indicative 
for a mosaic 45,X/46,XX. The other outliers in the box plots result in increased or decreased 
mean probe ratios, all related to broad confidence intervals. The expected values of 0.5, 1.0, or 
1.5 are within the confidence intervals in all outliers.
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close to the expected value of 1.0. The mean probe ratios for samples with a trisomy 21, 
18, or 13 were all significantly increased (mean ratios of >1.0 with 95% CI not including 
1.0) and close to the expected value of 1.5. In all normal male and female samples the 
mean probe ratios for X and Y were close to the expected values: 1.0 for X in female 
samples and 0.5 for X and Y in male samples, and for X in samples with a monosomy X. 
The variation in mean probe ratios was slightly higher for Y, which may be due to the 
limited number of targets included in the P095 kit for this chromosome.
Normal karyotypes
In 124 of the CVS the normal results of MLPA and TK were in concordance for all five 
target chromosomes (58 and 66 male and female samples, respectively). 
Aneuploidies in both STC and LTC
In total, 21 aneuploidies for one of the target chromosomes were detected; one with 
trisomy 13, five with trisomy 18, ten with trisomy 21 and five with monosomy X. There 
was complete concordancy between the MLPA and TK results. In all 145 non-mosaic 
samples, the unexplained SD of the mean probe ratio for the target chromosomes 13, 18, 
21 and X turned out to be 0.041. The Y chromosome was excluded in this calculation 
because of the presence of only four probes (see above). This residual variation was 
significantly lower (P<0.001, using F test to compare two variances) than the corresponding 
value of 0.068 determined in a set of amniotic fluid samples (Kooper et al, submitted). 
(Pseudo)mosaicisms
Seven samples displayed discordancies between TK (STC and/or LTC) and MLPA. 
The results of TK (STC and LTC), I-FISH, referral reason, gestational age and follow-up of 
these cases are summarized in Table 1. MLPA results of these mosaic cases were compared 
with the TK results (golden standard) and are summarized in Table 2.
Case 1: STC villi showed a mosaic karyotype 45,X[2]/46,XY[1] and a normal karyotype in 
LTC. I-FISH of STC nuclei resulted in a test failure. The MLPA results showed a decreased 
mean probe ratio for Y of 0.17 (95% CI: 0.14-0.21) and a normal mean probe ratio for X. 
A normal mean probe ratio for X indicates that the decrease of Y is not related to the 
presence of maternal contamination in this male sample. Case 1 is illustrated as an 
extreme (*) in the box plot in Figure 1 (with a mean probe ratio of more than three 
box-lengths from the boundaries of the box) and indicative for a mosaic 45,X/46,XY. 
Case 2: STC villi showed a mosaic karyotype 45,X[5]/47,XXX[1] and LTC villi showed a 
non-mosaic triple X karyotype. I-FISH of STC nuclei resulted in a mosaic monosomy X/
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disomy X/trisomy X in 68%, 3%, and 9% of the cells, respectively. The MLPA results 
showed a decreased mean probe ratio for X of 0.80 (95% CI: 0.70-0.90). The ratio is 
increased for the expected value of 0.5 for a monosomy X and decreased for the 
expected ratio of 1.0 for a disomy and, therefore, indicative for a mosaic 45,X/46,XX. Case 
2 is illustrated as an outlier ‘o’ in the box plot in Figure 1 with a mean probe ratio between 
1.5 and 3 box-lengths from the boundaries of the box. 
Case 3: STC villi showed a mosaic karyotype 47,XY,+21[2]/46,XY[5] and LTC villi showed a 
non-mosaic trisomy 21 karyotype. I-FISH of STC nuclei resulted in a mosaic trisomy 21/
disomy 21 in 76% and 24% of the cells, respectively. The mean probe ratio for chromosome 
21 was increased to 1.24 (95% CI: 1.02-1.46). Inspection of individual probe ratios of this 
chromosome showed an increase for all individual probes indicative for a mosaic trisomy 
21. There was discordance between the MLPA results and the results of TK of the LTC villi: 
the expected value of 1.5 was not within the 95% CI. 
Case 4: LTC villi showed a mosaic karyotype 45,X[3]/46,XX[27] and STC villi showed a 
normal female karyotype. I-FISH of STC nuclei showed disomy X in 95% of the nuclei. The 
MLPA resulted in normal mean probe ratios of all target chromosomes (mean probe ratio 
x 0.89, 95% CI: 0.80-0.99, this value is in the gray zone and interpreted as normal). 
Follow-up cytogenetic analysis of amniotic fluid cells was normal, indicating that the 
abnormal cell line was probably confined to the placenta and the LTC (CPM type II). 
Case 5: LTC villi showed a mosaic karyotype of a low-grade mosaicism 47,XY,+13[2]/46,XY[27] 
and STC villi showed a normal male karyotype. I-FISH of STC nuclei resulted in a test 
failure. The MLPA resulted in normal mean probe ratios of all target chromosomes. 
Follow-up cytogenetic analysis of amniotic fluid cells was normal, indicating that the 
abnormal cell line was confined to the placenta and the LTC (CPM type II). 
Case 6: both STC and LTC villi showed a mosaic karyotype 45,X/46,XX. I-FISH of STC nuclei 
confirmed a mosaic monosomy X/disomy X in 26% and 74% of the cells, respectively. 
The MLPA resulted in a slight decrease of all probe ratios for the X chromosome of 0.90 
(95% CI: 0.83-0.96). Follow-up cytogenetic analysis of amniotic fluid cells was normal, 
indicating that the abnormal cell line was confined to the placenta, both the STC and 
LTC (CPM type III). 
Case 7 showed a complete discrepancy between STC and LTC: the STC showed a 46,XY 
and the LTC a 47,XY,+18 karyotype. The MLPA resulted in a slight increase of the mean 
probe ratio for chromosome 18 of 1.18 (95% CI: 1.08-1.28). The MLPA results of DNA from 
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Table 2.   Overview of the chromosome mean probe ratios in seven mosaic cases 
after preparation of whole villi with proteinase K treatment.
Case  STC Karyotype LTC Karyotype Mean probe ratios target 
chromosomes (95% CI) 
1.
2.
3.
4.
5.
6.
7.
 45,X[2]/46,XY[1]
45,X[5]/47,XXX[1]
47,XY,+21[2]/46,XY[5]
46,XX[4]
46,XY[4]
45,X[3]/46,XX[1]
46,XY[12]
46,XY[29]
47,XXX[29]
47,XY,+21[29]
45,X[3]/46,XX[27]
47,XY,+13[2]/46,XY[27]
45,X[1]/46,XX[28]
47,XY,+18[29]
#13:  1.00 (0.90-1.09)
#18:  0.97 (0.94-1.01)
#21:  1.04 (0.95-1.13)
#X:    0.52 (0.48-0.56)
#Y:    0.17 (0.14-0.21)
#13:  1.04 (0.98-1.10)
#18:  0.93 (0.82-1.04)
#21:  1.05 (0.91-1.19)
#X:    0.80 (0.70-0.90)
#Y:    -
#13:  0.89 (0.62-1.16)
#18:  0.93 (0.75-1.10)
#21:  1.24 (1.02-1.46)
#X:    0.55 (0.45-0.65)
#Y:    0.43 (0.34-0.52)
#13:  1.00 (0.84-1.15)
#18:  0.97 (0.83-1.10)
#21:  1.07 (0.93-1.21)
#X:    0.89 (0.80-0.99)
#Y:    -
#13:  1.02 (0.91-1.13)
#18:  0.97 (0.89-1.05)
#21:  1.02 (0.94-1.11)
#X:    0.49 (0.45-0.52)
#Y:    0.48 (0.46-0.50)
#13:  1.05 (0.96-1.13)
#18:  0.96 (0.90-1.03)
#21:  1.01 (0.92-1.10)
#X:    0.90 (0.83-0.96)
#Y:    -
#13:  0.91 (0.83-0.99)
#18:  1.18 (1.08-1.28)
#21:  0.92 (0.85-0.99)
#X:    0.51 (0.47-0.56)
#Y:    0.45 (0.35-0.54) 
#, chromosome
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whole villi were compared to the results of the enzymatically dissociated cell pools 
(Table 3). The mean probe ratios for chromosome 18 in fraction C of both methods 
showed a 95% CI including the value of 1.0, indicating that the cell pool isolated in 
fraction C represented a pool of cytotrophoblastic cells. The mean probe ratios for 
chromosome 18 in fraction M of both methods showed a 95% CI including the value of 
1.5, indicating that the cell pool isolated in fraction M represented cells from the 
mesenchymal core. Fraction T, a mixture of fraction C and M (1:1), yielded results indicative 
for a mosaic trisomy 18, using both methods. 
We conclude that these modified protocols for CVS preparation have resulted in an 
accurate representation of the cytotrophoblast layer and the mesenchymal core, which 
is in full concordance with the results obtained by karyotyping of STC and LTC. 
Abnormalities undetectable by MLPA
In six samples abnormalities were revealed by TK that remained undetected by MLPA. 
These included three samples with a familial chromosomal rearrangement, two samples 
with a mosaicism with an extra marker chromosome with no clinical relevance (reason 
for referral nuchal translucency and advanced maternal age) and one sample with a 
mosaic trisomy 10 (reason for referral advanced maternal age). Follow-up by ultrasound 
in this latter pregnancy revealed an oligohydramnion.
Discussion
The suitability of the MLPA test on CVS as a replacement for TK in the detection of 
prevalent aneuploidies of chromosomes 21, 18, 13, X, and Y was assayed in 152 samples. 
By doing so, we found a complete concordance between the MLPA and TK results for the 
diagnosis of all euploidies and non-mosaic aneuploidies, respectively, yielding an 
absolute specificity and sensitivity of the MLPA test of 100%. However, a reliable prenatal 
diagnosis based on CVS may be complicated by several factors related to the cellular 
composition of CVS tissue, which at the cytogenetic level may be expressed as (pseudo)
mosaicisms and/or maternal contaminations. Between 1 and 2 percentage of the CVS 
karyotypes is mosaic, and in more than 80% of the cases the mosaicism is confined to 
the placenta (Hahnemann and Vejerslev, 1997; Grati et al., 2006). Mosaicism for trisomies 
21, 18 and 13 have been reported to occur in 0.26% of CVS (Smith et al., 1999). It is 
important to bear in mind that mosaicisms for one of these target chromosomes may 
also extend into the foetal cell lineages and, as such, they must be considered as risk 
factors for foetal abnormalities. Therefore, it is relevant to establish the detection level of 
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samples tested by MLPA, however, no evidence was found for the presence of maternal 
contamination. Additionally, we tested two of the male DNA samples for the presence of 
MCC using another PCR-based system (AmpFLSTR Identifiler Kit, Applied Biosystems). 
Again, we failed to obtain any evidence for MCC. It appears that the MCC problem can 
be minimized if maternal deciduas are carefully removed from the villi and/or if sample 
(DNA) preparation procedures are thoroughly optimized. Nevertheless, we suggest that 
validation studies are required to determine a further assessment of MCC as potential 
cause of misdiagnosis in prenatal testing of CVS. Enzymatic dissociation of CVS yields cell 
pools representative for the cytotrophoblast layer and mesenchymal core separately. 
Therefore, rapid aneuploidy testing with MLPA on these cell pools is comparable to 
karyotyping of STC and LTC. 
Although QF-PCR has the same inherent limitations as MLPA in that it will not detect 
structural chromosome aberrations (Cirigliano et al., 2004; Shaffer and Bui, 2007) it is 
sensitive for the detection of MCC and triploidy (69,XXX). In reverse, MLPA has the 
advantage of being able to assess the copy number of up to 50 loci in a single assay. As 
such, MLPA can easily be extended to other genomic regions of known clinical relevance 
(Faas et al., 2008) and can also be used as a highly efficient technique for the detection 
of sub-telomeric imbalances (Ahn et al., 2007). The MLPA technology involves ligation of 
probes corresponding to a chromosome-specific sequence that is unique within the 
genome. In contrast to polymorphic loci used for QF-PCR, these chromosome-specific 
sequences show little or no variation, which avoids non-informativeness of the targeted 
sequences. Therefore, the MLPA technology may be well-suited for combining speed 
and targeted testing of specific chromosomal inter- and/or intragenic regions. Until 
recently, rapid aneuploidy detection was mostly performed by I-FISH. MLPA and QF-PCR 
have some advantages over I-FISH, i.e., the tests are less labour-intensive, more 
cost-effective and/or better suited for high throughput analyses. QF-PCR and MLPA are 
considered to be valid alternatives to karyotyping for specific referral reasons, although 
some clinically significant abnormalities will remain undetected. In a retrospective study 
of 3,700 CVS of women with referral reason elevated maternal age, we determined that 
for every 1,000 CVS performed up to 25 chromosomal aberrations, of which six with 
potential clinical significance, would remain undetected if MLPA were to replace TK 
(unpublished data). As far as the clinical relevance of these anomalies is concerned, it 
should be borne in mind that 70% of the (structurally) unbalanced chromosomal 
anomalies lead to intrauterine death or miscarriage before birth, and/or are associated 
with abnormalities detectable by ultrasound (Leung et al., 2004b).
The development and implementation of additional novel molecular-cytogenetic 
techniques, such as array CGH, is continuously increasing the resolution of the detection 
of chromosome abnormalities (Shaffer and Bejjani, 2004). In prenatal diagnostics array 
the MLPA test in mosaic cases. We found that all mosaics tested exhibited a mean probe 
ratio outside the 95% CI, and that all individual probes of the target chromosomes 
involved yielded abnormal MLPA results. 
The mosaics in our study were only detected by MLPA if the abnormal cell line was 
present in the STC. This result suggests that proteinase K digestion of whole villi results 
in an over-representation of DNA from cytotrophoblastic cells and, as such, closely 
resembles STC cell DNA. This notion is in line with previous studies demonstrating the 
cellular complexity of CVS tissues and the relevance of CVS preparation methods for 
molecular testing to minimize the risk of false-positive or -negative results (Allen et al., 
2006; Waters et al., 2007). As such, MLPA analysis of CVS on DNA isolation of whole villi 
digested with proteinase K as presented here, is only appropriate as a replacement for TK 
of STC villi. In case 7, in which the abnormal cells were confined to the LTC, the MLPA 
result for chromosome 18 was indicative for a mosaic trisomy 18, with a 95% CI of 
1.08-1.28. Neither 1.0 or 1.5 was included in the 95% CI. This indicated that only a small 
proportion of the cells digested with proteinase K was of mesenchymal origin. In the 
other two cases, with an abnormality confined to the LTC (case 4 and 5), this phenomenon 
was not observed probably because the abnormalities in the LTC were present as 
low-grade mosaicisms and, therefore, were not observed in the MLPA results. 
In case 7, we tested two different methods for enzymatic dissociation of the villi to obtain 
cells from both the cytotrophoblast and the mesenchyme cell lineages. From our data, 
we conclude that these two methods resulted in proper representations of the 
cytotrophoblast layer and the mesenchymal core, and that the MLPA results obtained 
are in concordance with the results obtained by karyotyping of STC and LTC, respectively. 
Enzymatic dissociation with trypsin/EDTA followed by collagenase showed that the total 
cell population (fraction T) consisted predominantly of cells from the mesenchymal core. 
This notion was confirmed by the MLPA electropherogram from fraction C. Digestion 
with collagenase followed by trypsin/EDTA gave the best results, representing a total cell 
population (fraction T) with a distribution of 60% cytotrophoblastic layer and 40% 
mesenchymal core cells. QF-PCR results obtained with this CVS preparation method 
were consistent with the presence of mesenchyme and cytotrophoblast cells in almost 
equal proportions (Mann et al., 2007), it was proposed by Mori et al. that the 
cytotrophoblast layer of chorion villi becomes thinner during gestation, resulting in a 
gradual over-representation of the mesenchymal lineage (Mori et al., 2007). Since in case 
1 we found that the CVS in the 21st week of gestation displayed MLPA results 
representative of the cytotrophoblast lineage, we could not confirm this latter notion. 
The potential presence of maternal cell contamination (MCC) poses a serious risk for 
prenatal misdiagnosis (Schrijver et al., 2007). We have taken into account that MCC in 
female samples cannot be detected by MLPA (see material and methods). In the male 
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CGH may be applied to pregnancies with ultrasound abnormalities and a normal karyotype. 
However, retrospective validation studies have indicated that more insight into normal 
versus abnormal copy number variation within the human genome (Redon et al., 2006; 
Rickman et al., 2006) and a comprehensive detection of mosaicisms is required before 
such a technology can be applied into routine prenatal diagnostic care. 
We conclude that MLPA is a powerful technique for the detection of aneuploidies of 
chromosomes 21, 18, 13, X, and Y in CVS. In addition, we conclude that DNA extraction 
methods for CVS have a major impact on the genetic make-up of the DNA pool and 
affect the reliability of the molecular diagnosis of aneuploidies. In anticipation of 
molecular targeted testing for prevalent aneuploidies in CVS, we have designed a 
laboratory flowchart (Figure 2). In this flowchart, the implementation of rapid aneuploidy 
detection is based on DNA extracted from the cytotrophoblasts and the mesenchymal 
core, respectively. In contrast to Gerdes et al. (Gerdes et al., 2005b) concordant abnormal 
results in these duplicate measurements are considered as final test results, irrespective 
of whether an abnormality is detected by ultrasound or serum screening. 
Taken together, we conclude that MLPA as targeted stand-alone CVS test in pregnancies 
with an increased risk for Down syndrome is a fast and reliable alternative for traditional 
karyotyping on STC and LTC.
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Figure 2. 
Laboratory flowchart for integrating rapid aneuploidy detection (RAD) in CVS into the 
cytogenetic diagnostic service. Approximately 30 mg of cleaned villi is split into three fractions 
(10 mg each). Two independent cell preparation procedures based on enzymatic digestion with 
collagenase and/or trypsin/EDTA are performed on fractions I and II to obtain suspensions from 
cytotrophoblasts (fraction C) and the mesenchymal core (fraction M), separately. A small 
amount of fraction M is used for LTC. Fraction III is stored for back-up. DNA is extracted from 
fractions C and M and RAD by MLPA or QF-PCR are assayed independently. The blue and red 
arrows indicate the routing for RAD as stand-alone test and the routing for TK, respectively. In 
this flow chart, TK of the STC is replaced by RAD on DNA from the cytotrophoblast fraction. 
Discordant results with RAD between fractions C and M or test failures is indicative for TK of the 
LTC or a repeat experiment using back-up fraction III. When the results of RAD are abnormal, 
follow-up karyotype analysis is performed to confirm the nature of the aneuploidy.
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Introduction
In recent years, several prenatal diagnostic centres have, next to traditional karyotyping 
(TK), implemented molecular cytogenetic techniques such as fluorescence in situ 
hybridization (FISH), quantitative fluorescence polymerase chain reaction (QF-PCR) and 
multiplex ligation-dependent probe amplification (MLPA) for targeted rapid aneuploidy 
detection (RAD) in either amniotic fluid cells or chorionic villus samples (Bryndorf et al., 
1996; Ogilvie et al., 2005a; Kooper et al., 2008; Cirigliano et al., 2009; Kooper et al., 2009; 
Van Opstal et al., 2009). In case foetal ultrasound examination reveals developmental 
anomalies that are highly suspected for a chromosomal abnormality and its karyotype is 
normal, additional molecular tests have become available to detect sub-microscopic 
aberrations (deletions and/or duplications smaller than 5 Mb). At present, many recurrent 
developmental disorders are known to be associated with such sub-microscopic 
deletions and/or duplications. With the recent development of microarray-based 
comparative genomic profiling techniques, the relative DNA copy numbers of thousands 
of genomic regions can be measured simultaneously (Guillaud-Bataille et al., 2004; 
Veltman, 2006). Through the application of this technology, sub-microscopic 
abnormalities were e.g. detected in ~9% of patients with mental retardation and/or 
congenital anomalies (de Vries et al., 2005; Menten et al., 2006; Koolen et al., 2009). 
Similarly, the application of microarray-based comparative genomic profiling 
technologies (using either BAC, oligo or Single Nucleotide Polymorphism (SNP) arrays) 
has the potential to increase the diagnostic yield in pregnancies with foetal malformations. 
Cryptic or sub-microscopic imbalances of sub-telomeric regions in foetuses with 
ultrasound abnormalities are known to substantially contribute to anomalous phenotypes 
(Bendavid et al., 2006; Faas et al., 2008). Additionally, in case a specific foetal malformation 
is present, its interpretation may be facilitated by the application of advanced molecular 
cytogenetic methods (Batista et al., 2007; Friedman, 2009). For targeted microarrays 
probes are selected that are known to be involved in disease-causing (pathogenic) copy 
number variants (CNVs), whereas genome-wide microarrays with an overall high genome 
coverage may detect CNVs with unknown clinical relevance. Recently, a few studies have 
been published dealing with the application of targeted and/or genome-wide 
microarrays in prenatal diagnosis (Batista et al., 2007; Darilek et al., 2008; Tyreman et al., 
2009; Van den Veyver et al., 2009). The clinical interpretation of the analyses, however, 
appeared to be hampered by the increasing awareness that a plethora of polymorphic 
CNVs may be present within the genomes of apparently healthy individuals (Redon et al., 
2006). Before its clinical implementation, this notion therefore requires carefully designed 
clinical studies and the inclusion of parental (microarray) results in order allow a 
distinction between benign and pathogenic CNVs.
Abstract
Microarray-based genomic profiling allows the detection of chromosomal gains and 
losses at a resolution that is several magnitudes higher than that of traditional karyotyping 
(TK). As such, this technology allows the identification of relatively small genomic 
imbalances that may cause severe congenital birth defects and/or mental retardation. 
The diagnostic application of prenatal microarray analysis offers the promise of efficiently 
detecting clinically relevant sub-microscopic genomic gains and/or losses in a foetus. 
The chance of encountering genomic anomalies of uncertain clinical significance, 
however, is considered high. In this chapter, we report the application of microarray 
analysis using the Affymetrix NspI 250k SNP array platform to four foetuses. Prenatally, 
these four foetuses presented with ultrasound abnormalities that were highly suspect 
for a chromosomal aberration. In three of the four foetuses, however, TK did not reveal 
any chromosomal aberration. In the fourth foetus an apparently balanced translocation 
was encountered. Subsequent microarray analysis revealed genomic losses of 2.9 Mb 
(17p13) and 5 Mb (3q26q27) in two cases, respectively. In two other cases an atypical loss 
of ~1.5 Mb (22q11) and a loss of the ARSA region (22q13) were detected postpartum by 
other methods, respectively. Subsequent microarray analysis allowed the exact 
demarcation of the respective deletion breakpoints in these latter two cases. Our results 
underscore the relevance of the detection of sub-microscopic chromosome aberrations 
through microarray analysis in foetuses with an ultrasound abnormality. The potential 
clinical implications for the application of this technology as a prenatal test are 
discussed.
Clinical application of microarray-based genomic profiling in prenatal diagnosis Chapter 7
7
122 123
was performed using the P250 kit (MRC Holland, Amsterdam, the Netherlands) on DNA 
from blood according to the manufacturer’s specifications. An atypical 22q11.2 deletion 
was detected which was flanked by the low-copy repeats LCR22-C and LCR22-D.
Case 4
Amniocentesis was performed at 21+3 weeks of gestation since ultrasound examination 
had revealed a hypoplastic right heart and soft markers for Down syndrome. RAD in AF 
cells by MLPA revealed a female foetus with disomy 13, 18 and 21. Additional cytogenetic 
analysis using standard techniques revealed a normal 46,XX karyotype. A normal AFP 
concentration of 4.0 mg/l was measured in the AF sample. Postpartum examination 
revealed a hypertrophic right ventricle of the heart, and a perimembranous ventricular 
septal defect (VSD) combined with a slight dilatation of the right kidney. Dual-color FISH 
testing was performed on metaphases from cultured blood cells with the LSI TUPLE1 
(HIRA) and LSI ARSA probes (see under case 3) to exclude the 22q11 microdeletion 
syndrome. Remarkably, no aberrations were detected within the 22q11 region (HIRA) 
but, instead, the ARSA probe revealed a deletion of the 22q13 region.
Cytogenetic and fluorescence in situ hybridization analyses
Cytogenetic analyses were performed on metaphase spreads harvested from cultured 
amniotic fluid cells or peripheral blood-derived (parental) lymphocytes using standard 
techniques. For fluorescence in situ hybridization (FISH) analyses, BAC probe (BACPAC 
Resources) labelling, slide preparation, and hybridization were performed essentially as 
described elsewhere (de Bruijn et al., 2001). Visual examination of the slides was 
performed using a Zeiss Axiophote-2 microscope equipped with appropriate filters. 
Digital images were captured using a high-performance Leica DC 350FX camera coupled 
to a Leica CW 4000 software package.
Multiplex ligation-dependent probe amplification (MLPA)
MLPA was performed using kit P250 (www.mrc-holland.com) according to the 
manufacturer’s specifications. Briefly, sample DNAs were isolated using a QIAamp kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions. The MLPA 
probes were hybridized to the sample DNAs, ligated and amplified by PCR. Each resulting 
amplified probe product had a unique length and was identified and quantified by 
capillary electrophoresis on an ABI 3100 analyser, using Genescan analysis software 
(version 3.7) and Genemapper (version 4.0) software, all from Applied Biosystems. 
Genome-wide microarray-based genomic profiling
Microarray analyses were carried out on DNA from the four foetuses after foetal demise 
Here, we report four prenatal cases with ultrasound abnormalities in whom, through 
high resolution copy number profiling, CNVs were detected. The clinical interpretation 
of these CNVs is discussed in the context of what may be considered as ‘good clinical 
practice’ in future prenatal diagnostics. 
Material and methods
Case 1
Amniocentesis was performed at 22+6 weeks of gestation since ultrasound examination 
had revealed an oesophageal atresia with fistula, polyhydramnion and hydrocephalus. 
Rapid aneuploidy detection (RAD) in amniotic fluid (AF) cells by I-FISH revealed a male 
foetus with disomy 13, 18 and 21. Additional cytogenetic analysis of these cells using 
standard techniques revealed a normal 46,XY karyotype. In addition, a normal AFP 
concentration of 8.9 mg/l was measured in the AF sample. Foetal demise occurred in the 
24th week of gestation. 
Case 2
A 37 year-old pregnant female was referred at 16+2 weeks of gestation for amniocentesis 
because of advanced maternal age. RAD on DNA isolated from AF cells by MLPA revealed 
a female foetus with disomy 13, 18 and 21. Additional cytogenetic analysis of these cells 
using standard techniques revealed an apparently balanced de novo 46,XX,t(3;18)
(q26.2;q21.3) karyotype (Figure 2A). In addition, a normal AFP concentration of 16.7 mg/l 
was measured in the AF sample. Follow-up ultrasound examination at 20 weeks of 
gestation revealed an hydrocephalus and aqueduct stenosis, upon which the pregnancy 
was terminated. Subsequent foetal autopsy did not reveal any additional abnormalities.
Case 3
Amniocentesis was performed at 22+5 weeks of gestation since ultrasound examination 
had revealed a heart defect, suspect for tetralogy of Fallot and 22q11 microdeletion 
syndrome. RAD in AF cells by MLPA revealed a female foetus with disomy 13, 18 and 21. 
I-FISH testing was performed with probe LSI TUPLE1 (HIRA), a 117 kb (spectrum orange) 
probe that maps to 22q11, and the LSI ARSA (spectrum green) control probe (both from 
Vysis, Downers Groove, USA) that maps to the telomeric end of 22q (22q13). Results 
showed no aberration in the 22q11 and 22q13 regions. Additional cytogenetic analysis 
using standard techniques revealed a normal 46,XX karyotype. A normal AFP 
concentration of 7.8 mg/l was measured in the AF sample. Because postpartum 
examination revealed clinical features suspect for a 22q11 microdeletion, MLPA analysis 
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Results 
Identification of a chromosome 17p13 microdeletion in case 1
250k SNP array analysis was performed on DNA extracted from cultured amniotic fluid 
(AF) cells, which initially exhibited a normal 46,XY karyotype. This analysis revealed a 
DNA copy number loss on the p-arm of chromosome 17 (Figure 1), resulting in a revised 
karyotype denoted as 46,XY.arr snp 17p13.2p13.1(SNP_A-1870741SNP_A-2216514)x1. 
Further analysis of our data using the UCSC Genome Browser indicated that the deletion 
observed encompasses a region of ~2.9 Mb on 17p13.2p13.1, including 443 SNPs and 
more than 50 genes. The Ensembl v37 database indicated that the deleted region 
contained the following known disease causing genes: CHRNE (slow-channel congenital 
myasthenic syndrome: MIM #254200, #601462, #608930, #608931, *100725), GP1BA 
(Bernard-Soulier syndrome: MIM *606672, #153670, #231200, #177802), ACADVL (very 
long chain fatty acid dehydrogenase deficiency: MIM *609575, #201475, *609575), SLC2A4 
(diabetes mellitus, noninsulin-dependent: MIM #125853, *138190) and KCTD11 (hyper-
proreninemia: MIM not present). Subsequent region-specific FISH analysis of the cultured 
AF cells, using BAC probes RP11-374L01, RP11-220M19, RP11-636N17 (17p13.2) and 
RP11-558E15 (17p13.1), revealed deletions of these probes, thereby confirming the 
genomic loss indentified by SNP array analysis. FISH analysis with the same probes on 
parental blood cells did not reveal any anomalies, thus indicating that the deletion 
detected in the AF cells was de novo.
Identification of a chromosome 3q26q27 microdeletion in case 2
SNP array analysis was performed on DNA extracted from cultured AF cells, which 
exhibited a 46,XX,t(3;18)(q26.2;q21.3) karyotype (Figure 2A). Since both parental 
karyotypes were found to be normal, we conclude that the translocation had arisen de 
novo. SNP array analysis revealed a genomic loss on the q-arm of chromosome 3 
encompassing the 3q26.3q27.2 breakpoint region, resulting in a 46,XX,t(3;18)(q26.2;q21.3) 
dn.arr snp 3q26.33q27.2(SNP_A-2205925SNP_A-4237540)x1 karyotype (Figure 2B). Data 
from the UCSC Genome Browser indicated that the genomic loss is ~5 Mb in size, 
containing 307 SNPs and encompassing more than 50 genes, including the known 
disease causing gene THPO associated with thrombocythemia and thyroid iodine 
peroxidase deficiency (MIM *600041, *600044, #187950). Subsequent region-specific 
FISH analysis of the cultured AF cells, using BAC probes RP11-379M20 and RP11-624A13, 
revealed deletions of these probes, thereby confirming the loss in the 3q26.33 region 
indentified by SNP array analysis.
(case 1), termination of pregnancy (case 2), or birth (cases 3 and 4). DNA was extracted 
from 1x106 cultured AF cells (cases 1 and 2) or 4 ml uncultured AF cells (cases 3 and 4) 
with a QIAamp DNA Mini kit (Qiagen). SNP array-based genomic profiling analyses were 
carried out on stored DNA using the Affymetrix NspI 250k SNP array platform (www.
Affymetrix.com), which contains 262,264 SNPs each represented by 24 or 40, 25-mer oli-
gonucleotides, as reported before (Kuiper et al., 2007). Briefly, 250 ng of total genomic 
DNA was digested with the appropriate restriction enzyme, ligated to adaptors and 
amplified by a generic primer. After purification, the amplified DNA was digested with 
DNase I, labelled with biotin and hybridized onto the microarray. Hybridized probes 
were captured by streptavidin-phycoerythrin conjugates after which the array was 
scanned and genotypes were determined as described (Kuiper et al., 2007). 
Data analysis
Genomic copy numbers were calculated using the public domain software package 
CNAG (Copy Number Analyzer for Affymetrix GeneChip Mapping arrays), version 2.0. The 
underlying algorithm of CNAG strongly improves the signal-to-noise ratios of the final 
copy number output by i) correcting for length and GC content of the individual 
polymerase chain reaction (PCR) products using quadratic regressions and by ii) 
providing fully automated optimal sample selection. The normalized ratios were 
analyzed for loss and gain of regions by a standard Hidden Markov Model (HMM), which 
was optimized in order to maximize the detection of the known validated copy number 
aberrations, while minimizing the false-positive rate, as described before (de Vries et al., 
2005; Kuiper et al., 2007). The set HMM parameters were 0 for N=2, -0.38 for N=1, 0.3 for 
N=3, and 0.55 for N=4. An average of five or more consecutive SNPs showing a single 
copy number loss (N=1) and an average of seven or more consecutive SNPs showing a 
single copy number gain (N=3) provided a 95% confidence for representing a true copy 
number variation (Hehir-Kwa et al., 2007). 
Web resources
Database of Genomic Variants (March 2006): http://projects.tcag.ca/variation/
Online Mendelian Inheritance in Man (July 2009): http://www.ncbi.nlm.nih.gov/Omim/
UCSC Genome Browser (March 2006): http://genome.ucsc.edu/
Decipher (March 2009): https://decipher.sanger.ac.uk/ 
Ecaruca (July 2009): http://www.ecaruca.net/ 
Ensembl (Feb 2009): http://www.ensembl.org/ 
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del(22)(qter)(HIRA+,ARSA-).arr snp 22q13.31q13.33(SNP_A-2284753SNP_A-4279731)x1. 
Further analysis of the SNP array data using the UCSC Genome Browser and Ensembl 
indicated that the deletion observed encompasses 784 SNPs covering >30 genes, 
including the ARSA gene (MIM *607574, #250100, #272200) and the ARC gene (MIM 
*102480) associated with metachromatic leukodystrophy and male infertility due to 
acrosin deficiency, respectively. FISH analysis with the ARSA probe on parental blood 
samples did not reveal any anomalies, thus indicating that the deletion detected in the 
AF cells was de novo.
Identification of a chromosome 22q11.2 microdeletion in case 3
Postpartum examination of DNA extracted from blood with MLPA kit P250 revealed 
deletion of the low-copy repeats LCR-C and LCR-D on chromosome 22q11.2 (see also 
Figure 5), indicating an atypical deletion within this region (Figure 3A). Subsequently, 
SNP array analysis was performed on DNA extracted from uncultured AF cells for further 
characterisation of the breakpoints. By doing so, a loss of the 22q11.21q11.22 region was 
detected resulting in a 46,XX.arr snp 22q11.21q11.22(SNP_A-1859774SNP_A-1788873)x1 
karyotype (Figure 3B). Data from the UCSC Genome Browser indicated that the genomic 
loss was 1.3 Mb in size, containing 44 SNPs, and included the known disease causing 
genes SERPIND1 (serpin peptidase inhibitor clade D, associated with thrombophilia due 
to heparin cofactor II deficiency: MIM #188050, *142360) and GGT2 (gamma-glutamyl-
transferase, familial high serum: MIM *137181). 
Identification of a chromosome 22q13.3 microdeletion in case 4
In addition to previous prenatal karyotyping of AF cells and the postpartum detection of 
a deletion of a FISH probe encompassing the ARSA gene in the 22q13.3 region (see case 
3), SNP array analysis was performed to more precisely map the breakpoints of this 
deletion. This analysis, performed on DNA from uncultured AF cells, revealed a DNA 
copy number loss of 6.1 Mb (Figure 4), resulting in a karyotype denoted as 46,XX.ish 
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Figure 1. 
Chromosome copy number variations identified in case 1 by 250k SNP array analysis. The log2 
T/R (test-over-reference) ratio values are plotted on the Y-axis versus the genomic position on 
the respective chromosome represented by the idiogram on the X-axis in the lower part of the 
figure. The red dots in the upper panel represent individual SNP values. The thin blue line in this 
panel represents the effective HMM outcome with a normal (N=2) T/R ratio of 0. A significant 
imbalance is indicated by a rise or fall of this line by 0.3 identifying a single copy number gain 
and -0.38 identifying a single copy number loss. In the lower panel (blue) each dot represents 
the averaged value of 10 neighbouring SNPs. The array result revealed a loss of 2.9 Mb at 
17p13.2p13.1. The four encircled gains are common CNVs (i.e., polymorphisms).
Figure 2. 
GTG banded karyotype (A) of a cultured AF cell in case 2, showing a de novo apparently 
balanced translocation t(3;18)(q26.2;q21.3) (B). Chromosome copy number changes, identified 
by SNP array analysis, resulting in a loss of~ 5 Mb at 3q26.3q27.2 (C). 
A B
C
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Discussion
The four prenatal cases with ultrasound abnormalities reported here illustrate the clinical 
relevance of SNP array analysis for high resolution genomic profiling. In case 1, the 
relatively large size of the deletion (~2.9 Mb) and the fact that it encompasses several 
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MLPA and SNP array results of case 3. Panel A shows the electropherograms of the normalized 
MLPA ratios (Y-axis) of a negative control sample without a 22q11 deletion (blue), a positive 
control sample with a common 22q11.2 deletion (red) and case 3 (green) with an atypical 
22q11.2 deletion. The markers in kit P250 are chosen between 15.959.700 to 23.283.730. Case 3 
shows single copy losses of five probes, two in the LCR22-C region (SNAP29, LZTR1) and three 
in the LCR22-D region (HIC2, PPIL2 and TOP3B), represented by reduced peak ratios of ~0.5 in 
the electropherogram. In panel B the copy number profile revealed by SNP array analysis is 
shown, including a loss of 1.3 Mb at 22q11.21q11.22.
A
B
Figure 4. 
FISH analysis in case 4 showing the HIRA (red) and ARSA (green) regions, respectively  
(A). The arrow indicates the chromosome with the ARSA deletion. GTG banded chromosomes 
22 from blood cells (B). The deletion chromosomes are marked by arrows. SNP array analysis  
(C) revealing a loss of 6.1 Mb in 22q13.31q13.33 ranging from SNP_A-2284753 to SNP_A-4279731. 
A B
C
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Deletions of the 22q13.3 region (sizes varying from 100 kb to 8 Mb) on chromosome 22 
are associated with a phenotype that includes minor facial abnormalities, frequent 
neonatal hypotonia, normal or accelerated growth, and developmental and speech 
delay. The prevalence of the condition is unknown. The 22q13.3 deletion has previously 
been found in patients referred for the diagnosis of DiGeorge syndrome / velocardiofa-
cial syndrome (VCFS) and has remained under-diagnosed because of the non-specificity 
of the phenotype (Maitz et al., 2008). The results from case 3 indicate that in case of 
cardiovascular defects 22q11 deletion diagnosis is best performed with MLPA kit P250 
for the detection of common and atypical 22q11 deletions. With the unexpected finding 
of the 22q13.3 deletion in case 4, suspect for a 22q11 deletion, we show the relevance of 
microarray analysis for the detection of this microdeletion.
severe disease causing genes, highly suggests a causative role for this deletion in the 
intrauterine death in this pregnancy. As such, the application of SNP array analysis likely 
provides a diagnostic cause for the foetal pathology in this case. In case 2, SNP array 
analysis clearly showed that the cytogenetically detected apparently balanced de novo 
translocation is unbalanced in nature. Up till now, this 3q26.3q27.2 deletion has not been 
observed in healthy individuals and is, therefore, likely to be causally related to the 
congenital anomalies observed in the foetus. Apparently balanced translocations remain 
a challenge for geneticists, especially when they are detected prenatally. With an 
incidence of about 1 per 2,000 newborns it has been reported that the risk for a 
congenital anomaly in this population is 2-3 times higher than that in an unselected 
population of newborns, for which the risk of anomalies is 2-3% (Warburton, 1991). In 
cases with de novo translocations disease-causing copy number variants (CNVs) may be 
present not only at the breakpoints but also anywhere in the genome. This notion 
stresses the need for whole genome profiling approaches (Sismani et al., 2007). A major 
limiting factor for such approaches in prenatal diagnostics, however, is the chance of 
detecting CNVs with uncertain clinical relevance. Therefore, in terms of improvement of 
prenatal care, more information is required on the overall clinical relevance of CNVs. 
The MLPA P250 probe mix, used in case 3, contains 30 different probes in the 22q11 
region in addition to probes for a number of other regions such as 10p14, 4q35 and 
17p13, all associated with features of the DiGeorge anomaly. In addition, smaller deletions 
outside the typically deleted 22q11 region can be identified with this probe mix, and the 
MLPA test is more suited for the detection of duplications in this region than FISH (Jalali 
et al., 2008). The proximal 22q11.2 region is rich in low copy repeats (LCRs), genomic 
structures that are known to mediate meiotic recombination (Koolen et al., 2006; Vissers 
et al., 2009). The most common recombination event occurs between LCR-A and B, 
which gives rise to a 3 Mb deletion and the concurrent 22q11 deletion syndrome (Shaikh 
et al., 2000). The deletion observed in case 3 is similar in size to the one reported by 
Ogilvie et al. encompassing approximately 28 genes (Figures 3 and 5) (Ogilvie et al., 
2009a). The latter authors provided preliminary evidence for the involvement of one or 
more of the genes located within the deleted interval distal to LCR-D in cardiac defects 
and, more specifically, that haplo-insufficiency of the CRKL gene may cause abnormal 
cardiac development. The incidence of these atypical deletions has been considered 
low. It has been reported, however, that since only probes covering the TUPLE1/HIRA loci 
are generally used in routine diagnostics, about 6% of the 22q11.2 deletions may be 
missed (Rauch et al., 2005). A refined analysis of the exact deletion sizes in additional 
cases with variant breakpoints and/or atypical deletions is expected to facilitate the 
elucidation of the molecular basis of the 22q11 DiGeorge microdeletion syndrome 
(Stachon et al., 2007). 
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Figure 5. 
Schematic representation of the 22q11.2 region. The positions of FISH probe TUPLE/HIRA and 
the eight low copy repeat (LCR) clusters are marked (A to H from centromere to telomere). The 
positions the disease causing genes reported in the OMIM database are indicated. Several 
atypical 22q11.2 deletions that were previously reported (Mikhail et al., 2007; Shaikh et al., 2007; 
Ben-Shachar et al., 2008) are indicated. Case 3 and a recently reported case (Ogilvie et al., 2009a) 
exhibited deletions encompassing LCR-C and LCR-D (~1.3 Mb). These atypical deletions are not 
detected by FISH probe TUPLE/HIRA. Adapted from Descartes et al., 2008. 
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in 10% of 106 consecutive pregnancies with abnormal ultrasound findings and a normal 
karyotype putative pathogenic CNVs were detected (Tyreman et al., 2009). Preliminary data 
from our own prenatal service using whole genome 250k NspI SNP arrays in 24 foetuses with 
ultrasound abnormalities highly suspected for a sub-microscopic aberration revealed 4 
(16%) imbalances that otherwise would have remained undetected, all of which are likely to 
be clinically relevant (Faas et al., submitted).
Bejjani and Shaffer stated that ‘diagnostic laboratories should always remain at least one 
step behind the cutting edge of research’ (Bejjani and Shaffer, 2006) and argued that the 
use of genome-wide microarray analyses in clinical laboratories should await further 
understanding of the genome and its architecture. As yet, however, we agree with 
Tyreman and Friedman that prenatal diagnosis by genome-wide microarray analysis is 
valid for pregnancies known to be at risk for having a pathogenic CNV, and that careful 
implementation of genome-wide microarrays will yield relevant results in at least 10% of 
obstetric patients with abnormal ultrasound findings and a normal karyotype (Friedman, 
2009; Tyreman et al., 2009). It should be kept in mind, however, that with the clinical 
introduction of this technique result interpretation and genetic counselling strategies 
must be adopted to allow its implementation with a maximum benefit and a minimum 
risk (Darilek et al., 2008). The possibility to detect CNVs of uncertain clinical relevance 
necessitates agreements between patients, clinicians and laboratory geneticists on 
what should be reported. These agreements could be offered in a consent form to 
explain the risks and benefits of having prenatal microarray analysis. In the near future, 
national guidelines will be formulated in the Netherlands for reporting microarray results 
to prospective parents. Based on our preliminary results and those from others, we 
propose that in pregnancies with an ultrasound abnormality and a normal aneuploidy 
test result, genome-wide microarray analysis may replace traditional karyotyping. In 
addition, we recommend to store DNA of foetuses with a de novo balanced translocation 
in order to enable whole genome profiling in case a foetal ultrasound abnormality is 
detected during the pregnancy. Karyotyping and/or FISH, however, remain obligatory 
for a further delineation of the detected microarray alterations. 
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Taken together, the application of genome-wide high resolution microarray analysis will 
result in the detection of otherwise undetectable CNVs as shown in these four examples. 
On the other hand, the technique also visualizes CNVs in the human genome frequently 
encountered in healthy individuals. It has been estimated that such CNVs cover ~12% of 
the human genome (Redon et al., 2006). Discriminating between benign CNVs and 
pathogenic CNVs is a first step in the diagnostic process after having identified CNVs in an 
affected foetus or patient. The use of in-house control CNV data and publicly available 
databases such as the Database of Genomic Variants or the UCSC Genome Browser may 
provide a first clue regarding the possibility that a CNV may be associated with disease. At 
present, however, these data are still too limited to exclude uncommon (rare) CNVs from 
clinical significance. In addition, ethnicity-associated CNVs are known to exist, but as yet 
only limited control CNV data are available to discriminate between ethnic populations 
(Redon et al., 2006; White et al., 2007). Our understanding of benign and pathogenic CNVs 
is still in its infancy and, therefore, both clinicians and cytogeneticists are encouraged to 
deposit such information into databases such as DECIPHER and ECARUCA to increase 
common knowledge on phenotype/genotype correlations (Vermeesch et al., 2007). 
Currently, methods are being developed to evaluate and/or update CNVs generated by a 
classification scheme where the probability of a region being denoted as disease causing 
can be calculated (Marioni et al., 2008). Such information may also be of help in obtaining 
better insights into the extent and role of CNVs in health and disease.
Preliminary data on the detection of causative CNVs in pregnancies with ultrasound 
abnormalities have been provided by several authors. An additional 6% of CVS and AF cases 
with a normal karyotype would be diagnosed using whole genome microarrays (Batista et 
al., 2007) assuming that post- and prenatal detection rates are similar. With targeted 
microarrays in two (2.4%) of 84 prenatal samples with (major or minor) ultrasound 
abnormalities causative CNVs were detected (Van den Veyver et al., 2009). The latter authors 
suggested that reserving prenatal microarray analysis for pregnancies with an abnormal 
prenatal ultrasound result may not be optimal since many genomic disorders represented 
on the targeted microarray were not associated with clinical features that are detectable 
upon prenatal ultrasound examination. Congenital heart disease (CHD) combined with 
multiple congenital anomalies (MCA) showed a highest abnormality rate (28.6%) after 
microarray analysis of neonates (aged ≤ 28 days) in a study of the Baylor College of Medicine 
(Lu et al., 2007). In order to provide a better coverage of the targeted regions, and to reduce 
the number of genes identified for which termination would be ethically questionable (for 
example BRCA, AZF) and to reduce the number of regions of uncertain clinical relevance, 
targeted arrays in prenatal diagnosis may be preferred (Le Caignec and Redon, 2009). In a 
recent whole-genome microarray study using the Affymetrix GeneChip 6.0 array, however, 
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In recent years, significant advances have been made in the resolving power and speed 
of prenatal diagnosis, including an increased resolution in ultrasound scan (US) 
examination, the introduction of first trimester screening (FTS), the possibility to 
biochemically detect metabolic disorders and, last but not least, the implementation of 
novel molecular tests. In particular, the continuous development of more advanced 
molecular tests has had a major impact on invasive prenatal diagnosis. In the early 1990s, 
fluorescence in situ hybridization (FISH) and, later on, quantitative fluorescent polymerase 
chain reaction (QF-PCR) and multiplex ligation-dependent probe amplification (MLPA) 
have entered the field of prenatal diagnostic testing, thereby obviating the need to 
culture foetal cells. These techniques allow a rapid aneuploidy detection (RAD) of 
pre-selected chromosomal regions (Mann et al., 2004; Slater et al., 2003) and, as such, are 
particularly suited for high throughput targeted testing. Next to RAD, recent advances in 
microarray analysis have created the possibility to efficiently detect chromosomal 
imbalances at a genome-wide scale with a significantly higher resolution than traditional 
karyotyping (TK). High quality prenatal and obstetric care require well-considered 
diagnostic choices. In light of the above mentioned technical developments and its 
putative clinical applications in prenatal diagnosis, the question rises which test should 
be offered to assure that pregnant women receive appropriate prenatal care. Both these 
technical developments and its putative clinical implications are discussed below.
8.1 The efficacy of protein tests 
AFP measurement in amniotic fluid
Abnormal alpha foetoprotein (AFP) levels in amniotic fluid (AF) were historically 
employed to diagnose neural tube defects (NTDs) but, in recent years, AFP levels have 
been superseded by foetal US examination (Cameron and Moran, 2009). From an 
historical point of view, AF samples have been collected for TK and, simultaneously, for 
routine AFP level measurements in cases with and without an increased risk for a NTD. In 
Chapter 2, we show that routine AFP assays in AF samples, in pregnancies without an 
increased risk for a NTD, generate a significant number of false-positive results. Based on 
this observation, and taking the advances in US examinations into account, we expect 
that the 20-week scan will gradually replace AFP measurement as a screening tool for 
NTD detection. In 2004, the overall prenatal detection rate for NTDs through a 18 to 22 
week routine US examination in 18 European countries was already 88% (range 25-94%), 
with the highest detection rates in countries using standards determined by a national 
screening policy (Cameron and Moran, 2009).
In case of an increased risk for a NTD, the preferred strategy for NTD detection is an 
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binding protein 1 precursor was decreased in these AFs. Possibly of more significance 
was the discovery that splicing factor arginine/serine-rich 4 was only found in the DS 
samples and not in the normal ones. The proteins identified are encoded by genes 
located outside chromosome 21, implying that increases in copy numbers of genes 
located on chromosome 21 may affect the expression of genes on other chromosomes, 
possibly mediated by increased activities of certain transcription factors. The study of 
Tsangaris et al. illustrates the potential of proteomics for biomarker discovery in the AF of 
aneuploid pregnancies (Tsangaris et al., 2006). 
It must be emphasized, however, that the protein content of AF samples largely depends 
on its developmental stage. Therefore, certified reference materials must be developed, 
next to sample quality control and quality assurance protocols (Nagalla et al., 2007). 
Although the application of proteomic technologies in AF is still in its infancy, the 
identification and characterization of disease-related biomarkers in AF is expected to 
significantly improve in the near future. Furthermore, because differentially expressed 
proteins and peptides are likely to cross the placental barrier and, thus, are shed into the 
maternal serum, proteomic analysis has the potential to be employed for non-invasive 
prenatal testing of aneuploidies and pregnancy complications as well (Kolialexi et al., 
2008), without subjecting the developing foetus to the potential harm impinged by 
current invasive prenatal procedures (see below, future prospects).
8.2 The efficacy of molecular tests
RAD in prenatal diagnosis
In recent years FISH, MLPA and QF-PCR techniques have been developed and 
implemented for RAD in prenatal diagnosis. In Chapter 4, we show that the MLPA kit 
P095 exhibits a specificity and sensitivity of 100% for the detection of non-mosaic (an)
euploidies of the chromosomes 13, 18, 21, X and Y. In addition, we provide in this chapter 
a laboratory flowchart for the implementation of MLPA as a stand-alone diagnostic RAD 
test in AF for pregnancies at risk for Down syndrome (DS). At the national and international 
level, the clinical application of RAD in prenatal diagnostic centres is variable: RAD is 
either used as an alternative for I-FISH for pregnancies with US abnormalities, as 
stand-alone test for pregnancies at risk for DS, or as an adjunct to TK. The chance of 
approximately 1:1200 of missing a clinical relevant chromosomal finding detectable with 
TK but not by RAD has been used as a major argument against RAD testing as replacement 
for TK.
Up till now, the option for pregnant women to choose for RAD as stand-alone test in 
pregnancies at risk for DS in our clinic has led to a reduction in TK of ~60%. This result is 
advanced (targeted) US examination. This strategy is expected to lead to a reduction of 
iatrogenic miscarriages in pregnancies at risk for a NTD. US examination prevents 
prospective parents from uncertainty and anxiety concerning the health of the foetus 
caused by the high rate of false-positive AFP test results. In contrast to AFP measurement, 
US examination also allows the detection of closed NTDs. Using 2D and 3D protocols, 
trained sonographers can even delineate the lesion level of a NTD. Such information will 
be imperative for informing prospective parents about its implications for their unborn 
child. It is anticipated that, in the long run, AFP measurement in AF will be limited to 
particular foetal AFP-related disorders and/or perinatal distress conditions.
Identification of novel biomarkers
Proteomics-based identification of novel biomarkers for foetal abnormalities in maternal 
plasma, AF and reproductive fluids has made significant progress over the past five 
years. This progress is attributed mainly to advances in various technology platforms 
associated with mass spectrometry-based techniques (Choolani et al., 2009). In particular, 
AF is a significant contributor to foetal health and, therefore, it constitutes a potential 
rich source of biomarkers for the diagnosis of maternal and foetal disorders. The 
biochemical detection of metabolic disorders combined with gene mutation analysis 
has indicated that stipulated hereditary disorders can be detected early in pregnancy. In 
Chapter 3, we show that the measurement of 21 lysosomal enzymes in AF of foetuses 
with a non-immune hydrops foetalis (HF) and a normal karyotype, in conjunction with 
gene mutation analysis, identified at least 5% of foetuses with a lysosomal storage 
disease. Application of this strategy to the diagnosis of lysosomal diseases in pregnancies 
with a HF is, therefore, useful for risk assessment, genetic counselling and targeted 
prenatal diagnostics for ensuing pregnancies. As such, we recommend the inclusion of 
metabolic analyses in the routine diagnostic work-up of non-immune HF.
Most of the current prenatal proteomic research is focussing on premature birth, 
eclampsia, foetal cardiopathology and chromosomal aneuploidy cases. The major 
challenge to overcome, however, lies between protein discovery and target validation. 
Therefore, potential biomarkers should be subjected to further comparative analyses of 
both protein expression and structural modification using samples from chromosomally 
normal and abnormal pregnancies. Tsangaris et al. (2006) applied proteomics to the 
identification of proteins differentially expressed in AF samples derived from pregnancies 
with Down syndrome (DS) and from chromosomally normal cases. This comparison 
revealed significant quantitative and qualitative differences in protein expression levels 
in both groups. Proteins that were up-regulated in AF of DS pregnancies included alpha-
1-microglobulin, collagen alpha I, III and V chains and basement-membrane-specific 
heparin sulphate proteoglycan core protein, whereas the insulin-like growth factor 
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Microarray analysis in prenatal diagnosis
The clinical application of microarray-based genomic profiling in prenatal diagnosis 
(Chapter 7) has provided the capacity to detect more clinical relevant abnormalities than 
TK and/or RAD. Retrospective results obtained through 250k NspI SNP array analyses in 
24 foetuses with ultrasound abnormalities and a normal karyotype showed 16.6% 
chromosomal imbalances, all of which are likely clinically relevant (Faas et al., submitted). 
These data support a recent retrospective study in which it was concluded that genome- 
wide high resolution microarray analysis may allow the detection of at least 10% of all 
pathogenic copy number variants (CNVs) in pregnancies with abnormal US findings and a 
normal karyotype (Tyreman et al., 2009). It should be noted, however, that its prenatal use 
may also result in uncertain clinical significance leading to parental anxiety and, in the worst 
case scenario, to the termination of a normal pregnancy (Van den Veyver et al., 2009).
In Chapter 7, several prenatal cases with ultrasound abnormalities in whom 
sub-microscopic CNVs were detected are discussed in the context of what may be 
considered as ‘good clinical practice’ in prenatal diagnostics. In recent reviews of the 
potential application of microarray platforms for clinical use in prenatal diagnosis, 
implementation of targeted arrays has been favoured (Le Caignec et al., 2006; Manning 
and Hudgins, 2007; Stankiewicz and Beaudet, 2007). Targeted microarray platforms are 
recommended for the detection of interstitial microdeletions/duplications and known 
congenital syndromes, including those affecting sub-telomeric and pericentromeric 
regions, but need to be reviewed regularly since new microdeletion/duplication 
syndromes continue to be identified (Tyreman et al., 2009). The higher coverage of 
genome-wide microarrays allows the detection of more and smaller aberrations than 
targeted microarrays. Before diagnostic application, however, result interpretation and 
genetic counselling strategies must be refined to allow maximum benefit and minimum 
risk (Darilek et al., 2008). The possibility to detect CNVs of uncertain clinical relevance 
necessitates agreements between patients, clinicians and laboratory geneticists on 
what should be reported. These agreements could be offered in a consent form to 
explain the risks and benefits of having prenatal microarray analysis. In the near future, 
national guidelines will be formulated in the Netherlands for reporting microarray results 
to prospective parents. Based on our preliminary results and those from others, we 
propose that in pregnancies with an US abnormality and a normal RAD result, 
genome-wide microarray analysis may replace TK. TK and/or FISH, however, remain 
obligatory for further delineation of a genomic gain or loss. In the near future, the 
application of advanced next-generation sequencing platforms will provide digital 
profiling information for the detection of copy numbers and positional alterations at the 
ultimate (basepair) resolution (Shen and Wu, 2009). There is no doubt that this capacity 
will add yet another level of complexity to its ultimate (prenatal) clinical implementation.
concordant with an experience based Swedish study covering >6000 clinical samples, 
which indicated that ~70% of women choose RAD instead of TK (Bui, 2007). Remarkable 
is that choices for TK or RAD ranged from 40% to 90% between different prenatal clinics 
in our (Dutch) region. Whereas in all prenatal clinics the parents received identical 
brochures with information on genetic testing, differences were noted in transferring 
this information to the parents. In some of the prenatal clinics, in addition to the brochure, 
oral consults were held by genetic advisors and/or gynaecologists, whereas in other 
clinics the parents’ decisions were based on the information in the brochure only. 
Obviously, communication of information to parents may play a key role in its final 
outcome (Chapter 4).
In an attempt to further optimise the MLPA test, we assessed the individual probe 
performances of MLPA kit P095 (Chapter 5). The results obtained indicated that exclusion 
of the poorest performing probes only slightly affected the overall sensitivity of the test, 
thereby underscoring the robustness of the test. We additionally applied MLPA to 
chorionic villus samples (CVS) (Chapter 6). The cellular complexity of CVS tissue and the 
possibility of discrepant results between QF-PCR and TK was previously reported (Waters 
et al., 2007). This has led to a change in laboratory practice in the UK for RAD in CVS 
through the implementation of a specific enzymatic dissociation protocol (Mann et al., 
2007). We adapted this dissociation protocol for the application of RAD on DNA derived 
from cytotrophoblasts and the mesenchymal core, respectively. By using this adapted 
protocol, we found that complete discrepancies between cytotrophoblasts and 
mesenchymal core can be confirmed by MLPA (Chapter 6). QF-PCR, which is based on 
microsatellite genotyping, has advantages over MLPA, i.e., for MLPA more high quality 
DNA is required and, in contrast to MLPA, QF-PCR has the potential to detect all triploidies 
(Hulten et al., 2003). Major advantage of QF-PCR, however, is the possibility to detect the 
presence of a second cell line. This was nicely demonstrated by the detection of both 
maternal cell contaminations (MCC) and mosaicisms (Cirigliano et al., 2004). Cell lines 
contributing at least 20% to the total cell population were confidently identified. MLPA 
(and I-FISH) also have the capacity to detect mosaics at a 20% level, but MCC can only be 
detected in case of a male foetus. This makes QF-PCR particular suitable for the 
application of RAD to CVS. Next to the detection of MCC, STR markers also allow a 
distinction between meiotic and mitotic nondisjunction events in CVS. As such, a 
confined placental mosaicism (CPM) can be suspected in CVS when only di-allelic 
patterns are observed for all informative markers. Additionally, true mosaic foetuses can 
be identified by a tri-allelic STR pattern, which is indicative for a meiotic origin of the 
extra chromosome (Cirigliano et al., 2009). Nevertheless, the MLPA technology still serves 
as an efficient tool for RAD and for the targeted detection of sub-microscopic deletions 
and/or duplications in pregnancies suspected for a chromosomal aberration.
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molecular testing (MLPA/QF-PCR) may lead to the, unexpected, detection of sex 
chromosomal aberrations. In a cohort of 19,517 AF samples from pregnancies with 
advanced maternal age, 18% of the detected 333 chromosomal abnormalities involved 
sex chromosomes (Leung et al., 2008). In a retrospective study we revealed a rate of 19%, 
thus confirming the above findings (Kooper et al., unpublished data). Although it has 
been reported that the prenatal detection of sex chromosome anomalies may facilitate 
the identification of foetuses with Turner syndrome and/or 47,XYY syndrome (Vaknin et 
al., 2008), most individuals with sex chromosomal aneuploidies are only mildly affected. 
Nevertheless, the UK National Screening Committee (UKNSC) has recommended that in 
pregnancies at risk for Down syndrome, FISH or PCR tests should only include targets for 
the chromosomes 13, 18 and 21 (Caine et al., 2005). Additional research is needed to 
unravel the (non-medical) reason for prospective parents, and the (medical) reason for 
professionals, to know the foetal sex, taking into account that foetal sex determination 
by a 20 week scan has the potential to replace foetal sex determination by invasive 
genetic testing (Kooper et al., unpublished data). 
2. Results must be rapidly available early in gestation
Based on time constraints in prenatal care, tests results should be rapidly available. 
The desire of prospective parents to obtain confirmation of the good health of the foetus 
during pregnancy plays a central role. In psychological terms, prenatal diagnosis is an 
 anxiety-inducing procedure (Kowalcek et al., 2003), and a significant reduction in anxiety 
is obtained after a normal result. In this light, two types of stress can be discerned 
(Weimann and Johnston, 1988). The first is linked to the invasive nature of procedures, 
such as amniocentesis and CVS, and the attendant risk of a miscarriage. The second is 
related to the outcome of the test. RAD by QF-PCR takes 24-48 hours to complete, 
compared to 2-3 days for MLPA or up to 21 days for TK. It is, therefore, essential that 
prospective parents with a positive Down screening result qualify for RAD, which can 
effectively alleviate their anxiety (Leung et al., 2008) short after the invasive procedure. 
This targeted information is often preferred over more comprehensive information as long 
as the results are received rapidly (Ryan et al., 2005). In a randomized trial (ARIA; 
Amniocentesis Results: Investigation of Anxiety) held in twelve hospitals in the UK the 
issuing of RAD versus TK results was performed (Hewison et al., 2007). By doing so, it was 
found that women having RAD exhibited significantly less anxiety during the waiting 
period than those having TK. Anxiety levels were comparatively low in all groups a month 
after having received normal results. Another advantage of RAD is that it allows parents for 
earlier decision making in cases in which the foetus exhibits a significant anomaly. It has 
previously been shown that an earlier gestational age at termination acts as an independent 
factor for a lower level of posttraumatic stress symptoms (Korenromp et al., 2007).
8.3 Appropriate prenatal care 
Conditions of appropriate care
Until the end of the 19th century, medical care for pregnant women was almost 
exclusively limited to the delivery itself. Improvements therein began with the acquisition 
of new basic knowledge, which was subsequently implemented in routine medical 
practice. These developments created a multidisciplinary approach for prenatal care, 
involving obstetricians, neonatologists, clinical and laboratory geneticists, and US 
experts in centres for prenatal diagnosis. Nowadays, prenatal screening for Down 
syndrome and NTDs is an integral part of many routine screening programs. Additional 
invasive diagnostic tests are available to detect and/or confirm the presence of genetic 
defects before birth. In order to establish what can be considered as the most suited 
diagnostic laboratory test, understanding of its basic principles is a prerequisite. At least 
two conditions may be considered for suitable invasive diagnostic laboratory tests:
1. Undesirable findings must be avoided to optimize decision making
2. Results must be rapidly available early in gestation
1. Undesirable findings must be avoided to optimize decision making
In general, diagnostic tests should provide relevant information appropriate for clinical 
use. Within the current spectrum of prenatal tests, AFP measurements for the detection 
of NTDs and the application of genome-wide microarray analyses for the detection of 
chromosomal anomalies may yield abnormal AFP levels and CNVs with unknown clinical 
relevance, respectively. Obviously, such uncertainties must be avoided as much as 
possible. With TK chromosome abnormalities >5 Mb can be detected, thus providing 
information on abnormalities related to the referral reason for invasive testing. But, TK 
may also detect unrelated chromosomal abnormalities, including unexpected findings. 
Unexpected findings can be considered as undesirable when the clinical impact of the 
finding is unclear and/or when uncertainty about the phenotype of the child is imposed, 
thus presenting the prospective parents with a serious dilemma, i.e., whether or not to 
continue the pregnancy (van Zwieten et al., 2005). In contrast to TK, prenatal tests using 
QF-PCR and MLPA are limited to specific regions on chromosomes 13, 18, 21, X and Y, 
thus focussing on the most common chromosomal aneuploidies. This largely relieves 
prospective parents from the burden of unexpected and incomprehensible results and, 
by doing so, contributes to well-informed decision making. The inclusion of targets for 
the X and Y chromosomes is still a matter of debate. In most prenatal centres, pregnant 
women undergoing invasive testing have the option to know the sex of their unborn 
child, even if there is no medical reason for it. Sex chromosome analysis through TK or 
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suggest to reconsider the use of advanced maternal age as a referral reason for invasive 
testing. In addition, we suggest to reconsider the addition of routine TK in referrals for 
molecular or metabolic testing and recommend microarray analysis as a complement 
(or replacement) of TK to obtain a higher detection rate of sub-microscopic aberrations 
in pregnancies with foetal ultrasound abnormalities. 
The decision to use an age cut-off point was historically based on an attempt to balance 
the risk of a foetal chromosomal abnormality with the risk of a procedure-related 
pregnancy loss. However, maternal age is a poor screening criterion, since the majority 
of children with DS are born to women younger than 35 years of age. The American 
College of Obstetricians and Gynaecologists (ACOG) no longer recommends the use of 
a maternal age of 35 years as a cut-off point for eligibility for CVS or amniocenteses 
(Driscoll and Gross, 2009). Instead, they recommend to first refine the risk assessment 
with a FTS test. Maternal age is, next to nuchal translucency and biochemical 
measurements in maternal blood, the third parameter in the FTS test. When women 
undergo invasive testing because of their advanced maternal age, the number of 
iatrogenic miscarriages is even higher than the number of diagnosis of DS (detection/
miscarriage ratio 0.7). The use of the FTS test considerably improves the ratio (from 0.7 to 
3.3) (Health Council of the Netherlands, 2004). Therefore, compared to invasive testing, 
FTS has the potential to substantially lower screening-related miscarriages, which raises 
the question of whether invasive testing should still be offered in a screening program 
for DS based on maternal age only (Bornstein et al., 2008). An increased risk for FTS is, 
therefore, likely to replace the referral reason ‘advanced maternal age’ as primary criterion 
for invasive testing. The impact of such a policy change, when calculated retrospectively 
for the year 2005 in the Netherlands, would result in a reduction of 93% (6,040 to 423) of 
invasive tests for pregnancies referred for ‘advanced maternal age’ (cut-off level of 1:250 
at term and a screen positive rate of 7%), see Figure 1 (Wortelboer et al., 2009) and a 
reduction of iatrogenic miscarriages from 30 to 2 (based on an average miscarriage risk 
of 0.5% after invasive testing for amniocentesis or CVS). Wapner already reported that if 
FTS would replace advanced maternal age as the primary criterion whereby to 
recommend TK, 85% of women aged >36 years could avoid an invasive diagnostic 
procedure (Wapner et al., 2003). If FTS would replace advanced maternal age parents 
should be informed that screening tests do not detect all cases of aneuploidy and that 
diagnostic tests are also available to definitively determine whether the foetus has a 
major chromosomal abnormality. After a review of the potential risks and benefits of 
screening and diagnostic testing, parents may alternatively decide for screening and/or 
testing in this pregnancy. 
While women over the age of 36 have routinely been offered additional screening or 
testing options during pregnancy, 66% of the children with DS are born to women below 
Parents’ autonomy to choose 
There are national and international differences in offering prospective parents, with an 
increased risk of a foetus with DS, the autonomy to choose between different prenatal 
tests, i.e., TK or RAD. Questions that have been raised include: who is making the choice, 
i.e., parents or doctors or other health professionals, and are choices made according to 
receiving the best possible care and/or other criteria? Decisions made within the prenatal 
genetic testing domain entail potentially far-reaching consequences, including 
test-related risks to the foetus. Grimshaw (2003) assessed the attitude of pregnant women, 
medical professionals and the general public regarding this aspect, using a question-
naire-based approach (Grimshaw et al., 2003). Most obstetricians (57%), midwives (71.4%) 
and pregnant women (67%) preferred RAD to TK, whereas the majority of the non-pregnant 
general public (60%) expressed a preference for TK. Clearly there is disagreement, even 
among each category of respondents. Offering women the autonomy to choose may 
turn out to be clinically impractical, due to the overall complex nature of the counselling 
procedures (Leung et al., 2008), however, reported that parents should have the autonomy 
to choose after being fully informed about the pros and cons of the different prenatal 
tests. Greener (2007) has presented a thematic review of the assumptions underlying 
patient choice in medical care, based on who is meant to be making choices, what 
choices are meant to be made and how choices are meant to be made (Greener, 2007). It 
was concluded that doctor-patient relationships are usually asymmetric and that patients 
are usually not as well informed as doctors about the referral conditions. In times of 
increasing patient involvement and medically equivalent treatment options, shared 
decision-making has become an integral part of good medical practice (Smets et al., 
2007) in which both patients and clinicians participate in discussions on treatment 
options, thereby reaching mutually agreed decisions. In comparison to the paternalistic 
model (where the clinician is seen as acting in the patient’s best interest) or the informed 
model (where the clinician increases the patient’s knowledge so that the control over the 
decision making process lies with the patient), this shared decision-making approach 
provides an opportunity to go beyond simply presenting relevant facts in a value-free 
way (Hunt et al., 2005). Further research, however, will be needed to assess whether this 
general model of shared decision-making will comply to actual prenatal practice. 
8.4 Future prospects
Referral reasons for prenatal testing 
Based on the fact that a higher detection rate for DS and less iatrogenic miscarriages can 
be obtained when first trimester screening (FTS) risk assessment will be implemented as 
integral part of routine prenatal care, regardless the age of the pregnant women, we 
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rearrangements affecting telomeres, and any CNV >300-500 kb, regardless of maternal 
age. By doing so, they predicted a 1:300 to 1:600 chance of finding a CNV that will cause 
a serious disorder, which would otherwise not be detected by TK (Ogilvie et al., 2009b). 
According to their opinion some women/families would prefer to have maximum 
information and maximum autonomy. In a Dutch prospective study, Pieters et al. showed 
that only a minority of women with a low-risk pregnancy would opt for genome-wide 
prenatal testing (Pieters et al., 2009). Based on this result, the ethical-moral question was 
raised whether genome-wide testing should be offered to pregnant women at all. The 
application microarray analysis as a complement (or replacement) of current TK in 
pregnancies with foetal multiple congenital anomalies, however, can provide a higher 
detection rate of sub-microscopic aberrations.
Down syndrome screening in the Netherlands
In 2007, 23% of all pregnant women in the Netherlands requested a FTS test. This uptake 
rate is relatively low compared to for example the UK, where uptake percentages were 
over 95% (Spencer, 2003). The relatively low uptake rate in the Netherlands may be 
related to the fact that until recently prenatal care was not considered as something 
”medical” and was not part of customary care. Participation was based on informed 
choice and women <36 year had to pay for FTS. Once implemented in routine medical 
care, FTS will probably result in a lower participation in invasive testing of pregnant 
women >36 years when FTS risk assessment is lower than the risk based on age only. 
This, in turn, will result in a reduction of iatrogenic miscarriages (see above).
FTS detection rates in the Netherlands have been estimated to be 75.9% at a cut-off level 
of 1 in 250 at term, with a screen positive rate of 3.3%. The detection and false positive 
rates were comparable to results reported from screening programs in other countries, 
such as France, Scotland and Canada (Wortelboer et al., 2009). The performance, however, 
was lower compared to the UK with a detection rate of ~90% and a false-positive rate of 
5% (Nicolaides, 2005). Higher detection rates in DS screening and reductions in iatrogenic 
miscarriages can be obtained through the incorporation of a sequential second trimester 
screen into routine obstetric practice. Both stepwise sequential screening and fully 
integrated screening yield high detection rates for DS, with low false-positive rates 
(Malone et al., 2005). The FTS test, however, is preferred by the majority of women over 
a test with a marginally higher detection rate that provides test results later in pregnancy 
(Spencer and Aitken, 2004). 
An incidental consequence of FTS for DS is the possibility to obtain screening results for 
an increased risk of trisomy 18 or 13. Trisomy 18 and 13, which are the second and third 
most common trisomies after 21, are lethal and the rate of spontaneous abortions or 
foetal deaths between 12 and 40 weeks of gestation is ~80%. The remaining one-year 
the age of 35 (Howe et al., 2000). Based on this information, we suggest that FTS tests 
should be available (free of charge) for all pregnant women. For the Dutch situation, this 
would result in 181,336 pregnancies that may opt for FTS (Statistics Netherlands, 2007). 
We are aware of the fact that clinically significant, less common chromosome 
abnormalities may remain undetected when TK is no longer performed in referrals for 
molecular or biochemical testing and that the invasive procedure puts the pregnancy at 
risk. However, karyotypes with uncertain prognosis, such as mosaic findings and small 
marker chromosomes, have over twice this prevalence, thereby generating anxiety and 
potentially needless terminations (Ogilvie et al., 2009b).
It is anticipated that genome-wide microarray analyses will be implemented in the 
prenatal diagnosis of high-risk pregnancies. This premise is primarily based on the notion 
that our understanding of CNVs will improve with systematic CNV discovery efforts 
(Itsara et al., 2009). In a recent debate Beaudet (2009) strongly favoured offering a 
targeted microarray test to all pregnant women, and recommended the use of such a 
microarray to assess common microdeletion/microduplication syndromes, unbalanced 
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Figure 1. 
Modified data from Wortelboer et al. (2009) representing the results of FTS in the Dutch 
population, >36 years, in the period between May 2004 and July 2006. The screening process, 
outcomes and measures of accuracy for pregnant women with an advanced maternal age (>36 
year) and a cut-off level for FTS of 1:250 at term, resulted in a sensitivity of 83.6% and a specificity 
of 93.6% for the detection of DS, respectively. 
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over-expression in brains of DS patients strongly suggests that in humans the associated 
kinase needs to be tightly regulated and that both an increase and a decrease in its 
dosage could result in a disease phenotype (Moller et al., 2008). Gwack et al. (2006) noted 
that DYRK1A and DSCR1 are located in DSCRs, and suggested that their findings might aid 
in understanding the immunological and neurological defects in DS. The increased 
activity of DYRK1A and DSCR1 may contribute, not only to mental retardation, but also to 
many other features of DS (Arron et al., 2006; Epstein, 2006; Gwack et al., 2006), including 
molecular and cellular mechanism leading to neurological phenotypes and mental 
retardation in DS (Rachidi and Lopes, 2007). 
Although knowledge of brain abnormalities in DS models is evolving and various 
phenotypic expressions in mouse models have been studied, little information is 
available about other organs. Additional mouse DS model studies revealed a higher 
incidence of lymphomas (Levine et al., 2009). This observation is of interest in relation to 
the increased incidence of malignancies in human DS. The additional use of chromosome 
engineering to generate new trisomic mouse models are likely to significantly contribute 
to our future understanding of the aetiology of DS (Wiseman et al., 2009). Additionally, 
more accurate information on genotype-phenotype relationships in DS is needed to 
improve health care. Such information will allow more accurate predictions concerning 
the ultimate DS phenotype and, as such, may help parents and professionals to make 
better informed decisions about the pregnancy and its prospects. 
Future progress in prenatal diagnostics
The emerging possibilities of non-invasive prenatal diagnostics (NIPD) may imply another 
significant change to the testing and screening of pregnancies. Research on non-invasive 
testing began by examining the placental barrier between mother and foetus. The 
results obtained indicated that the foetus could release its DNA and RNA into the 
mother’s circulation. So, initially, interest was focused on genes, gene products and/or 
mutations therein passed on to the foetus by the father and which were distinguishable 
from those of the mother. Although some work has been carried out using foetal cells 
obtained from the cervical mucus (Fejgin et al., 2001; Mantzaris et al., 2005) or foetal DNA 
in maternal urine (Shekhtman et al., 2009), most research has been focused on strategies 
to detect cell-free nucleic acids (cffNA, i.e. DNA and RNA) from the foetus in the maternal 
circulation. Foetal cell-free DNA in maternal plasma originates from apoptotic placental 
cells (trophoblasts) (Tjoa et al., 2006; Alberry et al., 2007) and comprises about 3-6% of 
the total cell-free DNA during early and late pregnancy, respectively (Lo et al., 1998b). A 
number of clinical applications of cffDNA analysis in prenatal screening and/or diagnosis 
have been developed, based on distinct and detectable differences between foetal and 
maternal genomes like foetal sex or foetal Rhesus D. Foetal sex determination is feasible 
survival rate is approximately 5-10% (Rasmussen et al., 2003). Because of this lethality and 
high foetal death rate, it may be argued whether there is a diagnostic benefit of reporting 
screening results concerning these chromosomes to prospective parents when applying 
FTS test for DS risk assessment. The alternative view is that since many trisomy 18 and 13 
foetuses can be identified during the second trimester by foetal US, women have the 
option of second trimester termination and thus of avoiding the risk of invasive testing 
if the FTS result proves to be false positive (Kagan et al., 2008). Within the Netherlands, 
there is a discussion ongoing whether screening for DS should be extended with 
screening of trisomy 13 and 18. A WBO license is required for such an application and has 
recently been submitted.
Genomic characterization of Down syndrome
In order to understand the phenotypic consequences of DS, it is crucial both to understand 
the genomic content of human chromosome 21 and to evaluate how the expression 
levels of its genes are altered by the presence of a third copy of this chromosome. The 
length of 21q is 33.5 Mb and approximately 3% of its sequence codes for proteins. 
Although the phenotype of DS may be complex and variable, it often includes congenital 
heart defects, craniofacial abnormalities, gastrointestinal anomalies, cognitive impairment, 
and the development of leukemia and/or Alzheimer’s disease (Roizen and Patterson, 
2003). Over-expression of genes on chromosome 21 by 50% in many tissues is thought to 
elicit DS. However, there is currently no explanation for how this relatively small increase 
in transcript levels would result in any specific phenotypic feature of DS. Therefore, a 
central goal of DS research is to understand which of the genes on chromosome 21, when 
present in three copies, may lead to different DS-associated phenotypes, and how its 
increased expression levels lead to the molecular, cellular and physiological changes 
underlying DS. Two distinct approaches are being taken to address these issues, i) the 
application of genomic association (GWA) studies which may point at genes that play an 
important regulatory role in DS pathology and ii) the assessment of animal models with 
trisomy 21. Animal models have shown that trisomy 21 has a significant impact on the 
development of many tissues, most notably the heart and the brain (Wiseman et al., 
2009). Additional GWA studies (Lyle et al., 2008) have pointed at genomic regions 
harbouring genes that may be relevant for DS, but most of the identified DS critical 
regions (DSCRs) are still large (several Mb), and more cases are needed to narrow down 
the phenotypic maps to a reasonable number of candidate genes per phenotype. Two of 
the candidate genes in the DSCRs are DYRK1A and DSCR1. The latter encodes a known 
inhibitor of calcineurin (Arron et al., 2006). DYRK1A is a priming kinase that facilitates the 
further phosphorylation of numerous proteins by other kinases and is up-regulated in a 
number of tissues from patients with DS (Dowjat et al., 2007; Liu et al., 2008). DYRK1A 
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The future in reproduction 
As more pregnancies are undergoing testing, the benefits and limitations of prenatal 
testing are becoming more pertinent. At an increasing pace prenatal tests will allow the 
assessment of its potential outcomes including prognoses, recurrence risks, options for 
additional testing, and long-term management but, at a similar pace, they will create 
uncertainties when the test results remain ambiguous: progress in prenatal tests may 
raise both hopes and worries. Already, modern societies are entering an era of 
personalized genetics, in which anyone can opt for a read-out of known risk genes or, 
soon, a complete personal genome sequence. There is no doubt that these technologies 
will make their way into the fertility clinic. True, with thousands of genetic risk variants 
contributing to multiple different conditions, no embryo will have the ‘perfect‘ genetic 
future. But these techniques may allow prospective parents to create a top-five wish-list 
of the characteristics they most want for their child - avoiding, for example, Parkinson’s 
disease that plagues the family - and choose the embryo most likely to meet those 
criteria. Or the parents may focus on non-health-related aspects such as intelligence 
and/or ambition. Clearly, the ethical debate about genetic selection is likely to intensify 
over the next years, as it should (Editorial Nature, 2008). Realizing the potential of genetics 
in prenatal care as a potential source of continuing anxiety, we will have to keep the 
ultimate goal of genetic testing in mind, especially its prenatal diagnostic application. 
After all, advances in technologies need to serve as triggers for higher-quality prenatal 
care, beneficial to prospective parents and healthcare professionals. 
and reliable using cffDNA from 7 weeks of gestation through the detection of sequences 
on the Y chromosome and has been made available to all women at risk of X-linked 
disorders (Costa et al., 2002) and congenital adrenal hyperplasia (Rijnders et al., 2001). It 
has been estimated that this application may reduce the need for invasive testing by 
50% (Finning and Chitty, 2008). In addition, foetal RhD status determination has widely 
been used in pregnancies involving RhD-negative women (Lo et al., 1998a). 
The additional discovery of cell-free mRNA in the maternal circulation holds great 
promise for NIPD. Lo et al. discovered mRNA molecules that were specific to the foetus 
and that could be used for the diagnose foetal chromosomal aneuploidies (Lo et al., 
2007). They showed that the SNP allelic ratio of PLAC4 mRNA released in the maternal 
plasma reflects the allelic ratio of chromosome 21 in the placenta itself and, therefore, in 
the foetus. Both the sensitivity and the specificity of the test were found to be high (90% 
and 96.5%, respectively), and it seems possible to use this test throughout all three 
gestational trimesters. However, the technique is only applicable to cases that are 
informative (i.e., heterozygous) for the SNP studied. But, obviously, the test can be 
extended with SNPs in other candidate genes. Since foetal-derived mRNA is rapidly 
cleared from the maternal circulation following delivery, antepartum and postpartum 
samples were compared with paired newborn umbilical cord blood samples to identify 
unique foetal markers in maternal whole blood. Through gene expression analyses of 
such whole blood samples a unique set of biologically diverse foetal transcripts could 
be identified. These transcripts may serve to identify foetuses affected by a variety of 
pathologic conditions (Maron et al., 2007). In a very recent report, the same group 
showed that amniotic fluid samples may provide unique molecular windows into 
developmental disorders, i.e., in addition to identifying genes relevant to the DS 
phenotype by transcriptional profiling, they were also able to identify several disrupted 
biological pathways (Slonim et al., 2009). 
In recent years, groups led by Dennis Lo and Stephen Quake have applied next generation 
sequencing (NGS) to the detection of foetal chromosomal aneuploidies (Chiu et al., 
2008; Fan et al., 2009). They independently showed the feasibility of converting cell-free 
DNA from maternal blood into genomic libraries, followed by sequencing and mapping 
the reads to the reference human genome. Subsequent assessment of the number of 
reads that map to each chromosome allowed a determination of the relative dosage of 
each chromosome to be ascertained. These studies have opened up new avenues for 
non-invasively assessing foetal aneuploidies and have provided a foundation for 
NGS-based analyses of cell-free DNA (Lo and Chiu, 2009). There is no doubt that NIPD will 
be the future and, as such, will form a basis for the establishment of large scale prenatal 
screening programs (Kooij et al., 2009). Over the next few years, several clinical trials 
involving at least some of the NIPD strategies mentioned above are anticipated.
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Summary 
The aim of invasive prenatal diagnosis is to detect foetal anomalies by examination of 
chorionic villi and/or amniotic fluid (Chapter 1). Traditionally, cytogenetic analysis of 
foetal cells is performed by karyotyping, with reporting times ranging from 10 days 
(chorionic villi) to 3 weeks (amniotic fluid). However, the development and implementation 
of new molecular tests such as fluorescence in situ hybridization (FISH), multiplex liga-
tion-dependent probe amplification (MLPA) and quantitative fluorescent polymerase 
chain reaction (QF-PCR) have changed prenatal diagnostics. Through these tests it has 
become possible to detect the most common aneuploidies of chromosomes 13, 18, 21, 
X and Y within 24 to 48 hours. The additional application of microarray technologies 
provides almost unlimited possibilities for the detection of sub-microscopic chromosomal 
aberrations. Potential pathogenic genetic defects, such as sub-microscopic deletions 
and/or duplications can efficiently be identified. These advances in prenatal diagnostics, 
in conjunction with advances in ultrasonography and the implementation of prenatal 
screening programs, lead to more detailed (genetic) knowledge of the unborn child. In 
this thesis new diagnostic tests and their concomitant clinical applications are described 
in relation to improved prenatal care.
 In Chapter 2 the relevance of routine measurement of α-foetoprotein (AFP) in 
amniotic fluid (AF) for the detection of neural tube defects (NTD) is discussed. The 
improved quality of ultrasound examinations and the implementation of foetal anomaly 
scans in the 2nd trimester of pregnancy, as part of a national screening program, provide 
new possibilities for the detection of NTD.
 In Chapter 3 the relevance of measuring lysosomal enzymes in AF supernatants 
and amniocytes for the detection of lysosomal storage diseases in pregnancies with a 
non-immune hydrops foetalis is described. In 5% of the pregnancies a lysosomal storage 
disease was detected as causal factor. In conjunction with gene mutation analysis, 
prenatal testing can be offered in a next pregnancy. A laboratory workflow for routine 
metabolic analyses of foetuses with a non-immunological hydrops foetalis and a normal 
karyotype is proposed. 
 In Chapter 4, the detection of the most common foetal aneuploidies in AF samples 
with a rapid DNA test, based on MLPA kit P095, is described. The application of this DNA 
test as a stand-alone test for rapid aneuploidy detection (RAD) in pregnant women at 
risk for a child with Down syndrome is debated, since in approximately 1:1,500 of the 
cases clinical relevant chromosomal abnormalities will remain undetected. With a rapid 
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associations will in the future generate possibilities to predict the phenotype of an 
unborn child with Down syndrome. This will enable prospective parents and professionals 
to make better informed choices about the pregnancy and the future of their child.
 In summary, it can be concluded that it is of utmost importance to join technological 
advances and changing insights into prenatal diagnostics in order to (continue to) 
provide optimal patient healthcare. 
 
DNA test as stand-alone test, however, fast and targeted answers can be provided to the 
referral question. 
 In an attempt to further optimise the MLPA test, individual probe performances of 
MLPA kit P095 were assessed (Chapter 5). The results obtained indicated that exclusion 
of the poorest performing probe only slightly affected the overall sensitivity of the test, 
thereby underscoring the robustness of the test. 
 In Chapter 6, the application of the MLPA test for chorionic villus samples (CVS) is 
described. Routinely, cytogenetic analyses are performed on extra-embryonic chorionic 
tissue, composed of cytotrophoblasts and mesenchymal cells. Metaphases from these 
cells can be analysed in short-term cultures (STC) and long-term cultures (LTC), 
respectively, generating reliable test results representing the foetal karyotype. In order 
to assess DNA from both cell types with the MLPA test, a chorionic villi dissociation 
protocol was tested. By doing so, cytotrophoblasts and mesenchymal cells could be 
obtained separately for DNA isolation, thus creating the possibility to offer RAD as a CVS 
option to pregnant women at risk for having a child with Down syndrome. 
 In Chapter 7, clinical prenatal examples with ultrasound abnormalities and a normal 
karyotype are presented in which sub-microscopic aberrations were detected by MLPA 
and/or microarray analysis. This retrospective study has shown that with the microarray 
technology the level of detection of clinically relevant sub-microscopic aberrations may 
increase substantially. However, prenatal application of the microarray technology is as 
yet debated, since this technology may generate test results of which the clinical 
relevance is uncertain.
 Finally, in Chapter 8 a number of factors is described that contributes to improved 
prenatal diagnosis in relation to patient healthcare. A central dogma herein is that the 
reason of referral must determine the choice for a diagnostic test. Uncertain test results 
should be avoided as much as possible, the test should preferably be rapid and its results 
available early in pregnancy. The chapter ends with a preview on future developments 
in prenatal diagnostics. Via increases in knowledge on the aetiology of hereditary and 
congenital diseases acquired through the Human Genome Project, and its concomitant 
technological innovations, it is anticipated that prenatal diagnostics will continue to 
change in the coming years. In particular, major changes are expected with respect to 
foetal detection of Down syndrome in maternal plasma (non-invasive diagnostics). A 
number of aspects of this new form of diagnostics, and its relation to developments in 
mass spectrometry and/or next-generation-sequencing, are discussed. Additional 
genome association studies and animal models to assess genotype-phenotype 
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Samenvatting 
Invasieve prenatale diagnostiek, door middel van een vlokkentest of vruchtwateronder-
zoek, is gericht op het detecteren van afwijkingen bij de foetus (Hoofdstuk 1). 
Chromosomen onderzoek in foetale cellen gebeurt vanouds door middel van 
karyotypering, met rapportagetijden variërend van 10 dagen (vlokkentest) tot 3 weken 
(vruchtwateronderzoek). Echter, de ontwikkeling en implementatie van nieuwe 
moleculaire testen zoals fluorescentie in situ hybridisatie (FISH), multiplex ligatie-afhan-
kelijke probe amplificatie (MLPA) en kwantitatieve fluorescente polymerase kettingreactie 
(QF-PCR) hebben de prenatale diagnostiek veranderd. Via deze testen is het mogelijk 
geworden om de meest voorkomende aneuploïdieën van chromosomen 13, 18, 21, X en 
Y binnen 24 tot 48 uur op te sporen. Daarnaast biedt de toepassing van microarray 
technieken ongekende mogelijkheden voor de detectie van submicroscopische 
chromosomale afwijkingen. Potentiële pathogene genetische afwijkingen, zoals submi-
croscopische deleties en/of duplicaties, kunnen op efficiënte wijze worden 
geïdentificeerd. Deze ontwikkelingen in de prenatale diagnostiek, in combinatie met 
verbeteringen in ultrageluidonderzoek en de implementatie van prenatale screenings-
programma’s, leiden tot meer gedetailleerde (genetische) kennis over het ongeboren 
kind. In dit proefschrift worden nieuwe diagnostische testen en de daarmee 
samenhangende klinische toepassingen beschreven in relatie tot kwaliteitsverbetering 
van prenatale zorg.
 In Hoofdstuk 2 wordt de relevantie van het routinematig meten van α-foetoproteïne 
(AFP) in vruchtwater voor de detectie van neurale buisdefecten (NBD) ter discussie 
gesteld. De verbeterde kwaliteit van ultrageluidonderzoek en de implementatie van 
structureel echoscopisch onderzoek (SEO) in het 2de trimester van de zwangerschap, als 
onderdeel van een nationaal screeningsprogramma, bieden nieuwe mogelijkheden 
voor de detectie van NBD.
 In Hoofdstuk 3 wordt de relevantie van het meten van lysosomale enzymen in 
vruchtwater voor de detectie van stapelingsziekten in zwangerschappen met een niet-
immunologische hydrops foetalis beschreven. In 5% van de zwangerschappen kon een 
lysosomale stapelingsziekte als oorzakelijke factor worden aangemerkt. In combinatie 
met genmutatie analyse kan bij een eventuele volgende zwangerschap prenatale 
diagnostiek worden aangeboden. Een laboratoriumprotocol voor het routinematig 
uitvoeren van metabole analyses bij foetussen met een niet-immunologische hydrops 
foetalis en een normaal karyotype wordt voorgesteld. 
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Onduidelijke testresultaten moeten zoveel mogelijk worden voorkomen en de 
testresultaten moeten bij voorkeur snel en vroeg tijdens de zwangerschap beschikbaar 
zijn. Het hoofdstuk wordt afgesloten met een vooruitblik op toekomstige ontwikkelingen 
in de prenatale diagnostiek. Door toename in kennis over het ontstaan van erfelijke en 
aangeboren aandoeningen verkregen via het Humane Genoom Project, en de daarmee 
samenhangende technologische vernieuwingen, wordt verwacht dat de prenatale 
diagnostiek in de komende jaren verder zal veranderen. Met name worden grote 
veranderingen verwacht op het gebied van foetale diagnostiek naar Down syndroom in 
moederlijk plasma (niet-invasieve diagnostiek). Een aantal aspecten van deze nieuwe 
vorm van diagnostiek en hun relatie tot ontwikkelingen op het gebied van massaspec-
trometrie en/of next-generation-sequencing worden besproken. Ook zullen genoom 
associatiestudies en diermodellen voor onderzoek naar genotype-fenotype relaties in 
de toekomst betere mogelijkheden gaan bieden om het fenotype van een ongeboren 
kind met het syndroom van Down te kunnen voorspellen. Hierdoor zullen a.s. ouders en 
professionals een beter geïnformeerde keuze kunnen maken over het vervolg van de 
zwangerschap en de toekomst van hun kind. 
 Samenvattend kan geconcludeerd worden dat het van groot belang is om de 
technologische ontwikkelingen en de veranderende inzichten in verbeterde prenatale 
diagnostiek te integreren om zodoende een optimale patiëntenzorg te kunnen (blijven) 
leveren. 
 In Hoofdstuk 4 wordt de detectie van de meest voorkomende foetale aneuploïdieën 
in vruchtwater met behulp van een DNA sneltest, gebaseerd op MLPA kit P095, 
beschreven. De toepassing van deze DNA test als 'stand-alone' test voor sneldetectie bij 
zwangeren met een verhoogd risico op een kind met Down syndroom wordt ter 
discussie gesteld, omdat in ongeveer 1:1500 van de gevallen klinisch relevante 
chromosomale afwijkingen niet zullen worden gedetecteerd. Echter, met deze DNA 
sneltest als stand-alone test kan wel snel en gericht antwoord worden gegeven op de 
onderzoeksvraag.
 In een poging om de MLPA test verder te optimaliseren werden prestaties van 
individuele probes uit de MLPA kit P095 onderzocht (Hoofdstuk 5). De verkregen 
resultaten lieten zien dat het uitsluiten van de probe met de grootste standaarddeviatie 
de diagnostische gevoeligheid van de test vrijwel onveranderd liet, hetgeen de 
robuustheid van de test bevestigt.
 In Hoofdstuk 6 wordt de toepassing van de MLPA test op vlokken (chorionvilli) 
beschreven. Chromosomenonderzoek in vlokken wordt standaard uitgevoerd op extra-
embryonaal weefsel, bestaande uit cytotrofoblasten en mesenchymale cellen. Metafasen 
van deze cellen kunnen respectievelijk uit de STC (short-term culture) en de LTC 
(long-term culture) worden bestudeerd, welke gezamenlijk op betrouwbare wijze het 
foetale karyotype representeren. Om met de MLPA test het DNA van beide celtypen te 
onderzoeken werd gebruik een celdissociatieprotocol getest. Gebleken is dat op deze 
manier cytotrofoblasten en mesenchymale cellen gescheiden kunnen worden verkregen 
voor DNA isolatie. Daarmee werd de mogelijkheid gecreëerd om zwangeren met een 
verhoogd risico op een kind met Down syndroom, nu ook de DNA sneltest op vlokken 
als optie aan te bieden. 
 In Hoofdstuk 7 worden prenatale voorbeelden met een echoscopische afwijking 
en een normaal karyotype gepresenteerd waarin met behulp van de MLPA en/of 
microarray technologie submicroscopische afwijkingen werden gevonden. Dit 
retrospectieve onderzoek heeft laten zien dat door middel van de microarray technologie 
het detectieniveau van klinisch relevante submicroscopische afwijkingen substantieel 
kan toenemen. Echter, prenatale toepassing van de microarray technologie wordt 
vooralsnog ter discussie gesteld omdat deze technologie kan leiden tot onderzoeksre-
sultaten waarvan de klinische betekenis onduidelijk is. 
 Tenslotte wordt in Hoofdstuk 8 een aantal factoren beschreven die bijdragen aan 
verbeterde prenatale diagnostiek in relatie tot patiëntenzorg. Centraal hierbij staat het 
dogma dat de onderzoeksvraag bepalend is voor de keuze van de diagnostische test. 
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Het schrijven van een proefschrift wordt vaker vergeleken met het beklimmen van een 
berg. Uit ervaring weet ik hoe het is om, als onervaren klimmer, de berg Kala Pattar te 
beklimmen, een uithoudingsslag die me bracht aan de top met een onvergetelijk uitzicht 
op de Mount Everest. Het promotieonderzoek gedurende de afgelopen vijf jaar ervaar ik 
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Gomes, Irma Derks-Prinsen, Judith Derks-Willemen, Liesbeth van Rossum, Linda van der 
Wijst, Linda Garms, Loes Moerkerken, Maja Scharroo, Marjo van Brakel-Kaiser, Miriam 
Zweers, Monique Geurds, Monique Kuipers, Peterine Huissoon en Sandra Kemp bedanken 
voor het genereren van veel van de onderzoeksgegevens.
Prof. dr. A. Geurts van Kessel, beste Ad, vertrouwen in eigen kunnen is belangrijk bij een 
promotieonderzoek, maar het in mij gestelde vertrouwen dit te kunnen is niet 
vanzelfsprekend. Ik wil je hiervoor bedanken. Ik heb veel van je geleerd, met name het 
wetenschappelijk schrijven was een uitdaging om op basis van grote hoeveelheden 
data te komen tot een goed gestructureerde en leesbare tekst. Ik heb jouw snelle revisie 
van manuscripten en enthousiasme bijzonder gewaardeerd.
Dr. A.P.T. Smits, beste Arie, initiator van dit promotieonderzoek en tevens werkgroepleider, 
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medewerkers van de sectie Cytogenetica voor de prettige dagelijkse werksfeer. In het 
bijzonder dank ik Brigitte Faas voor de adviezen bij het schrijven van de verschillende 
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Derks-Willemen voor het ontwerpen en onderhouden van verschillende databases.  
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Miranda, ik voel een diepe verbondenheid met jou en ben supertrots dat ik Koen en 
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Figure 1. 
(A) GTG banded karyotype. One chromosome 9 homolog exhibiting an enlarged hetero-
chromatic region is marked by an arrow. (B) Metaphase spread from the same sample again 
showing a chromosome 9 homolog (arrow) with an enlarged heterochromatic region.  
(C) C-banding confirming the heterochromatic nature of the enlarged region of one of the 
chromosome 9 homologs (arrow). Together, these analyses result in a 46,XY,9qh+ karyotype.
A
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Figure 2. 
Overview of the participation of pregnant women in first trimester screening and invasive 
testing in the period 2000-2007.
Figure 3. 
Examples of FISH on interphase (A) and metaphases (B,C and D). FISH probes can be classified into 
centromere-specific (A), locus-specific  (B), chromosome-specific (C), or telomere-specific (D). 
A B C D
Figure 4. 
Genotyper profile of a male trisomy 21 sample obtained after QF-PCR and subsequent 
processing using a genetic analyzer. One marker (D21S1414) on chromosome 21 shows a 
trisomic tri-allelic pattern (1:1:1), two markers (D21S1411 and D21S1446) show 2:1 ratios and one 
marker (D21S1435) shows a homozygous (non-informative) pattern. Both the X- and Y-specific 
products (AMXY) are present in a normal 1:1 ratio, together with the SRY-specific product. The 
XY male chromosome constitution is also evident from the normal heterozygous pattern of 
both pseudo-autosomal markers (X22 and DXYS218) and the single product obtained from the 
X-linked HPRT locus.
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Figure 5. 
Detection of trisomy 18 by MLPA. Capillary electrophoresis patterns from a normal female 
sample (upper panel) and a female sample with a trisomy 18 (lower panel) analysed with kit 
P095 are shown. The P095 probe-mix contains 36 different markers with amplification products 
ranging in size from 136 to 454 bp. Four of the probes will only generate a signal on male DNA 
samples (i.e., Y chromosome-specific). Every set of four peaks represents markers on 
chromosome 21, 18, 13 and X, respectively. The arrows mark the alterations: an increase of the 
fluorescent signals for 18m1-18m8 in the trisomy 18 sample relative to the same markers in the 
normal sample. 
Figure 6. 
Microarray profile showing a deletion of a 2.7 Mb region on chromosome 12. Each probe 
present on the array is arranged along the X-axis according to its location on the chromosome, 
with the distal p-arm clones towards the left and the distal q-arm clones towards the right. The 
log2 test-over-reference (T/R) ratio values are plotted on the Y-axis. The red dots in the upper 
panel represent individual probes. In the lower panel (blue) each dot represents the averaged 
T/R value of 10 neighbouring probes.
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Figure 2. 
Thin layer chromatography of oligosaccharides in amniotic fluid from two pregnancies affected 
by HF (orcinol dye). Lane 1: dextran hydrolysate, Lane 2: GM1-gangliosidosis (case 2), Lane 3: 
normal amniotic fluid, Lane 4: galactosialidosis (case 1), Lane 5: reference containing (from top 
to bottom) fucose/xylose, glucose, galactose, maltose/glucuronic acid, lactose, raffinose, 
tetraglucoside, sialyllactose. Abnormal lanes of both HF amniotic fluid samples are indicated by 
arrows. In both HF cases, amniotic fluid was aspirated in the 27th week of pregnancy, shortly 
after HF had been established. 
Figure 3. 
Proposed flowchart for prenatal diagnosis of non-immune hydrops foetalis
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Figure 2. 
Mean probe ratios of the chromosome 21, 18, 13, X and Y targets, with 50% of the mean probe 
ratios within the box.
Figure 5. 
Three dilution experiments in which samples with a trisomy 21, 18 or 13 were mixed with a 
normal sample. Eleven dilutions are plotted on the horizontal axis representing mixtures of 
(from left to right) 100-0, 90-10, 80-20, 70-30, 60-40, 50-50, 40-60, 30-70, 20-80, 10-90, 0-100% 
normal DNA and DNA with trisomy 21, 18 or 13, respectively. In this plot, the mean probe ratios 
for chromosome 21, 18 and 13 show a shift from a normal value of 1.0 towards a complete 
trisomy with a value close to 1.5. The black circle marks the lowest detectable mosaics (80-20% 
mixtures), with a mean probe ratio of 1.17 (95% CI: 1.01-1.32) for chromosome 21, a mean probe 
ratio of 1.13 (95% CI: 1.08-1.19) for chromosome 18 and a mean probe ratio of 1.11 (95% CI: 
1.10-1.12) for chromosome 13. The red circle marks the dilutions of 20% normal DNA with 80% 
of trisomy 21, 18 or 13 DNA. These mixtures show a mean probe ratio of 1.43 (95% CI: 1.40-1.46) 
for chromosome 21, 1.39 (95% CI: 1.33-1.46) for chromosome 18 and 1.35 (95% CI: 1.31-1.38) for 
chromosome 13. 
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Figure 6. 
Electropherograms illustrating a normal female reference sample (A) and a patient sample  
(B). The eight series of four peaks represent MLPA probes for chromosomes 21, 18, 13 and X, 
respectively. Three peaks in sample B, representing 18m2, 18m4 and 18m6, are decreased as 
compared to the peaks of the normal reference sample and, therefore, indicative for a partial 
imbalance of chromosome 18. The corresponding probe ratios showed a mean of 1.09 (95% CI: 
0.82-1.35) for 21, 0.84 (95% CI: 0.47-1.21) for 18, 1.14 (95% CI: 0.83-1.45) for 13 and 1.09 (95% CI: 
0.93-1.25) for the X chromosome, respectively. The ideogram of chromosome 18 (C) shows the 
locations of the three decreased probes (18m2, 18m6 and 18m4) on the distal region of the long 
arm of chromosome 18. Follow-up karyotyping revealed a 46,XX,del(18)(q21.2) karyotype (D).
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Figure 2. 
Laboratory flowchart for integrating rapid aneuploidy detection (RAD) in CVS into the 
cytogenetic diagnostic service. Approximately 30 mg of cleaned villi is split into three fractions 
(10 mg each). Two independent cell preparation procedures based on enzymatic digestion with 
collagenase and/or trypsin/EDTA are performed on fractions I and II to obtain suspensions from 
cytotrophoblasts (fraction C) and the mesenchymal core (fraction M), separately. A small 
amount of fraction M is used for LTC. Fraction III is stored for back-up. DNA is extracted from 
fractions C and M and RAD by MLPA or QF-PCR are assayed independently. The blue and red 
arrows indicate the routing for RAD as stand-alone test and the routing for TK, respectively. In 
this flow chart, TK of the STC is replaced by RAD on DNA from the cytotrophoblast fraction. 
Discordant results with RAD between fractions C and M or test failures is indicative for TK of the 
LTC or a repeat experiment using back-up fraction III. When the results of RAD are abnormal, 
follow-up karyotype analysis is performed to confirm the nature of the aneuploidy.
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Figure 1. 
Chromosome copy number variations identified in case 1 by 250k SNP array analysis. The log2 
T/R (test-over-reference) ratio values are plotted on the Y-axis versus the genomic position on 
the respective chromosome represented by the idiogram on the X-axis in the lower part of the 
figure. The red dots in the upper panel represent individual SNP values. The thin blue line in this 
panel represents the effective HMM outcome with a normal (N=2) T/R ratio of 0. A significant 
imbalance is indicated by a rise or fall of this line by 0.3 identifying a single copy number gain 
and -0.38 identifying a single copy number loss. In the lower panel (blue) each dot represents 
the averaged value of 10 neighbouring SNPs. The array result revealed a loss of 2.9 Mb at 
17p13.2p13.1. The four encircled gains are common CNVs (i.e., polymorphisms).
Figure 2. 
GTG banded karyotype (A) of a cultured AF cell in case 2, showing a de novo apparently 
balanced translocation t(3;18)(q26.2;q21.3) (B). Chromosome copy number changes, identified 
by SNP array analysis, resulting in a loss of~ 5 Mb at 3q26.3q27.2 (C). 
A B
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Figure 3. 
MLPA and SNP array results of case 3. Panel A shows the electropherograms of the normalized 
MLPA ratios (Y-axis) of a negative control sample without a 22q11 deletion (blue), a positive 
control sample with a common 22q11.2 deletion (red) and case 3 (green) with an atypical 
22q11.2 deletion. The markers in kit P250 are chosen between 15.959.700 to 23.283.730. Case 3 
shows single copy losses of five probes, two in the LCR22-C region (SNAP29, LZTR1) and three 
in the LCR22-D region (HIC2, PPIL2 and TOP3B), represented by reduced peak ratios of ~0.5 in 
the electropherogram. In panel B the copy number profile revealed by SNP array analysis is 
shown, including a loss of 1.3 Mb at 22q11.21q11.22.
A
B
Figure 4. 
FISH analysis in case 4 showing the HIRA (red) and ARSA (green) regions, respectively  
(A). The arrow indicates the chromosome with the ARSA deletion. GTG banded chromosomes 
22 from blood cells (B). The deletion chromosomes are marked by arrows. SNP array analysis  
(C) revealing a loss of 6.1 Mb in 22q13.31q13.33 ranging from SNP_A-2284753 to SNP_A-4279731. 
A B
C
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Figure 5. 
Schematic representation of the 22q11.2 region. The positions of FISH probe TUPLE/HIRA and 
the eight low copy repeat (LCR) clusters are marked (A to H from centromere to telomere). The 
positions the disease causing genes reported in the OMIM database are indicated. Several 
atypical 22q11.2 deletions that were previously reported (Mikhail et al., 2007; Shaikh et al., 2007; 
Ben-Shachar et al., 2008) are indicated. Case 3 and a recently reported case (Ogilvie et al., 2009a) 
exhibited deletions encompassing LCR-C and LCR-D (~1.3 Mb). These atypical deletions are not 
detected by FISH probe TUPLE/HIRA. Adapted from Descartes et al., 2008. 
